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Summary	  	  Detailed	   metabolic	   characterization	   of	   cancer	   cells	   provides	   an	   important	   cellular	  footprint	  in	  addition	  to	  well-­‐studied	  genomic	  features	  and	  could	  play	  an	  important	  role	  for	   understanding	   sensitivity	   of	   cancer	   cells	   to	   drug	   treatment.	   Thus,	   detailed	  understanding	  of	  metabolism	  and	  gene	  expression	  profiles	  of	   cancer	   cells	   could	  be	  an	  important	  guideline	  supporting	  the	  steps	  of	  drug	  selection	  and	  a	  determining	  factor	  for	  designing	  treatment	  strategies	  with	  available	  anticancer	  drugs.	  	  	  The	   aim	   of	   the	   presented	   study	   was	   to	   analyze	   the	   metabolic	   activities	   and	   cell-­‐cell	  interaction	   and	   cell-­‐matrix	   adhesion	   properties	   of	   a	   large	   number	   of	   cancer	   cell	   lines	  and	   correlate	   these	   cellular	   characteristics	   with	   drug	   sensitivity	   and	   compare	   this	  relation	  to	  established	  knowledge	  using	  gene	  expression	  and	  drug	  sensitivity	  prediction.	  For	  this,	  correlations	  among	  these	  different	  set	  of	  analytical	  information	  were	  analyzed	  to	  obtain	  cancer	  cell	  profiles	  linking	  metabolism,	  gene	  expression	  and	  drug	  IC50	  values,	  by	  calculating	  Pearson	  correlation	  coefficients.	  	  	  The	   results	   obtained	   clearly	   corroborate	   well-­‐known	   relations	   but	   also	   provide	  important	  novel	   findings	  underlying	   the	   importance	  of	   cancer	  cell	  metabolism	   in	  drug	  sensitivity.	  As	  expected,	  the	  proliferation	  rate	  correlates	  well	  with	  the	  glycolytic	  activity	  of	   cancer	   cells	   (r	   =	   0.71**)	   as	   well	   as	   with	   HOXA7	   expression	   (r	   =	   0.95***).	   The	  metabolism-­‐related	  candidate	  genes	  are	  PGLS,	  COX5B,	  RHBDL2,	  IFI16,	  GCN1L1,	  INPP5B,	  and	   LGALS8.	   Furthermore,	   the	   calculated	   Pearson	   product-­‐moment	   correlation	  coefficients	  show	  that	  the	  sensitivity	  of	  seven	  known	  drugs	  correlate	  with	  some	  of	  the	  analyzed	  cellular	  features	  of	  cancer	  cells.	  These	  compounds	  are	  elesclomol,	  Nutlin	  3a,	  PF	  4708671,	  EHT	  1864,	  IPA3,	  RDEA119,	  and	  methotrexate.	  	  	  The	  detailed	  metabolic	  and	  electrochemical	  profiling	  of	  cancer	  cells	  carried	  out	  for	  this	  study	   reveals	  new	  relationships	  between	  genes	  expression,	  drug	   sensitivity/tolerance,	  and	   basic	   metabolic	   features	   of	   cancer	   cells.	   New	   insights	   are	   provided	   into	   cancer	  metabolism,	   genomic	   regulation,	   and	   a	   potential	   application	   to	   designing	   new	  chemotherapeutic	  strategies.	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Zusammenfassung	  	  Die	   detaillierte	   metabolische	   Charakterisierung	   von	   Krebszellen	   liefert	   eine	   Reihe	  wichtiger	  Parameter	  zum	  zellulären	  Wachstumsverhalten,	  die	  bisher	  noch	  nicht	  genauer	  erfasst	  wurden.	  Diese	  metabolischen	  Informationen	  liefern	  eine	  wichtige	  Ergänzung	  zu	  bereits	   sehr	   gut	   untersuchten	   genomischen	   Veränderungen,	   die	   in	   Tumorzellen	  auftreten.	   Die	   metabolischen	   Informationen	   könnten	   daher	   eine	   neue	   ergänzende,	  wichtige	   Rolle	   für	   unser	   Verständnis	   zum	  Ansprechen	   der	   Krebszellen	   auf	   anti-­‐tumor	  Wirkstoffe	  bieten.	  Langfristig	  könnte	  die	  Kombination	  aus	  genetischen	  Veränderungen,	  Genaktivität	   und	   Metabolismus	   ein	   wichtiger	   Leitfaden	   für	   die	   Auswahl	   geeigneter	  Wirkstoffen	   und	   ein	   bestimmender	   Faktor	   für	   die	   Planung	   und	   Festlegung	   der	  Therapiestrategie	  sein.	  	  	  Das	  Ziel	  der	  vorliegenden	  Arbeit	  war	  es	  die	  metabolische	  Aktivität,	  Zell-­‐Zell-­‐Interkation	  und	   Zell-­‐Matrix-­‐Adhäsion-­‐Eigenschaften	   einer	   großen	   Zahl	   von	   Tumorzelllinien	   zu	  bestimmen	   und	   diese	   mit	   anderen	   zellulären	   Eigenschaften	   wie	   Empfindlichkeit	   auf	  Wirkstoffe	  zu	  verknüpfen	  und	  diesen	  Zusammenhang	  mit	  bekannten	  Informationen	  zur	  Wirkung	   von	  Arzneistoffen	   in	   Abhängigkeit	   Zell-­‐spezifischer	   Genexpressionsprofile	   zu	  vergleichen.	   Dazu	   wurden	   die	   Korrelationen	   zwischen	   diesen	   verschiedenen	  analytischen	   Datensätzen	   ermittelt	   und	   Tumorzell-­‐spezifische	   Profile	   ermittelt,	   die	  Metabolismus,	   Genexpression	   und	   IC50	   Werte	   der	   Wirkstoffe	   durch	   Berechnung	   von	  Pearson	  Korrelationskoeffizienten	  verknüpfen.	  	  Die	   erhaltenen	   Ergebnisse	   unterstützen	   sehr	   gut	   bereits	   bekannte	   Beziehungen	   und	  liefern	  zusätzlich	  eine	  Reihe	  neuer	  Ergebnisse,	  die	  die	  Bedeutung	  des	  Zellmetabolismus	  für	  das	  Ansprechen	  von	  Tumorzellen	  auf	  Wirkstoffe	  bestätigen.	  Wie	  erwartet	  korreliert	  die	   Proliferationsrate	   sehr	   gut	   mit	   der	   glykolytischen	   Aktivität	   der	   Krebszellen	   (r	   =	  0,71**)	   sowie	   mit	   der	   Expression	   von	   HOXA7	   (r	   =0,95***).	   Neue	   hier	   gefundene	  Metabolismus-­‐bezogene	   Markergene	   sind	   PGLS,	   COX5B,	   RHBDL2,	   IFI16,	   GCN1L1,	  INPP5B	  und	   LGALS8.	  Darüber	   hinaus	   zeigen	  die	   errechnete	   Pearson	  Produkt-­‐Moment	  Korrelationskoeffizienten,	  dass	  das	  Ansprechen	  auf	  sieben	  bekannte	  Wirkstoffe	  sehr	  gut	  mit	  den	  zellulären	  Eigenschaften	  der	  Krebszellen	  übereinstimmt.	  Diese	  Wirkstoffe	  sind	  Elesclomol,	  Nutlin	  3a,	  PF	  4708671,	  EHT	  1864,	  IPA3,	  RDE119	  und	  Methotrexat.	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  Die	   hier	   vorgelegten	   detaillierten	   metabolischen	   und	   elektrochemischen	  Untersuchungen	  von	  Krebszellen	  zeigen	  bisher	  nicht	  bekannte	  Verknüpfungen	  zwischen	  Genexpression,	   Empfindlichkeit	   auf	  Wirkstoffe,	   und	   der	   grundlegenden	  metabolischen	  Aktivität	   von	   Krebszellen.	   Die	   Ergebnisse	   lassen	   auch	   erwarten,	   dass	   die	   neuen	  Einsichten	   in	   den	   Tumormetabolismus	   und	   dessen	   Verknüpfung	   mit	   genomischen	  Veränderungen	   eine	   vielversprechende	   Option	   für	   die	   Entwicklung	   neuer	  chemotherapeutischer	  Strategien	  liefern	  können.	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1. Introduction	  
1.1 Cellular	  Features	  
1.1.1 Glycolysis	  and	  Gluconeogenesis	  	   Glycolysis	  is	  an	  ancient	  pathway	  preserved	  in	  evolution	  and	  present	  in	  almost	  all	  living	  organisms	  (Berg	  et	  al.	  2002,	  Zheng	  2012).	  There	  are	  variations	  of	  glycolysis	   like	  the	   Entner-­‐Doudoroff	   pathway	   that	   occurs	   in	   some	   bacteria	   and	  which	   produces	   just	  one	   molecule	   of	   ATP.	   Other	   organisms	   like	   phototrophs	   use	   an	   alternative	   glycolysis	  pathway	   where	   no	   ATP	   is	   produced	   at	   all	   and	   that	   simply	   serves	   to	   form	   carbon	  skeletons	   (Bar-­‐Even	   et	   al.	   2012).	   On	   the	   other	   hand,	   some	   microorganisms	   show	  variants	  of	  glycolysis	  with	  a	  high	  yield	  of	  ATP,	  producing	  three	  or	  four	  ATP	  molecules	  at	  the	   end	   of	   the	   pathway	   (Bar-­‐Even	   et	   al.	   2012).	   Glycolysis	   and	   variations	   are	   found	   in	  eukaryotes,	  bacteria,	  and	  archaeans	  (Romano	  &	  Conway	  1996).	  	  	   The	   term	   glycolysis	   comes	   from	   the	   Greek	   “to	   split	   sugar”	   in	   where	   the	  monosaccharide	  glucose	  is	  converted	  into	  two	  three-­‐carbon	  molecules	  (pyruvate),	   two	  ATP,	   and	   two	  NADH	  molecules.	   Glycolysis	   takes	   place	   in	   the	   cytosol.	   The	   synthesis	   of	  glucose	   from	   pyruvate,	   lactic	   acid,	   or	   glycerol	   is	   called	   gluconeogenesis.	   It	   is	   used	   in	  animals	   and	   humans	   to	   balance	   the	   sugar	   level	   in	   the	   blood.	   Gluconeogenesis	   shares	  most	  of	   the	  enzymes	  with	  glycolysis	  but	   is	  not	  exactly	   the	  reverse	  process	   (Berg	  et	  al.	  2002)	   and	   different	   enzymes	   in	   gluconeogenesis	   perform	   the	   irreversible	   steps	   in	  glycolysis.	   For	   example,	   the	   conversion	   of	   fructose	   6-­‐phosphate	   to	   fructose	   1,6-­‐phosphate	  is	  an	  irreversible	  step	  catalyzed	  by	  phosphofructokinase	  in	  glycolysis	  and	  the	  reversion	  is	  done	  by	  fructose	  biphosphatase	  in	  gluconeogenesis.	  	   Elucidating	   the	   entire	   glycolysis	   pathway	   took	   more	   than	   80	   years	   and	   began	  with	   Louis	   Pasteur	   in	   1860	   who	   discovered	   that	   fermentation	   always	   involves	   a	   life	  process,	   either	   by	   yeast	   or	   some	   other	   microorganism.	   The	   Buchner	   brothers	  accidentally	  discover	   that	   fermentation	   can	  also	  occur	  by	  yeast	   extracts,	  meaning	   that	  the	  process	  can	  also	  take	  place	  outside	  a	  living	  cell.	  Gustav	  Embden	  eventually	  compiled	  the	  contributions	  of	  generations	  of	  researchers	  and	  elucidated	  the	  complete	  pathway	  in	  1940.	  	   The	  aim	  of	   glycolysis	   is	   to	  provide	  energy	   to	   the	   cells	   and	  although	   it	   is	  not	  an	  efficient	  way	   to	  produce	  ATP,	   it	   is	   the	  only	  way	   for	  cells	   to	  do	  not	  have	  mitochondria,	  like	  erythrocytes,	  and	  the	  most	  used	  pathway	  for	  this	  purpose	  for	  some	  other	  cells	  like	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those	  derived	  from	  brain,	  skin,	  and	  cancer	  cells.	  In	  glycolysis,	  just	  two	  ATP	  molecules	  are	  synthesized	   in	   comparison	   with	   the	   36	   ATPs	   produced	   by	   oxidative	   phosphorylation	  (OXPHOS).	   OXPHOS	   is	   the	   process	   by	   which	   the	   cells	   produce	   ATP	   from	   ADP	   plus	  inorganic	   phosphate	   in	   mitochondria.	   Cancer	   cells	   are	   estimated	   to	   use	   glycolysis	  around	  200	  times	  more	  than	  their	  normal	  counterpart	  cells	  (Akram	  2013).	  This	  feature	  that	   cancer	   glycolysis	   is	   much	   more	   active	   than	   that	   of	   healthy	   tissue	   is	   called	   the	  Warburg	  effect.	   In	  1930,	  Otto	  Warburg	  described	  this	  phenomenon	  and	  proposed	  that	  the	  mitochondria	  of	  cancer	  cells	  are	  dysfunctional	  and	  that	  this	  could	  be	  the	  main	  reason	  for	  cancer	  abnormalities,	  rather	  than	  the	  increase	  in	  proliferation	  (Akram	  2013,	  Zheng	  2012).	   Recent	   investigations	   have	   demonstrated	   that	   the	   enzymes	   in	   OXPHOS	   are	  functional	   in	  most	   tumors	  and	  cancer	  cell	   lines	  do	  not	   carry	  mutations	   that	  disengage	  their	  performance	  (Vander	  et	  al.	  2009,	  Zheng	  2012).	  	  	   The	  increase	  in	  glycolytic	  activity	  by	  cancer	  cells	  has	  been	  shown	  to	  be	  regulated	  by	   oncogenes,	   the	   inactivation	   of	   tumor	   suppressors,	   mutations	   in	   the	   mitochondrial	  DNA,	   and	   the	   rapid	   proliferation	   of	   cancer	   cells.	   In	   solid	   tumors,	   generation	   of	   new	  vessels	  (angiogenesis)	  is	  limited	  due	  to	  the	  fast	  tumor	  growth	  and	  therefore	  cells	  suffer	  from	  hypoxic	  conditions	  (Zheng	  2012).	  It	  is	  also	  known	  that	  genes	  involved	  in	  glycolysis	  are	   overexpressed	   in	   many	   cancers.	   In	   70%	   of	   human	   cancers	   there	   is	   an	  overexpression	  of	  glycolysis	  genes	  especially	  in	  prostate,	  brain,	  and	  lymph	  node	  cancers	  where	   almost	   all	   of	   the	  mentioned	   pathway	   genes	   are	   highly	   expressed	   (Altenberg	  &	  Greulich	  2004).	  The	  genes	  that	  are	  overexpressed	  in	  most	  cancer	  types	  are	  the	  ones	  for	  encoding	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase,	   enolase	   1,	   and	   pyruvate	   kinase	  (Altenberg	  &	  Greulich	  2004).	  On	   the	  other	  hand,	  many	  of	   the	  glycolytic	  enzymes	  have	  pro-­‐cancer	  non-­‐glycolytic	   functions,	  an	  example	  being	  hexokinase	  and	  phosphoglucose	  isomerase	   that	   have	   antiapoptotic	   functions;	   phosphoglucose	   isomerase	   together	  with	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  have	  a	  positive	   role	   in	   survival	  pathways;	  phosphofructokinase	   1	   and	   triose	   phosphate	   isomerase	   activate	   the	   cell	   cycle	   and	  aldolase	  promotes	  epithelial	  to	  mesenchymal	  transition	  (Lincet	  &	  Icard	  2015).	  	   It	   is	   important	   to	   highlight	   that	   aerobic	   glycolysis	   (the	   type	   of	   glycolysis	   that	  occurs	  both	  in	  normoxic	  or	  hypoxic	  conditions)	  acts	  together	  with	  OXPHOS,	  cooperating	  and	  keeping	  a	  balance	  to	  fulfill	  the	  energy	  demand	  of	  the	  cell.	  The	  metabolism	  of	  cancer	  cells	  differs	  markedly	  from	  the	  metabolism	  of	  normal	  tissues.	  Cancer	  cells	  have	  a	  higher	  level	   of	   plasticity	   and	   are	   more	   heterogeneous,	   being	   able	   to	   adapt	   themselves	   to	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adverse	  conditions	  and	  different	  media	  giving	  them	  a	  survival	  advantage	  in	  comparison	  with	  normal	  cells.	  	  
1.1.2 The	  Contribution	  of	  Mitochondria	  to	  Cellular	  Respiration	  	  	   Mitochondria	  are	  organelles	  responsible	  for	  energy	  production	  of	  a	  cell,	  and	  are	  involved	  in	  cell	  signaling	  and	  regulation	  of	  the	  cell	  cycle	  and	  growth	  as	  well	  as	  apoptosis	  (Yang	  et	  al.	  2016).	  It	  has	  been	  shown	  that	  the	  mitochondria	  of	  cancer	  cells	  are	  different	  in	  function	  and	  structure	  as	  compared	  to	  normal	  cells	  (Yang	  et	  al.	  2016).	  In	  healthy	  cells	  under	  normal	  O2	  environments,	  between	  70%	  and	  90%	  of	  the	  energy	  is	  supplied	  by	  the	  mitochondrial	   OXPHOS.	   Under	   hypoxic	   conditions,	   that	   most	   cancerous	   cells	   are	  exposed	  to,	  ATP	  is	  mainly	  produced	  via	  glycolysis	  and	  the	  pentose	  phosphate	  pathways	  (Zheng	  2012,	  Yang	  et	  al.	  2016).	  Mutations	   in	  mitochondrial	  DNA	  has	  been	  reported	   to	  play	   an	   important	   role	   for	   the	   transformation	   of	   normal	   cells	   into	   cancerous	   ones,	   as	  well	   as	   cancer	   progression	   and	   drug	   resistance	   that	   lead	   to	   an	   increase	   of	   cellular	  glycolytic	  activity	  (Rogalinska	  2016).	  	   Cellular	   respiration	   consists	   of	   a	   series	   of	   biochemical	   reactions	   taking	   place	  within	   the	   cells	   to	   produce	   energy	   as	   ATP	   from	   glucose,	   fatty	   acids,	   and	   amino	   acids.	  Respiration	   starts	   in	   the	   cytosol	   with	   the	   production	   of	   pyruvate	   from	   glucose	   in	  glycolysis.	   In	   low	   oxygen	  microenvironments,	   pyruvate	  will	   be	   reduced	   to	   lactic	   acid.	  Under	  normoxic	  conditions,	  pyruvate	  will	  be	  oxidized	  into	  acetyl-­‐CoA	  plus	  one	  molecule	  of	  CO2	  and	  one	  molecule	  of	  NADH	  in	  the	  mitochondria	  by	  the	  pyruvate	  dehydrogenase	  complex.	   Acetyl-­‐CoA	   in	   combination	  with	   oxaloacetate	   in	   the	   tricarboxylic	   acid	   (TCA)	  cycle	  will	  be	  further	  oxidized	  to	  CO2	  at	  the	  same	  time	  that	  NAD	  is	  reduced	  to	  NADH.	  The	  NADH	  molecules	  enter	  the	  electron	  transport	  chain	  to	  synthesize	  more	  ATP.	  	  	   In	   cancer	   cells	   within	   tumors	   metabolism	   greatly	   varies.	   It	   has	   been	  demonstrated	   that	   not	   all	   cancer	   types	   follow	   a	  Warburg	   effect,	   and	   they	   show	   great	  heterogeneity	  within	  the	  same	  tumor	  (Hensley	  et	  al.	  2016).	  In	  recent	  years	  it	  has	  been	  shown	  that	  some	  cancers	  use	  principally	  the	  OXPHOS	  to	  obtain	  their	  energy	  (Corbet	  &	  Feron	  2017,	  Zheng	  2012).	  The	  substrate	  necessary	   for	   the	  TCA	  cycle	   is	  provided	   from	  different	  sources	  such	  as	  amino	  acids	  and	  fatty	  acids,	  and	  it	  is	  possible	  to	  simultaneously	  observe	   elevated	   levels	   of	   fermentation	   and	  mitochondrial	   respiration	   (Hensley	   et	   al.	  2016).	  During	  the	  last	  decades	  several	  studies	  have	  suggested	  that	  cancer	  cells	  rely	  on	  glycolysis	   to	  obtain	  ATP	  due	   to	  damaged	  and	  nonfunctional	  OXPHOS	   (Warburg	  effect)	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and	   Otto	   Warburg	   to	   some	   extend	   misinterpreted	   his	   observations	   (Koppenol	   et	   al.	  2011).	  	  	   Moreover,	  nowadays	  it	  is	  known	  that	  in	  some	  cancers	  mitochondrial	  metabolism	  is	   necessary	   for	   tumorigenesis	   and	   to	   support	   tumor	   progression	   (Corbet	   &	   Feron	  2017).	  Mutations	  of	  the	  TCA	  cycle	  enzymes	  lead	  to	  a	  formation	  of	  oncometabolites	  (TCA	  intermediaries,	   like	   citrate)	   that	   are	   responsible	   for	   the	   inhibition	   of	   the	   tumor	  suppressor	   p53,	   the	   stabilization	   of	   hypoxia-­‐inducible	   factor,	   the	   activation	   of	   cell	  growth	  pathways,	  glycolysis,	  and	  reactive	  oxygen	  species	  (ROS)	  formation	  (Sajnani	  et	  al.	  2017).	   The	   coordinated	   redox	   balance	   existing	   in	   normal	   tissues	   is	   out	   of	   control	   in	  cancer	   cells.	  Mitochondrial	   DNA	  mutations	   can	   elevate	   ROS	   production	   and	   high	   ROS	  levels	  induce	  genetic	  instability	  responsible	  for	  mutations	  (Yang	  et	  al.	  2016,	  Okon	  &	  Zou	  2015,	   Kang	   et	   al.	   2015).	   In	   normal	   cells	   the	   production	   of	   ROS	   is	   proportional	   to	   the	  activity	   of	   the	   electron	   transport	   chain,	   and	   as	  mentioned	   earlier,	   is	   controlled	   by	   an	  antioxidant	  system	  that	  keeps	  the	  necessary	  amount	  of	  ROS	  high	  enough	  to	  function	  in	  protein	  regulation	  and	  signaling	  (Okon	  &	  Zou	  2015,	  Kang	  et	  al.	  2015).	  The	  elevated	  ROS	  in	   cancer	   cells	   has	  multiple	   functions	   apart	   from	   the	   induction	   of	  mitochondrial	   DNA	  mutations.	  The	  impact	  of	  ROS	  in	  cancer	  will	  depend	  on	  i)	  the	  levels	  of	  ROS,	  ii)	  the	  type	  of	  tumor	  and	  tissue,	  iii)	  the	  disease	  stage,	  and	  iv)	  the	  type/duration	  of	  treatment	  (Okon	  &	  Zou	  2015).	  Elevated	  ROS	   levels	  have	  been	   implicated	   in	  cancer	   initiation,	  progression,	  and	   drug	   resistance	   (Okon	   &	   Zou	   2015).	   Among	   ROS	   functions,	   elevated	   ROS	  accumulation	  has	  been	  attributed	  to	  the	  stabilization	  of	  the	  hypoxia-­‐inducible	  factor	  1A	  creating	  a	  pseudohypoxic	  environment	  under	  normoxic	  conditions,	  the	  hyperactivation	  of	   oncogenes	   to	   promote	   cancer	   development,	   and	   tumorigenesis	   mediated	   by	   K-­‐ras,	  cancer	  cell	  proliferation	  and	  survival	  (Yang	  et	  al.	  2016).	  	  	  
1.1.3 Cellular	  Proliferation	  	   Cellular	  proliferation	  is	  the	  process	  by	  which	  cells	  grow	  and	  divide	  resulting	  in	  an	  increasing	  number	  of	  cells.	  The	  proliferation	  rate	  in	  adults	  is	  in	  equilibrium	  with	  cell	  loss	  by	  cell	  differentiation	  and	  cell	  death.	  A	  key	  characteristic	  of	  tumors	  is	  the	  uncontrolled	  nonregulated	  proliferation	  rate	  by	  which	  the	  signals	  that	  control	  a	  normal	  cell	  division	  behavior	   are	   no	   longer	   properly	   working.	   The	   uncontrolled	   proliferation	   of	   cells	   is	  considered	  one	  of	  the	  first	  symptoms	  in	  cancer	  development.	  A	  continued	  noninvasive	  proliferation	  of	  cells	  without	  spreading	  into	  distant	  tissues	  is	  observed	  in	  benign	  tumors	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(Cooper	   &	   Hausman	   2000).	   Malignant	   tumors	   (cancers)	   are	   the	   ones	   that	   apart	   of	  present	   abnormal	   and	   uncontrolled	   proliferations	   are	   also	   capable	   of	   invading	   the	  surrounding	   tissue	   and	  migrating	   to	   distant	   sites	   (Cooper	   &	   Hausman	   2000).	   Several	  biomarkers	   connected	   to	   cell	   proliferation	   are	   widely	   used	   in	   the	   clinical	   context	   to	  characterize	  human	  cancers	  as	  to	  tumor	  grade,	  therapy	  responses,	  and	  prognosis	  (Wood	  et	  al.	  2015).	  	   Most	  of	  these	  upregulated	  proteins	  (biomarkers)	  used	  for	  therapeutic	  application	  are	  needed	  for	  efficient	  uptake	  of	  nutrients	  for	  producing	  the	  necessary	  biomass	  for	  new	  cells	   in	   fast-­‐proliferating	   tumor	   cells.	   Evidence	   demonstrates	   that	   several	   signaling	  pathways	   that	   regulate	   proliferation	   do	   also	   regulate	   cell	   metabolism	   in	   cancer	   cells	  regarding	  the	  uptake	  and	  incorporation	  of	  nutrients	  for	  ATP	  production	  (Vander	  Heiden	  et	  al.	  2009,	  Agathocleous	  &	  Harris	  2013).	  Some	  of	  the	  pathways	  involved	  in	  regulating	  proliferation	  and	  metabolism	  are	   the	  mTOR,	  RAS,	  MYC,	  PI3K,	  and	  Hedgehog	  pathways	  (Agathocleous	   &	   Harris	   2013).	   Changes	   in	   metabolism	   observed	   in	   cancer	   cells	  (Warburg	  effect	  and	  disruption	  of	   the	  redox	  balance,	  TCA	  cycle	  enzymes	  and	   lipid	  and	  amino	   acid	   metabolism)	   lead	   to	   utilization	   of	   metabolites	   for	   energy-­‐producing	  pathways	  and	  biosynthetic	  anabolism	  for	  cell	  growth	  and	  proliferation	  (Agathocleous	  &	  Harris	  2013).	  This	  behavior	  can	  also	  be	  observed	  in	  normal	  cells	  that	  display	  a	  Warburg	  effect	  mode	  in	  the	  production	  of	  ATP	  when	  stimulated	  to	  proliferate	  (Brand	  &	  Hermfisse	  1997).	  This	   is	  not	  surprising	   if	  one	   takes	   into	  consideration	  that	  glycolysis	  serves	  as	  a	  starting	  point	   for	  pathways	   leading	   to	   the	   synthesis	  of	  nucleic	   acids,	   amino	  acids,	   and	  polysaccharides,	  all	  of	  which	  needed	  as	  building	  blocks	   in	  cell	  proliferation	  (Toyoda	  &	  Saitoh	  2015).	  	  
1.1.4 Membrane	  Capacitance	  	   Capacitance	   is	   defined	   as	   the	   ability	   to	   store	   electrical	   energy.	   Cells	   in	   their	  conductive	  electrolyte	  solution	  media	  (water	  plus	   ions)	  act	  as	  capacitors	  being	  able	   to	  store	  electricity	  (Mosgaard	  et	  al.	  2015).	  A	  capacitor	  is	  formed	  by	  two	  conductive	  plates	  separated	   by	   a	   dielectric	   (an	   insulating	  material).	   Cell	  membranes	   act	   as	   an	   insulator	  (nonconductive	  material)	  and	  the	  inner	  and	  outer	  space	  of	  the	  cell	  as	  conductive	  plates	  with	  free	  ions	  that	  can	  transport	  electrical	  charges	  (Niebur	  2008).	  A	  completely	  sealed	  membrane	  or	  insulator	  does	  not	  allow	  the	  passage	  of	  current	  from	  one	  side	  to	  the	  other.	  Artificial	  membranes	  built	  of	  pure	  phospholipid	  bilayers	  are	  quite	  good	  insulators.	  They	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are	   highly	   impermeable	   to	   polar	   solutes,	   meaning	   that	   there	   are	   no	   ions	   that	   can	  transport	   charges	   across	   the	   hydrophobic	   central	   core	   of	   the	   bilayer	   (Niebur	   2008).	  Nevertheless,	   natural	  membranes	   in	   cells	   are	  made	   up	   not	   only	   of	   phospholipids	   but	  also	  of	  different	  ion	  transporters	  and	  transmembrane	  proteins.	  The	  transmembrane	  ion	  transporter	  proteins	   that	   act	   as	   ion	   channels	  need,	   in	  order	   to	   cross	   the	  polar	   solutes	  through	  the	  membrane	  without	  a	  solvent,	  to	  build	  special	  interactions	  with	  the	  ions,	  and	  organize	   themselves	   to	   be	   selective	   and	   efficient	   in	   the	   transport	   (Fyles	   2007).	   The	  composition	  of	  the	  lipid	  bilayer	  and	  the	  characteristics	  of	  the	  ion	  transporters	  give	  the	  cells	  different	  electrical	  properties.	  Depending	  on	  the	  cellular	  function,	  ion	  transporters	  differ	  in	  their	  distribution	  and	  quantity	  in	  different	  cell	  lines	  (Jones	  2012).	  	   Cell	  membranes	  themselves	  can	  also	  act	  as	  capacitors	  (Mosgaard	  et	  al.	  2015).	  In	  this	   model,	   the	   hydrophobic	   central	   core	   of	   the	   phospholipid	   bilayer	   is	   the	  nonconductive	  material.	  	  	   Capacitors	  can	  be	  charged	  connecting	  a	  cathode	  to	  one	  of	   the	  conductive	  plates	  and	   the	   anode	   to	   the	   second	   conductive	   plate	   producing	   a	   flow	   of	   electron	   (current).	  Cells	  can	  be	  charged	  applying	  a	  current	  across	  the	  membrane.	  The	  two	  conductive	  plates	  or	  in	  the	  case	  of	  a	  cell,	  the	  lipid	  bilayer,	  on	  one	  side,	  will	  be	  positively	  charged	  and,	  on	  the	   other	   side,	   negatively	   charged.	   For	   example,	   during	   the	   nerve	   impulse,	   neuron	  membranes	  are	  transiently	  charged	  due	  to	  the	  flow	  of	  current	  (charged	  molecules	  of	  Na+	  and	  K+)	   through	   the	   ion	   channels	   (Mosgaard	   et	   al.	   2015).	  Depending	  on	   the	   structure	  and	  composition	  of	   the	  cell	  membranes,	  different	  amounts	  of	  electrical	  charges	  can	  be	  stored.	  The	  charge	  stored	  by	  the	  capacitor	  is	  measured	  in	  Farads	  (F).	  	   Cell	  membranes	   differ	   due	   to	   the	   particular	   lipid	   concentration,	   the	   number	   of	  lipid-­‐rich	  microdomains,	   fatty	  acid	  composition	  and	  cell	  surface	  proteins,	  their	  content	  and	  degree	  of	  modification	  like	  by	  glycosylation	  (Christiansen	  et	  al.	  2014).	  The	  plasma	  membrane	   is	   a	   complex	   structure	   and	   in	   charge	   not	   only	   for	   maintaining	   particular	  environments	   inside	   and	   outside	   of	   the	   cell	   (due	   to	   its	   function	   as	   a	   barrier	   and	   ion	  transporter),	   it	   also	   is	   a	   key	   component	   in	   cell	   signaling	   giving	   feedback	   between	   the	  extracellular	   and	   intracellular	   media	   (exocytosis	   and	   endocytosis,	   protein	   secretion,	  membrane	   receptors,	   etc).	   It	   is	   also	   implicated	   in	   compartmentalization	   and	  organization	   of	   the	   inside	   of	   organelles	   forming	   an	   endomembrane	   system	   with	   the	  Golgi	   apparatus,	   endoplasmic	   reticulum,	  nuclear	  membrane,	   and	   lysosomes	   (O'Connor	  et	   al.	   2010)	   and	   for	   cell	   interactions,	   being	   responsible	   for	   cell-­‐cell	   binding	   and	   cell-­‐matrix	  contact	  in	  cell	  tissue	  organization.	  The	  plasma	  membrane's	  complexity	  in	  cells	  is	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so	   important	   that	   it	   has	   been	   referred	   to	   as	   the	   capacitor	   for	   energy	   and	  metabolism	  (Ray	  et	  al.	  2016).	  The	  different	  structures	  that	   form	  and	  provide	  the	  complexity	  of	  the	  plasma	  membrane	  are	  attributed	  to	  play	  specific	  rolls	  in	  the	  electrical	  properties	  of	  cells	  and	   tissues	   (Eisenberg	   1980).	   Therefore,	   one	   can	   postulate	   that	   the	   insulating	  properties	  of	  the	  membranes,	  and	  in	  consequence	  their	  capacitance	  abilities,	  are	  unique	  characteristics	  for	  each	  cell	  line.	  	  	  
1.2 	  Public	  Data	  Repositories	  	   A	  public	  data	  repository	  is	  an	  online	  database	  service	  used	  for	  long-­‐term	  storage,	  preservation,	   archiving,	   managing,	   sharing,	   and	   accessing	   research	   data	   (Uzwyshyn	  2016).	   The	   aim	   of	   a	   public	   repository	   is	   to	   provide	   benefit	   by	   sharing	   and	   improving	  knowledge	   allowing	   faster	   research	   and	   discoveries	   (Uzwyshyn	   2016).	   “The	   ability	   to	  
build	  upon	  the	  findings	  of	  others	  is	  one	  of	  the	  cornerstones	  of	  science”	  (Joung	  et	  al.	  2015).	  To	  do	  research	  using	  the	  findings	  of	  others	  it	  is	  necessary	  that	  this	  information	  is	  made	  available	   and	   this	   information	   must	   be	   easily	   and	   permanently	   accessible	   and	  trustworthy.	   Therefore,	   data	   repositories	  must	   have	   the	   resources	   to	   secure	   the	   long-­‐term	  preservation	  of	  the	  data,	  update	  the	  data,	  and	  provide	  a	  user-­‐friendly	  platform	  to	  upload,	  download,	  and	  search	  the	  data,	  and	  to	  provide	  stable	  and	  resolvable	  identifiers	  and	  above	  all,	  the	  necessary	  technology	  for	  the	  data	  curation	  (Lemberger	  2015).	  	   Since	   the	   development	   of	   new	   sequencing	   technologies	   and	  microarrays,	   huge	  amounts	  of	  genome	  data	  have	  been	  accumulated	  in	  public	  archives.	  Every	  year	  more	  and	  more	   big	   data	   are	   generated	   that	   give	   information	   about	   genome	   evolution,	   gene	  regulation,	  cancer	  genetics	  and	  their	  effects	  on	  patients,	  drugs	  targets,	  etc.	  The	  explosion	  of	   data	   started	   in	   2009	   and	   in	   2012	   the	   amount	   of	   data	   produced	   was	   4	   times	   that	  produced	   in	   2011	   (Marx	   2013).	   By	   the	   end	   of	   2015,	   the	   European	   Bioinformatics	  Institute	   (EMBL-­‐EBI),	   one	   of	   the	   largest	   data	   repositories	   for	   biology,	   had	   stored	   75	  petabytes	   (1	  petabyte	   is	  1015	  bytes)	  of	  data	  and	  backups	  of	  genes,	  proteins,	  and	  small	  molecules	   (Cook	   et	   al.	   2016);	   being	   in	   2013	   just	   20	   petabytes	   (Marx	   2013).	   The	   data	  generated	  is	  continuously	   increasing	  nowadays.	  With	  the	  low	  price	  of	  high-­‐throughput	  technology	   almost	   every	   small	   laboratory	   can	   be	   a	   big	   data	   generator	   and	   of	   course	  thanks	  to	  the	  online	  repositories	  a	  big	  data	  user	  (Marx	  2013).	  The	  data	  curation	  process	  and	   the	   maintaining	   and	   development	   of	   the	   tools	   necessary	   to	   deal	   with	   the	   data	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explosion	   require	   that	   new	   types	   of	   professionals	   and	   carriers	   evolve;	   data	   scientist,	  data	  archivist,	  data	  visualization	  experts,	  data	  curators,	  among	  others,	  will	  be	  more	  and	  more	  required	  (Uzwyshyn	  2016).	  	   Knowledge	   of	   gene	   expression	   has	   dramatic	   increased	   since	   the	   utilization	   of	  high-­‐density	  immobilized	  oligonucleotide	  probes	  in	  arrays	  (Illumina,	  Affymetrix)	  (Rung	  &	  Brazma	  2013)	  and	  the	  RNA	  sequencing	  (RNA-­‐Seq)	  technique.	  Due	  to	  the	  requirements	  of	   being	   able	   to	   deal	   with	   and	   handle	   huge	   volumes	   of	   computational	   data,	  bioinformatics	   has	   become	   a	   central	   and	   important	   area	   of	   biology	   (Rung	   &	   Brazma	  2013).	  Microarray	  analyses	  require	  expertise	  and	  computational	  resources	  based	  on	  the	  development	  of	  new	   tools	  and	  methods.	  Biologists	  benefit	   from	  such	  environments	  as	  Bioconductor	   (Huber	   et	   al.	   2015)	   provided	   by	   the	   bioinformatics	   community	   to	   take	  advantage	   of	   the	   gene	   expression	   data	   generated	   and	   freely	   available	   in	   public	  repositories	   for	  microarray	   data	   like	   the	   Gene	   Expression	   Omnibus	   (GEO)	   of	   the	   U.S.	  National	  Center	  for	  Biotechnology	  Information	  (NCBI)	  or	  the	  ArrayExpress	  of	  EBI	  (Rung	  &	  Brazma	   2013).	   To	   date,	   GEO	   contains	  more	   than	   2	  million	   samples	   freely	   available	  with	  raw	  data	  that	  every	  researcher	  in	  the	  world	  can	  work	  with	  (GEO,	  NCBI	  accessed	  12	  April	  2017).	  A	  sample	  is	  an	  array	  measurement,	  for	  example,	  the	  gene	  expression	  of	  the	  complete	  genome	  of	  a	  determined	  cell	  line	  using	  one	  of	  the	  Affymetrix	  platforms.	  Other	  public	   repositories	   like	   The	   Genomics	   of	   Drug	   Sensitivity	   in	   Cancer	   Project	   (GDSC)	  funded	   by	   the	   Wellcome	   Trust	   Sanger	   Institute	   or	   The	   Cancer	   Imaging	   Archive	  supported	  by	  the	  NIH	  (U.S.	  National	  Cancer	  Institute)	  are	  focused	  on	  the	  improvement	  of	  cancer	  treatment.	  The	  GDSC	  is	  a	  freely	  available	  resource	  with	  curated	  data	  for	  reuse	  by	  the	   academic	   and	  medical	   communities.	  GDSC	   is	   performing	   a	   large-­‐scale	  drug	   screen	  with	   compounds	   that	   include	   cytotoxic	   chemotherapeutics	   and	   targeted	   therapeutics	  from	   commercial	   sources,	   academic	   collaborators,	   and	   from	   the	   biotech	   and	  pharmaceutical	  industries.	  The	  drugs	  are	  tested	  in	  more	  than	  1000	  characterized	  human	  cancer	   cell	   lines	   and	   an	   incorporation	   of	   genomic	   analyses	   to	   identify	   drug	   response	  biomarkers	   and	   correlate	   them	   with	   the	   drug	   sensitivity	   patterns	   are	   in	   continued	  progress	  (Yang	  et	  al.	  2012).	  	   There	  is	  an	  enormous	  scientific	  and	  economic	  cost	  saving	  by	  the	  general	  access	  to	  previously	  published	  data.	   It	  allows	  the	  reanalysis	  of	  existing	  data	  to	  address	  different	  questions	   and	   the	   possibility	   to	   integrate	   and	   combine	   different	   data	   types	   giving	  enormous	  perspectives	  for	  leading	  research	  forward.	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1.3 Correlations	  in	  Cellular	  Biology	  	  	   Correlation	  is	  a	  statistical	  method	  used	  to	  evaluate	  the	  presence	  or	  not	  of	  a	  linear	  relationship	   between	   two	   variables	   and	   is	  measured	   by	   the	   correlation	   coefficient	   (r)	  (Mukaka	   2012).	   The	   correlation	   coefficient	   gives	   the	   strength	   of	   the	   association.	   The	  calculated	   r	   is	   a	  dimensionless	  quantity	  between	  –1	  and	  1,	  with	   –1	   a	  perfect	  negative	  correlation,	   1	   a	   perfect	   positive	   correlation,	   and	   0	   indicating	   the	   absence	   of	   a	  relationship	  among	  the	  two	  variables.	  A	  negative	  r	   indicates	  that	  the	  two	  variables	  are	  indirectly	  related,	  meaning	  that	  when	  the	  value	  of	  one	  variable	  goes	  up,	  the	  value	  of	  the	  other	   one	   goes	   down.	   On	   the	   other	   hand,	   a	   positive	   r	   shows	   that	   the	   variables	   are	  directly	  related:	  when	  the	  value	  of	  one	  variable	  goes	  up,	  the	  value	  of	  the	  second	  variable	  behaves	   the	   same	   (Fenton	  &	  Neil	   2012,	  Mukaka	   2012,	  McDonald	   2009).	   In	   statistical	  terms,	   any	   other	   form	   of	   relation	   that	   does	   not	   follow	   linearity	   is	   not	   a	   correlation	  (Mukaka	   2012).	   The	   calculation	   of	   a	   correlation	   or	   a	   linear	   regression	   needs	   two	  measurement	   variables	   (the	   ones	   that	   will	   be	   tested	   in	   order	   to	   find	   or	   not	   a	   linear	  relation)	   and	   a	   nominal	   variable.	   The	   nominal	   variable	   is	   not	   used	   directly	   for	   the	  calculation	   but	   is	   necessary	   to	   attribute	   the	   common	   measurements	   to	   the	   two	  measurement	  variables	  putting	  them	  together,	  for	  example	  a	  patient	  ID,	  a	  gene	  name,	  a	  cell	  line,	  etc.	  (McDonald	  2009).	  	  	   There	  are	  mainly	  two	  ways	  to	  calculate	  the	  correlation	  coefficients:	  the	  Pearson's	  product	  moment	  correlation	  coefficient	  and	  the	  Spearman's	  rank	  correlation	  coefficient.	  Pearson	  correlation	  is	  the	  most	  common	  statistical	  test	  used	  to	  evaluate	  the	  presence	  of	  a	  linear	  relationship	  between	  two	  variables	  and	  is	  the	  one	  used	  when	  the	  variables	  are	  normal	  distributed	  (data	  distributed	  in	  a	  bell-­‐shape	  curve).	  Otherwise,	  Spearman's	  rank	  correlation	  is	  used	  when	  the	  data	  show	  skewness	  (non-­‐normal	  distributed	  data	  with	  the	  presence	   of	   an	   asymmetry	   in	   the	   distribution),	   or	   one	   of	   the	   variables	   is	   ordinal	  (categorical)	  and	   is	  robust	  when	  outliers	  are	  present	  (Mukaka	  2012,	  McDonald	  2009).	  However,	  controversial	  information	  is	  found	  about	  the	  better	  performance	  test	  in	  non-­‐normal	   distributed	   data.	   While	   some	   authors	   indicate	   that	   Pearson's	   formula	   is	  inadequate	  when	  one	  or	  both	  variables	  do	  not	  distribute	  normal	  (Mukaka	  2012)	  others	  point	  out	  that	  Pearson's	  formula	  is	  sufficiently	  robust	  to	  deal	  with	  non-­‐normal	  data	  and	  that	   should	   not	   be	   worried	   about	   when	   using	   regression	   or	   correlation	   coefficients	  (McDonald	  2009).	  As	  stated	  by	  Chok	  (2010):	  “Pearson's	  correlation	  coefficient	  could	  have	  
significant	   advantages	   for	   continuous	   non-­normal	   data,	   which	   does	   not	   have	   obvious	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outliers.	  Thus,	   the	  shape	  of	   the	  distribution	  should	  not	  be	  a	  sole	  reason	   for	  not	  using	  the	  
Pearson	   product	   moment	   correlation	   coefficient”.	   Moreover,	   Bishara	   &	   Hittner	   (2012)	  tested	  12	  different	  methods	  in	  non-­‐normal	  distributed	  data	  to	  calculate	  correlations	  and	  concluded	  that	  Pearson's	   formula	  performs	  better	  after	  data	   transformation	  than	  non-­‐parametric	   statistics	   like	   Spearman's.	   Important	   to	   highlight	   that	   when	   outliers	   are	  present,	   type	   I	  and	   II	  errors	  appear	  with	   the	  Pearson	  algorithm	  but	   there	  are	  ways	   to	  solve	  that.	  An	  increase	  in	  the	  robustness	  of	  Pearson	  in	  non-­‐normal	  distributed	  data	  with	  outliers	  is	  done	  excluding	  the	  outlier	  or	  transforming	  the	  data	  to	  a	  normal	  shape	  before	  running	   Pearson	   correlations	   (Bishara	   &	   Hittner	   2012,	   McDonald	   2009).	   A	  transformation	   can	  be	  done	  using	   log-­‐transformed	  data,	  natural	   log-­‐transformed	  data,	  transformation	   to	   rank	   scores,	   square-­‐root	   transformation,	   etc.	   (Bishara	   &	   Hittner	  2012).	   Existing	   infinitive	  ways	   to	   transform	   the	   data	   to	   perform	   a	   properly	   statistical	  analysis	  of	  the	  data	  leaves	  them	  to	  follow	  a	  normal	  distribution	  (McDonald	  2009).	  	   In	   Pearson's	   product	   moment	   correlation,	   the	   null	   hypothesis	   (H0)	   is	   that	   no	  relation	  between	  the	  two	  variables	  is	  present,	  meaning	  that	  the	  r	  coefficient	  is	  equal	  to	  0,	   therefore	  a	  positive	  or	  negative	  r	   indicates	  a	  direct	  or	   inverse	  relation,	  respectively.	  The	  significance	  of	  the	  correlation	  analysis	  is	  calculated	  using	  the	  p-­‐value.	  H0	  is	  rejected	  when	  the	  p-­‐value	  is	  less	  than	  0.05.	  A	  significant	  level	  (p-­‐value)	  of	  0.05	  indicates	  the	  risk	  of	  finding	  a	  correlation	  when	  no	  relation	  exists,	  in	  percentages	  this	  means	  that	  there	  is	  a	  5%	   probability	   of	   getting	   a	   relation	   when	   no	   relation	   actually	   exists	   (Fenton	   &	   Neil	  2012).	   Rejecting	   the	   null	   hypothesis	   when	   it	   actually	   is	   true	   is	   called	   type-­‐I	   error	   or	  significance	  level	  (false	  positive	  or	  to	  find	  a	  relation	  when	  no	  relation	  exists).	  A	  type-­‐II	  error	   is	   to	   accept	  H0	  when	   it	   is,	   in	   fact,	   false	   (false	  negative	   or	   to	  not	   find	   an	   existing	  relation).	  	   One	  important	  and	  widespread	  use	  of	  correlation	  coefficients	  in	  cellular	  biology	  is	  the	  use	  of	  Pearson's	  correlations	  on	  fluorescence	  microscopy	  as	  a	  statistic	  to	  quantify	  colocalization.	   Karl	   Pearson	   developed	   the	   correlation	   coefficient	   in	   1896	   and	   almost	  100	   years	   later	   Manders	   introduced	   its	   use	   in	   microscopy	   (Dunn	   et	   al.	   2011).	   For	  evaluating	   the	   colocalization	   of	   two	   or	   more	   different	   fluorescence	   labels,	   almost	   all	  image	  analysis	  software	  uses	  Pearson	  coefficients	  to	  correlate	  the	  overlap	  of	  the	  pixels	  measuring	  the	  covariance	   in	  the	  signal	   level	  of	   the	   images	  (Dunn	  et	  al.	  2011).	  Pearson	  correlation	   has	   been	   used	   also	   for	   searching	   relations	   between	   gene	   expression	   and	  cancer	   (Győrffy	   et	   al.	   2016,	   Liu	   et	   al.	   2014).	   Győrffy	   et	   al.	   used	   Pearson	   correlation	  analysis	   to	   search	  correlations	  between	  gene	  expression,	  breast	   cancer	  prognosis,	   and	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the	  DNA	  methylation	  of	  genes.	  They	   found	  48	  genes	   that	  were	  significantly	  associated	  with	   breast	   cancer	   prognosis	   (p	   <	   0.05)	   and	   32	   of	   these	   prognostic	   genes	   showed	   a	  direct	   correlation	   between	   its	   expression	   and	   its	   DNA	   methylation	   confirming	   that	  epigenetic	  aberrations	  like	  DNA	  methylations	  are	  associated	  with	  breast	  cancer	  features	  (Fleisher	   et	   al.	   2014).	   Liu	   et	   al.	   (2014)	   performed	   gene	   expression	   analyses	   of	  hepatocellular	   carcinoma	   tissues	   and	   found	   that	   miR-­‐122	   levels	   correlated	   with	  glycolytic	   genes	   and	   that	   pyruvate	   kinase	   showed	   a	   highly	   significant	   negative	  correlation	  with	  the	  miRNA	  (p	  <	  0.0001).	  Furthermore,	  Pearson	  correlation	  analysis	  has	  been	  used	   to	  search	   transcription	   factor	   target	  genes.	  The	  expression	   levels	  of	  a	  given	  transcription	   factor	   is	   correlated	   with	   the	   expression	   of	   candidate	   target	   genes.	   The	  relations	  obtained	  are	  corroborated	  by	  biochemical	  and	  functional	  analysis	  (Mansson	  et	  al.	   2004).	   Moreover,	   gene	   expression	   levels	   also	   have	   been	   correlated	   using	   Pearson	  correlation	   on	   chemosensitivity	   in	   order	   to	   find	   candidate	   genes	   associated	   with	   a	  sensitivity	   of	   anticancer	   drugs	   in	   cancer	   cell	   lines	   (Nakamura	   et	   al.	   2009).	   Other	  important	   uses	   of	   Pearson	   correlations	   are	   in	   attempts	   to	   find	   improvement	   in	   drug	  treatment	   of	   cancer,	   like	   in	   the	   prediction	   of	   anticancer	   drug	   responses	   using	  information	  of	  cell	   line	  similarity	  network	  data	  and	  drug	  similarity	  network	  data	   from	  the	  Cancer	  Cell	  Line	  Encyclopedia	  and	  Cancer	  Genome	  Project	  public	  databases	  (Zhang	  et	  al.	  2015).	  	  	   The	  aim	  of	  this	  study	  has	  been	  to	  perform	  a	  large	  number	  of	  assays	  in	  different	  human	  cell	   lines	   to	  characterize	   the	   inherent	  electrical	  and	  metabolic	  properties.	  Data	  on	  cellular	  features	  were	  used	  to	  search	  for	  correlations	  between	  gene	  expression	  of	  the	  entire	   genome	   and	   drug	   sensitivity	   of	   the	   cells.	   In	   addition	   to	   confirming	   some	  previously	   well-­‐known	   relations,	   we	   found	   a	   sizeable	   amount	   of	   new	   relationships	  between	   cellular	   features	   and	   new	   candidate	   genes	   that	   may	   involve	   in	   cancer	  metabolism.	   Moreover,	   the	   sensitivity	   of	   cancer	   cells	   to	   widespread	   drugs	   was	  associated	   with	   certain	   cellular	   properties,	   giving	   further	   insights	   for	   possible	  improvements	  in	  cancer	  drug	  treatment.	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2. Experimental	  Methods	  
	  
2.1 Cellular	  Properties	  Acquisition	  
	  
2.1.1 Cell	  Cultures	  
	  Human	   cell	   lines	   were	   cultivated	   under	   standard	   conditions	   in	   Dulbecco's	  modified	  eagle	  medium	  (DMEM)	  (PAA	  Laboratories)	  supplemented	  with	  10%	  FBS	  (v/v)	  (PAA	  Laboratories)	  and	  1%	  PenStrep	   (10,000	  units/ml	  penicillin	  and	  10,000	  units/ml	  streptomycin)	  (Gibco	  Invitrogen)	   in	  a	  5%	  CO2	   incubator	  at	  37°C	  with	  a	  95%	  humidity.	  When	  confluence	  arrived	  cells	  were	  split	  under	  sterile	  conditions.	  The	  detachment	  of	  the	  cells	   from	   the	   flask	  was	   done	   by	   using	   a	   trypsin	   substitute	   TrypLE	   Express	   (Thermo	  Fisher),	  afterwards	  washed	  with	  Dulbecco’s	  phosphate	  buffered	  saline	  (DPBS)	  (Thermo	  Fisher)	  and	  recultivated,	  seeded	  or	  directly	  used	  for	  further	  analysis.	  The	  cell	  lines	  used	  in	  this	  study	  are	  shown	  in	  Table	  1.	  	  	  
Table	  1.	  List	  of	  cell	  lines	  used	  in	  this	  work	  	  
Cell	  line	   Tissue	   Disease	   Cell	  type	  MCF7	   Breast	   Adenocarcinoma	   Epithelial	  MDA-­‐MB-­‐231	   Breast	   Adenocarcinoma	   Epithelial	  HCT	  116	   Colon	   Carcinoma	   Epithelial	  HT-­‐29	   Colon	   Carcinoma	   Epithelial	  LS174T	   Colon	   Adenocarcinoma	   Epithelial	  AsPC-­‐1	   Pancreas	   Adenocarcinoma	   *	  BxPC-­‐3	   Pancreas	   Adenocarcinoma	   Epithelial	  JoPaca-­‐1	   Pancreas	   Carcinoma	   *	  MIA	  PaCa-­‐2	   Pancreas	   Carcinoma	   Epithelial	  Panc-­‐1	   Pancreas	   Carcinoma	   Epithelial	  LNCaP	   Prostate	   Adenocarcinoma	   Epithelial	  PC-­‐3	   Prostate	   Adenocarcinoma	   Epithelial	  DU	  145	   Prostate	   Carcinoma	   *	  HaCaT	   Skin	   No	  malignancy	   Keratinocyte	  MDA-­‐MB-­‐435	   Skin	   Melanoma	   Melanocyte	  HeLa	   Cervix	   Adenocarcinoma	   Epithelial	  Hep	  G2	   Liver	   Carcinoma	   Epithelial	  1321N1	   Central	  nervous	  system	   Astrocytoma	   Glial	  *Not	  specified
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2.1.2 Online	   Monitoring	   of	   Membrane	   Capacitance	   and	   Cellular	  
Metabolism	  
	  Bionas	   Discovery	   2500	   instrument	   (Bionas	   GmbH)	   was	   used	   to	   measure	   the	  glycolytic	   activity,	   respiration,	   and	   the	   capacitance	   of	   cells	   seeded	   in	   sensor	   chips	  (Bionas	  Discovery	  SC1000)	  in	  real	  time	  (Fig.	  1).	  	  	   The	  glycolytic	   and	   respiratory	  activities	   are	   indirectly	  measured	  as	  pH	  changes	  and	  oxygen	  depletion	  in	  the	  media,	  respectively.	  The	  capacitance	  is	  measured	  directly	  by	  the	  sensor.	  To	  estimate	  glycolysis,	  respiration,	  and	  to	  measure	  capacitance	  each	  Bionas	  sensor	   chips	   contains	   five	   pH	   ISFET	   sensors	   (ion-­‐sensitive	   field-­‐effect	   transistors)	  (Bergveld	   1981),	   two	   Clark-­‐type	   electrode	   sensors	   (Clark	   et	   al.	   1953)	   and	   one	   IDES	  sensor	  (Interdigitated	  Electrodes)	  (Ehret	  et	  al.	  1997).	  	  	   The	   pH	   ISFET	   sensors	   measure	   the	   pH	   changes	   by	   detecting	   ion	  concentrations	   in	   solution.	   The	   current	   between	   the	   reference	   electrode	   and	   the	  electrode	   in	   the	   solution	   changes	   according	   to	   the	   ion	   concentration	   in	   the	   media.	  Acidification	   in	   cancer	   cells	   is	   mainly	   due	   to	   lactic	   acid	   production	   at	   the	   end	   of	   the	  glycolysis.	  	  	   The	  Clark	   sensor	  measures	   the	   free	   oxygen	   in	   the	  media.	   A	   fixed	   voltage	   is	  applied	  to	  the	  sensor,	  which	  contains	  a	  cathode	  and	  an	  anode.	  In	  the	  platinum	  cathode,	  the	   oxygen	   in	   the	  media	   is	   reduced	  while	   silver	   is	   oxidized	   in	   the	   anode	   generating	   a	  current.	  The	  current	  that	  is	  produced	  is	  proportional	  to	  the	  oxygen	  reduced.	  	  	   The	  membrane	   capacitance	   of	   the	   cells	   is	   measured	   by	   the	   IDES	   sensor.	  Alterations	  in	  the	  capacitance	  value	  of	  the	  cells	  are	  the	  product	  of	  the	  changes	  in	  cellular	  morphology,	   adhesion/confluence,	   cell-­‐cell	   contacts	   and	   cell-­‐matrix	   binding.	   The	   IDES	  sensor	   contains	   an	   interdigitated	   palladium	   electrode	   pair	   in	   which	   an	   alternating	  current	  is	  applied.	  The	  flow	  of	  the	  current	  through	  the	  two	  electrodes	  is	  interrupted	  by	  the	  cells	  that	  adhere	  to	  the	  sensor	  surface,	  and	  such	  interruption	  is	  recorded.	  	  	   The	  Bionas	  2500	   system	  allows	   reading	  of	   six	   independent	   chips.	   The	   influx	  of	  new	  media	  and	  an	  outflux	  of	  the	  used	  media	  are	  done	  in	  the	  fluid	  head	  of	  "biomodules"	  (Fig.	  1).	   In	  each	  chip	  a	  different	  cell	   line	  can	  be	  seeded.	  The	  perfusion	  system	  supplies	  the	   cells	   with	   a	   constant	   flow	   of	   medium	   (running	   medium)	   and	   enables	   to	   do	  noninvasive,	   label-­‐free	   measurements.	   The	   Bionas	   running	   medium	   consists	   of	  ultrapure	   water	   (Werner	   Reinstwassersysteme)	   with	   1mM	   HEPES,	   1	   g/l	   glucose,	   10	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mg/l	   phenol	   red,	   8.22	   g/l	   DMEM	   powder,	   1%	   PenStrept,	   0.1%	   FCS	   and	   2	   mM	   L-­‐glutamine.	   The	   pH	   was	   adjusted	   to	   7.4	   and	   the	   running	   medium	   was	   sterilized	   by	  filtration	  with	  a	  0.2	  μm	  hydrophobic	  filter	  (Millipore).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Fig.	  1.	  Real-­time	  monitoring	  of	  cell	  properties	  with	  the	  Bionas	  Discovery	  2500	  instrument	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2.1.2.1 Sensor	  Chip	  Seeding	  
	  Confluent	   cell	   cultures	   were	   used	   to	   seed	   ~200,000	   cells	   per	   chip	   in	   450	   μl	  DMEM	  medium	   supplemented	   with	   10%	   FCS	   and	   1%	   PenStrept.	   Before	   seeding,	   the	  chips	  were	   sterilized	  with	  ethanol	  70%	   for	  20	  min	  and	  washed	  with	  PBS	   three	   times.	  Chips	  with	  cells	  were	  incubated	  overnight	  with	  5%	  CO2	  at	  37°C	  and	  95%	  humidity	  in	  a	  cell	  culture	  incubator.	  	  
2.1.2.2 Measurements	  	  
	  Before	   the	   cell-­‐loaded	   sensor	   chips	   were	   placed	   in	   the	   system	   and	   the	  measurement	   program	   started,	   the	   Bionas	   tubes	   were	   disinfected	   with	   ethanol	   70%.	  The	  disinfection	  program	  consists	  in	  sterilization	  with	  a	  continuous	  ethanol	  70%	  flow	  of	  12	  min,	  followed	  by	  4	  min	  of	  rinsing	  with	  PBS.	  Finally,	  the	  tubes	  were	  filled	  with	  running	  medium.	  The	  measurement	  program	  performs	  a	   cycle	  of	  4	  min	   "go"	   and	  4	  min	   "stop"	  with	  running	  medium.	  In	  the	  4	  min	  "go"	  step	  the	  system	  injects	  running	  medium	  with	  a	  constant	  flow	  of	  56	  μl/min	  and	  in	  the	  "stop"	  step	  leaves	  the	  cells	  with	  ~6	  μl	  of	  medium.	  At	   that	  point,	   the	   cells	  will	   consume	  oxygen	  and	  acidify	   the	  media.	  At	   the	  end	  of	   each	  cycle	   a	   measurement	   of	   the	   acidification	   of	   the	   media	   (as	   voltage	   in	   time	   μV/s),	   the	  cellular	  oxygen	  consumption	  (as	  current	   in	   time	  pA/s),	  and	   the	  cellular	  capacitance	   in	  nF	  are	  taken.	  To	  prevent	  contamination,	  a	  cleaning	  program	  was	  run	  at	  the	  end	  of	  each	  experiment.	  This	  program	  consists	  of	  30	  min	  constant	  flow	  of	  ethanol	  70%.	  Finally,	  the	  cleaning	  program	  removes	  all	  the	  liquid	  from	  the	  tubes	  by	  pumping	  air.	  
	  
2.1.2.3 Data	  Collection	  and	  Analysis	  
	  Data	   for	   the	   glycolytic	   activity	   estimation,	   cellular	   respiration,	   and	   cellular	  capacitance	   were	   obtained	   from	   the	   Bionas	   analyzer	   data	   file.	   Selected	   data	   contain	  measurements	   of	   human	   cell	   lines,	   cultivated	   under	   standard	   conditions	   (in	   DMEM	  supplemented	  with	  10%	  FCS	  and	  1%	  PenStrept	  in	  a	  5%	  CO2	  incubator	  at	  37°C)	  run	  with	  a	  4	  min	  "go"	  and	  4	  min	  "stop"	  cycle,	  and	  for	  which	  at	  least	  4	  independent	  experiments	  were	   performed.	   Eighteen	   cell	   lines	   met	   the	   quality	   requirements	   and	   the	   total	   data	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generated	  by	  the	  sensors	  from	  ~1,300	  chips	  was	  used	  for	  the	  analysis.	  The	  analyzer	  data	  files	   contain	   sensor	   measurements	   at	   a	   time	   point	   in	   which	   the	   cells	   showed	   stable	  cellular	   metabolism.	   This	   status	   was	   achieved	   around	   4	   h	   from	   the	   start	   of	   the	  measurement	  program.	  The	  analyzer	  data	  files	  were	  collected	  with	  the	  R	  programming	  
language	  for	  statistical	  computing	  and	  graphics	  (Team,	  R.	  Core	  2015)	  versions	  2.7.0	  and	  3.2.1	  (Supplements	  5.1.1).	  	  	  
2.1.3 End	  Point	  Assays	  to	  Measure	  Cellular	  Metabolism	  
	  
2.1.3.1 Adenosine	  Triphosphate	  (ATP)	  Production	  
	  The	  amount	  of	   extracellular	  ATP	   in	   the	  different	   cell	   lines	  was	  measured	  using	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer)	  and	  read	  in	  a	  Tecan	  ULTRA	  plate-­‐reader.	  The	  ATPlite	  1step	  estimates	  the	  amount	  of	  ATP	  based	  on	  the	  firefly	  (Photinus	  pyralis)	   luciferase	  activity.	  Light	  emitted	  by	  the	  ATP	  +	  luciferase	  +	  D-­‐luciferin	  reaction	  is	  proportional	  to	  the	  ATP	  concentration.	  	   The	   measurements	   were	   done	   according	   to	   the	   manufacturer's	   instructions.	  Briefly,	  cells	  were	  seeded	  in	  96-­‐well	  plates	  and	  ~10,000	  cells	  per	  well	  were	  used.	  Plates	  were	  incubated	  under	  standard	  conditions	  for	  24	  h.	  Before	  adding	  the	  ATP	  reagent	  the	  plates	  were	  taken	  out	  from	  the	  incubator	  and	  kept	  at	  room	  temperature	  for	  30	  min.	  To	  each	  well,	  100	  μl	  of	  DMEM	  (without	  FCS)	  plus	  100	  μl	  of	  the	  ATP	  reagent	  was	  added.	  The	  cell	  suspension	  was	  shook	  for	  2	  min	  in	  the	  dark	  at	  700	  rpm	  in	  a	  thermo-­‐mixer,	  and	  the	  luminescence	   was	   measured	   in	   a	   Tecan	   Safire	   microplate	   reader.	   Per	   cell	   line,	   three	  technical	  replicates	  and	  at	  least	  three	  independent	  measurements	  were	  carried	  out.	  	  
2.1.3.2 Mitochondrial	  Mass	  Content	  
	  The	   mitochondrial	   mass	   content	   of	   the	   cells	   in	   the	   different	   cell	   lines	   was	  estimated	   using	   MitoTracker	   Green	   =	   benzoxazolium,	   2-­‐[3-­‐[5,6-­‐dichloro-­‐1,3-­‐bis[[4-­‐(chloromethyl)	  phenyl]methyl]-­‐1,3-­‐dihydro-­‐2H-­‐benzimidazol-­‐2-­‐ylidene]-­‐1-­‐propenyl]-­‐3-­‐methyl	  chloride	  201860-­‐17-­‐5	  (Thermo	  Fisher).	  MitoTracker	  diffuses	   into	   the	  cells	  and	  labels	  active	  mitochondria.	  Cells	  were	   trypsinized	   for	  15	  to	  20	  min	  until	  getting	  single	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cells.	   The	   trypsinization	   was	   stopped	   with	   DMEM	   and	   ~250,000	   cells	   were	   used	   to	  estimate	   the	  mitochondrial	   mass.	   The	   cells	   were	   centrifuged	   for	   3	   min	   at	   1,600	   rpm	  (Heraeus	  Multifuge	  Thermo	  Electronic)	  and	  washed	  two	  times	  with	  DPBS.	  Prewarmed	  (37°C)	  MitoTracker	  Green	  at	  a	  final	  concentration	  of	  7.5	  nM	  in	  DMEM	  (without	  FCS)	  was	  used	  to	  resuspend	  the	  cell	  pellet.	  The	  cell	  suspension	  was	  incubated	  by	  shaking	  for	  30	  min	  in	  the	  dark,	  repelleted	  and	  resuspended	  in	  prewarmed	  (37°C)	  DMEM	  without	  FCS.	  Mitochondrial	  mass	  was	  measured	  by	  flow	  cytometry	  using	  a	  FACSCalibur	   instrument.	  Excitation	  and	  emission	  settings	  were	  490	  nm	  and	  516	  nm,	  respectively	  (FL1	  filter).	  At	  least	  three	  independent	  measurements	  were	  done	  per	  cell	  line.	  	  
2.1.3.3 Reactive	  Oxygen	  Species	  (ROS)	  Accumulation	  
	  ROS	  accumulation	   in	   cells	  was	  measured	  using	  dihydroethidium	  (DHE)	   (Sigma-­‐Aldrich).	   DHE	   permeates	   cell	   membranes	   and	   freely	   diffuses	   to	   the	   cytosol	   where	   it	  exhibits	   blue	   fluorescence,	   until	   oxidized	   by	   superoxide	  when	   it	   turns	   into	   a	   product	  showing	   red	   fluorescence,	   and	   is	   retained	   by	   the	   cells.	   Cells	   were	   detached	   from	   the	  culture	  flask	  by	  trypsinization	  for	  10	  min.	  The	  reaction	  was	  stopped	  with	  DMEM.	  Cells	  were	  pelleted	  and	  resuspended	  in	  500	  μl	  DMEM	  (without	  FCS)	  containing	  7.5	  μM	  DHE.	  The	  cell	  suspension	  was	   incubated	   for	  15	  min	   in	   the	  dark	  with	  shaking	  and	  repelleted	  and	  later	  resuspended	  in	  DMEM	  without	  FCS.	  Accumulation	  of	  ROS	  was	  measured	  using	  the	  FACSCalibur	   flow	  cytometer	   (Becton	  Dickinson).	  The	  excitation	  was	  set	  at	  488	  nm	  and	   emission	   at	   564–606	   nm	   (FL2	   filter).	   At	   least	   three	   independent	   measurements	  were	  done	  per	  cell	  line.	  	  
2.1.3.4 Proliferation	  Assays	  
	  To	  estimate	  the	  proliferation	  rate	  of	  the	  different	  cell	  lines,	  data	  from	  nontreated	  cells	  obtained	  from	  at	  least	  three	  independent	  measurements	  was	  used.	  Values	  obtained	  represent	   the	   mean	   of	   three	   technical	   replicates.	   All	   the	   data	   collected	   comes	   from	  experiments	  employing	  standard	  culture	  conditions.	  Confluent	  cells	  were	  plated	  in	  96-­‐well	   plates,	   3,000	   cells	   per	  well,	   incubated	   in	  DMEM	  medium	   for	   72	   h	   at	   37°	   C	   in	   an	  incubator	  set	  with	  5%	  CO2	  and	  95%	  humidity.	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   The	   proliferation	   rate	   of	   each	   cell	   line	   was	   determined	   using	   two	   different	  approaches;	   MTT	   =	   3-­‐(4,5-­‐dimethylthiazolyl-­‐2)-­‐2,5-­‐diphenyltetrazolium	   bromide	  reagent	   (Sigma-­‐Aldrich)	   and	   SRB	   =	   sulforhodamine	   B	   reagent	   (Sigma-­‐Aldrich).	   MTT	  penetrates	   viable	   eukaryotic	   cells.	   Cells	   with	   a	   mitochondrial	   activity	   reduce	   MTT	  producing	  a	  purple-­‐colored	  product.	  The	  SRB	  assay	  measures	  the	  total	  protein	  content.	  The	   dye	   is	   incorporated	   into	   fixed	   cells	   and	   the	   amount	   of	   incorporated	   dye	   is	  proportional	   to	   the	  amount	  of	   cells	   (Vichai	  &	  Kanyawim	  2006).	  The	   specific	  protocols	  are	  shown	  below:	  	  
MTT:	  The	  medium	  of	  the	  cells	  in	  the	  96-­‐well	  plates	  was	  replaced	  with	  100	  µl	  DMEM	  1%	  FCS	  containing	  0.5	  mg/ml	  MTT	  reagent	  per	  well.	  Plates	  were	  then	  incubated	  for	  3	  h	  at	  37°C	   in	   a	  5%	  CO2	   incubator.	  The	  absorbance	  was	  measured	   in	   a	  Tecan	  Safire	   (Tecan)	  microplate	  reader	  at	  595	  nm	  adding	  200	  µl	  per	  well	  of	  DMSO	  (Sigma-­‐Aldrich).	  	  	  
SRB:	  Cells	  were	  fixed	  with	  10%	  (w/v)	  cold	  trichloroacetic	  acid	  (Sigma-­‐Aldrich)	  for	  1	  h	  at	  4°C.	  The	  trichloroacetic	  acid	  was	  removed	  washing	  the	  plates	  carefully	  with	  water	  two	  times.	  The	  excess	  of	  water	  was	  removed	  with	  a	  paper	  towel	  by	  tapping	  the	  plate	  several	  times.	  The	  rest	  of	  water	  in	  the	  plates	  was	  evaporated	  in	  an	  oven	  at	  56°C.	  Dry	  cells	  were	  stained	  with	  SRB	  for	  30	  min	  at	  room	  temperature	  by	  adding	  100	  µl	  of	  0.057%	  (w/v)	  SRB	  in	   1%	   acetic	   acid	   (Sigma-­‐Aldrich)	   in	   each	   well.	   The	   excess	   of	   dye	   was	   removed	   by	  washing	  three	  times	  with	  1%	  (v/v)	  acetic	  acid	  (200	  µl	  per	  well).	  The	  plates	  were	  dried	  in	  an	  oven	  at	  56°C.	  The	  boundary	  between	  the	  SRB	  and	  the	  proteins	  was	  dissolved	  in	  10	  mM	  Tris	   (pH	   10.5)	   adding	   200	   µl	   per	  well	   and	   shaking	   them	   for	   10	  min.	   The	   optical	  density	  determination	  was	  done	  at	  510	  nm	  in	  a	  Tecan	  Safire	  microplate	  reader.	  	  
2.2 Hierarchical	  Clustering	  
	  To	  group	  the	  cell	   lines	  based	  on	  metabolic	   features	  or	  gene	  expression,	  clusters	  were	   drawn	   using	   R	   programming	   language	   packages	   plyr	   version	   1.8.4	   library	   plyr	  (Wickham	   2011)	   and	   rafalib	   version	   1.0.0	   library	   rafalib	   (Irizarry	   &	   Love	   2016)	   The	  cluster	  method	  used	  was	  the	  hierarchical	  clustering	  with	  the	  hclust	  function,	  Euclidean	  distance	  and	  method	  complete	  (Supplements	  5.1.6).	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2.3 Gene	  Expression	  Analyses	  
	  Raw	  data	   (.CEL	   files)	   from	   gene	   expressions	   obtained	   using	   Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  were	  obtained	   from	  GEO,	  NCBI	   (De	  Schutter	  et	   al.	   2013,	  Barretina	  et	  al.	  2012).	  The	  according	  public	  accession	  numbers	  and	  cell	  lines	  are	  listed	  in	  Table	  2.	  All	  the	  analyzed	  data	  comes	  from	  cell	  lines	  cultivated	  in	  DMEM	  supplemented	  with	   10%	   FCS	   in	   a	   5%	   CO2	   incubator	   at	   37°C.	   Data	   for	   HaCaT	   and	   HeLa	   lines	   were	  available	  in	  triplicate;	  a	  mean	  of	  the	  calculated	  expression	  value	  was	  used.	  	  	   	  
Table	  2.	  Cell	  lines	  and	  gene	  accession	  numbers	  
	  
Cell	  line	   Gene	  accession	  number	  MCF7	   GSM887291	  MDA-­‐MB-­‐231	   GSM887295	  HCT	  116	   GSM887062	  HT-­‐29	   GSM887141	  AsPC-­‐1	   GSM886870	  BxPC-­‐3	   GSM886896	  MIA	  PaCa-­‐2	   GSM887320	  PANC-­‐1	   GSM887501	  LNCaP	   GSM887271	  PC-­‐3	   GSM887506	  DU	  145	   GSM886988	  MDA-­‐MB-­‐435	   GSM887298	  Hep	  G2	   GSM887079	  1321N1	   GSM886835	  HeLa	  control	  a	   GSM960275	  HeLa	  control	  b	   GSM960283	  HeLa	  control	  c	   GSM960291	  HaCaT	  control	  a	   GSM960278	  HaCaT	  control	  b	   GSM960286	  HaCaT	  control	  c	   GSM960294	  	  	  	   Preprocessing	   of	   the	   .CEL	   files	  was	   done	   using	   the	  Robust	  Multi-­‐array	  Average	  (RMA)	   normalization	   method	   (Irizarry	   et	   al.	   2003).	   This	   method	   allows	   background	  subtraction,	   quantile	   normalization,	   and	   summarization	   (calculation	   of	   expression	  values).	  RMA	  was	  applied	  in	  all	  probe	  sets	  belonging	  to	  the	  16	  cell	  lines	  listed	  in	  Table	  2.	  RMA	   calculations	  were	   done	   using	   Bioconductor	   (Huber	   et	   al.	   2015),	   an	   open	   source	  software	   for	  bioinformatics	   that	  uses	  R	  statistics	  programming	   language.	  Bioconductor	  version	  3.2	  was	  run	  under	  R	  version	  2.7.0.	  For	  the	  calculation,	  the	  package	  affy	  version	  1.32.0	   and	   the	   annotation	   package	   pd.ht.hg.u133.plus.pm	   were	   used	   (Gautier	   et	   al.	  2004).	  The	  RMA	   function	   (rma())	  was	   run	  with	   the	  default	   options	   (normalize=TRUE,	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background=TRUE)	  (Supplements	  5.1.2).	  Official	  gene	  symbols	  were	  downloaded	  from	  affymetrix.com	   and	   the	   comma	   separated	   value	   file	   HGU133.Plus2.na34.annot.csv	  was	  used.	  	  
2.3.1 Selection	   of	   Genes	   Related	   to	   Metabolism	   Pathways	   with	   Extreme	  
Expression	  in	  the	  Affymetrix	  Array	  
	  The	   Entrez	   gene	   ID	   belonging	   to	   the	   glycolysis-­‐gluconeogenesis,	   pentose	  phosphate,	   tricarboxylic	  acid	  cycle	  (TCA),	  and	  electron	  transport	  chain	  pathways	  were	  downloaded	  from	  Wikipathways	  (Kelder	  et	  al.	  2011).	  The	  entire	  downloaded	  gene	  lists	  regards	   Homo	   sapiens.	   The	   specific	   Wikipathways	   used	   were:	   WP134	   for	   pentose	  phosphate,	   WP534	   for	   glycolysis-­‐gluconeogenesis,	   WP78	   for	   TCA,	   and	   WP111	   for	  respiratory	   electron	   transport	   chain	   pathways.	   The	   Entrez	   gene	   identifiers	   acquired	  from	  Wikipathways	  were	  uploaded	   in	  DAVID	  6.7	   (Huang	  et	   al.	   2009).	  DAVID	   is	   a	   free	  online	  bioinformatics	  resource	  database	  for	  annotation	  and	  gene	  list	  visualization.	  Using	  the	  gene	  ID	  conversion	  tool	  from	  DAVID,	  the	  official	  gene	  symbols	  were	  obtained.	  A	  total	  of	  seven	  genes	  were	  selected	  for	  further	  analysis	  of	  the	  pentose	  phosphate	  pathway,	  48	  genes	   from	   glycolysis-­‐gluconeogenesis,	   and	   116	   genes	   of	   the	   TCA	   plus	   electron	  transport	  chain	  (Tables	  3,	  4,	  and	  5).	  	  	  
Table	  3.	  Entrez	   gene	   identifiers	   of	   genes	   belonging	   to	   the	   pentose	   phospate	   pathway	  WP134	  from	  Wikipathways.	  Official	  gene	  symbols	  and	  gene	  names	  were	  obtained	  with	  DAVID	  6.7	  online	  database.	   	  
Wikipathways	   DAVID	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Table	  4.	  Entrez	  gene	   identifiers	  of	  genes	  belonging	   to	   the	  glycolysis-­‐gluconeogenesis	  pathway	  WP534	   from	  Wikipathways.	  Official	  gene	  symbols	  and	  gene	  names	  were	  obtained	  with	  DAVID	  6.7	  online	  database.	   	  
Wikipathways	   DAVID	  
Identifier	   Database	   From	   To	   Species	   DAVID	  gene	  name	  226	   Entrez	  Gene	   226	   ALDOA	   Homo	  sapiens	   Aldolase,	  fructose-­‐bisphosphate	  A(ALDOA)	  229	   Entrez	  Gene	   229	   ALDOB	   Homo	  sapiens	   Aldolase,	  fructose-­‐bisphosphate	  B(ALDOB)	  230	   Entrez	  Gene	   230	   ALDOC	   Homo	  sapiens	   aldolase,	  fructose-­‐bisphosphate	  C(ALDOC)	  1737	   Entrez	  Gene	   1737	   DLAT	   Homo	  sapiens	   dihydrolipoamide	  S-­‐acetyltransferase(DLAT)	  1738	   Entrez	  Gene	   1738	   DLD	   Homo	  sapiens	   dihydrolipoamide	  dehydrogenase(DLD)	  2023	   Entrez	  Gene	   2023	   ENO1	   Homo	  sapiens	   enolase	  1(ENO1)	  2026	   Entrez	  Gene	   2026	   ENO2	   Homo	  sapiens	   enolase	  2(ENO2)	  2027	   Entrez	  Gene	   2027	   ENO3	   Homo	  sapiens	   enolase	  3(ENO3)	  2203	   Entrez	  Gene	   2203	   FBP1	   Homo	  sapiens	   fructose-­‐bisphosphatase	  1(FBP1)	  2538	   Entrez	  Gene	   2538	   G6PC	   Homo	  sapiens	   glucose-­‐6-­‐phosphatase	  catalytic	  subunit(G6PC)	  2645	   Entrez	  Gene	   2645	   GCK	   Homo	  sapiens	   glucokinase(GCK)	  2805	   Entrez	  Gene	   2805	   GOT1	   Homo	  sapiens	   glutamic-­‐oxaloacetic	  transaminase	  1(GOT1)	  2806	   Entrez	  Gene	   2806	   GOT2	   Homo	  sapiens	   glutamic-­‐oxaloacetic	  transaminase	  2(GOT2)	  2821	   Entrez	  Gene	   2821	   GPI	   Homo	  sapiens	   glucose-­‐6-­‐phosphate	  isomerase(GPI)	  3098	   Entrez	  Gene	   3098	   HK1	   Homo	  sapiens	   hexokinase	  1(HK1)	  3099	   Entrez	  Gene	   3099	   HK2	   Homo	  sapiens	   hexokinase	  2(HK2)	  3101	   Entrez	  Gene	   3101	   HK3	   Homo	  sapiens	   hexokinase	  3(HK3)	  3939	   Entrez	  Gene	   3939	   LDHA	   Homo	  sapiens	   lactate	  dehydrogenase	  A(LDHA)	  3945	   Entrez	  Gene	   3945	   LDHB	   Homo	  sapiens	   lactate	  dehydrogenase	  B(LDHB)	  3948	   Entrez	  Gene	   3948	   ldhc	   Homo	  sapiens	   lactate	  dehydrogenase	  C(LDHC)	  4190	   Entrez	  Gene	   4190	   MDH1	   Homo	  sapiens	   malate	  dehydrogenase	  1(MDH1)	  4191	   Entrez	  Gene	   4191	   MDH2	   Homo	  sapiens	   malate	  dehydrogenase	  2(MDH2)	  5091	   Entrez	  Gene	   5091	   PC	   Homo	  sapiens	   pyruvate	  carboxylase(PC)	  5105	   Entrez	  Gene	   5105	   PCK1	   Homo	  sapiens	   phosphoenolpyruvate	  carboxykinase	  1(PCK1)	  5160	   Entrez	  Gene	   5160	   PDHA1	   Homo	  sapiens	   pyruvate	  dehydrogenase	  (lipoamide)	  alpha	  1(PDHA1)	  5161	   Entrez	  Gene	   5161	   PDHA2	   Homo	  sapiens	   pyruvate	  dehydrogenase	  (lipoamide)	  alpha	  2(PDHA2)	  5162	   Entrez	  Gene	   5162	   PDHB	   Homo	  sapiens	   pyruvate	  dehydrogenase	  (lipoamide)	  beta(PDHB)	  5211	   Entrez	  Gene	   5211	   PFKL	   Homo	  sapiens	   phosphofructokinase,	  liver	  type(PFKL)	  5213	   Entrez	  Gene	   5213	   PFKM	   Homo	  sapiens	   phosphofructokinase,	  muscle(PFKM)	  5214	   Entrez	  Gene	   5214	   PFKP	   Homo	  sapiens	   phosphofructokinase,	  platelet(PFKP)	  5223	   Entrez	  Gene	   5223	   PGAM1	   Homo	  sapiens	   phosphoglycerate	  mutase	  1(PGAM1)	  5224	   Entrez	  Gene	   5224	   PGAM2	   Homo	  sapiens	   phosphoglycerate	  mutase	  2(PGAM2)	  5230	   Entrez	  Gene	   5230	   PGK1	   Homo	  sapiens	   phosphoglycerate	  kinase	  1(PGK1)	  5232	   Entrez	  Gene	   5232	   PGK2	   Homo	  sapiens	   phosphoglycerate	  kinase	  2(PGK2)	  5313	   Entrez	  Gene	   5313	   PKLR	   Homo	  sapiens	   pyruvate	  kinase,	  liver	  and	  RBC(PKLR)	  5315	   Entrez	  Gene	   5315	   PKM	   Homo	  sapiens	   pyruvate	  kinase,	  muscle(PKM)	  6513	   Entrez	  Gene	   6513	   SLC2A1	   Homo	  sapiens	   solute	  carrier	  family	  2	  member	  
	  34	  
1(SLC2A1)	  6514	   Entrez	  Gene	   6514	   SLC2A2	   Homo	  sapiens	   solute	  carrier	  family	  2	  member	  2(SLC2A2)	  6515	   Entrez	  Gene	   6515	   SLC2A3	   Homo	  sapiens	   solute	  carrier	  family	  2	  member	  3(SLC2A3)	  6517	   Entrez	  Gene	   6517	   SLC2A4	   Homo	  sapiens	   solute	  carrier	  family	  2	  member	  4(SLC2A4)	  6518	   Entrez	  Gene	   6518	   slc2a5	   Homo	  sapiens	   solute	  carrier	  family	  2	  member	  5(SLC2A5)	  7167	   Entrez	  Gene	   7167	   TPI1	   Homo	  sapiens	   triosephosphate	  isomerase	  1(TPI1)	  8050	   Entrez	  Gene	   8050	   PDHX	   Homo	  sapiens	   pyruvate	  dehydrogenase	  complex	  component	  X	  (PDHX)	  8789	   Entrez	  Gene	   8789	   FBP2	   Homo	  sapiens	   Fructose-­‐bisphosphatase	  2(FBP2)	  25874	   Entrez	  Gene	   25874	   MPC2	   Homo	  sapiens	   Mitochondrial	  pyruvate	  carrier	  2	  (MPC2)	  
26330	   Entrez	  Gene	   26330	   GAPDHS	   Homo	  sapiens	   Glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase,	  spermatogenic	  (GAPDHS)	  51660	   Entrez	  Gene	   51660	   MPC1	   Homo	  sapiens	   Mitochondrial	  pyruvate	  carrier	  1	  (MPC1)	  92483	   Entrez	  Gene	   92483	   LDHAL6B	   Homo	  sapiens	   Lactate	  dehydrogenase	  A	  like	  6B	  (LDHAL6B)	  	  	  	  
Table	  5.	  Entrez	  gene	  identifiers	  of	  genes	  belonging	  to	  the	  tricarboxylic	  acid	  cycle	  and	  electron	  transport	   chain,	   pathways	   WP78	   and	   WP111	   from	  Wikipathways.	   Official	   gene	   symbols	   and	  gene	  names	  were	  obtained	  with	  DAVID	  6.7	  online	  database.	  	  	  
Wikipathways	   DAVID	  
Identifier	   Database	   From	   To	   DAVID	  gene	  name	  50	   Entrez	  Gene	   50	   ACO2	   aconitase	  2	  (ACO2)	  291	   Entrez	  Gene	   291	   SLC25A4	   solute	  carrier	  family	  25	  member	  4	  (SLC25A4)	  292	   Entrez	  Gene	   292	   SLC25A5	   solute	  carrier	  family	  25	  member	  5	  (SLC25A5)	  293	   Entrez	  Gene	   293	   SLC25A6	   solute	  carrier	  family	  25	  member	  6	  (SLC25A6)	  498	   Entrez	  Gene	   498	   ATP5A1	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  alpha	  subunit	  1,	  cardiac	  muscle	  (ATP5A1)	  506	   Entrez	  Gene	   506	   ATP5B	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  beta	  polypeptide	  (ATP5B)	  509	   Entrez	  Gene	   509	   ATP5C1	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  gamma	  polypeptide	  1	  (ATP5C1)	  513	   Entrez	  Gene	   513	   ATP5D	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  delta	  subunit	  (ATP5D)	  514	   Entrez	  Gene	   514	   ATP5E	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  epsilon	  subunit	  (ATP5E)	  515	   Entrez	  Gene	   515	   ATP5F1	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  B1	  (ATP5F1)	  516	   Entrez	  Gene	   516	   ATP5G1	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  C1	  (subunit	  9)	  (ATP5G1)	  517	   Entrez	  Gene	   517	   ATP5G2	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  C2	  (subunit	  9)	  (ATP5G2)	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518	   Entrez	  Gene	   518	   ATP5G3	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  C3	  (subunit	  9)	  (ATP5G3)	  521	   Entrez	  Gene	   521	   ATP5I	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  E	  (ATP5I)	  522	   Entrez	  Gene	   522	   ATP5J	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  F6	  (ATP5J)	  539	   Entrez	  Gene	   539	   ATP5O	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  F1	  complex,	  O	  subunit	  (ATP5O)	  1327	   Entrez	  Gene	   1327	   Cox4I1	   cytochrome	  c	  oxidase	  subunit	  4I1	  (COX4I1)	  1329	   Entrez	  Gene	   1329	   Cox5b	   cytochrome	  c	  oxidase	  subunit	  5B	  (COX5B)	  1337	   Entrez	  Gene	   1337	   Cox6a1	   cytochrome	  c	  oxidase	  subunit	  6A1	  (COX6A1)	  1339	   Entrez	  Gene	   1339	   COX6A2	   cytochrome	  c	  oxidase	  subunit	  6A2	  (COX6A2)	  1340	   Entrez	  Gene	   1340	   Cox6b1	   cytochrome	  c	  oxidase	  subunit	  6B1	  (COX6B1)	  1345	   Entrez	  Gene	   1345	   COX6C	   cytochrome	  c	  oxidase	  subunit	  6C	  (COX6C)	  1346	   Entrez	  Gene	   1346	   Cox7a1	   cytochrome	  c	  oxidase	  subunit	  7A1	  (COX7A1)	  1347	   Entrez	  Gene	   1347	   COX7A2	   cytochrome	  c	  oxidase	  subunit	  7A2	  (COX7A2)	  1349	   Entrez	  Gene	   1349	   COX7B	   cytochrome	  c	  oxidase	  subunit	  7B	  (COX7B)	  1350	   Entrez	  Gene	   1350	   COX7C	   cytochrome	  c	  oxidase	  subunit	  7C	  (COX7C)	  1351	   Entrez	  Gene	   1351	   COX8A	   cytochrome	  c	  oxidase	  subunit	  8A	  (COX8A)	  1353	   Entrez	  Gene	   1353	   cox11	   COX11,	  cytochrome	  c	  oxidase	  copper	  chaperone	  (COX11)	  1355	   Entrez	  Gene	   1355	   Cox15	   COX15,	  cytochrome	  c	  oxidase	  assembly	  homolog	  (COX15)	  1431	   Entrez	  Gene	   1431	   CS	   citrate	  synthase	  (CS)	  1738	   Entrez	  Gene	   1738	   DLD	   dihydrolipoamide	  dehydrogenase	  (DLD)	  1743	   Entrez	  Gene	   1743	   DLST	   dihydrolipoamide	  S-­‐succinyltransferase	  (DLST)	  2271	   Entrez	  Gene	   2271	   FH	   fumarate	  hydratase	  (FH)	  3418	   Entrez	  Gene	   3418	   IDH2	   isocitrate	  dehydrogenase	  (NADP(+))	  2,	  mitochondrial	  (IDH2)	  3419	   Entrez	  Gene	   3419	   IDH3A	   isocitrate	  dehydrogenase	  3	  (NAD(+))	  alpha	  (IDH3A)	  3420	   Entrez	  Gene	   3420	   IDH3B	   isocitrate	  dehydrogenase	  3	  (NAD(+))	  beta	  (IDH3B)	  3421	   Entrez	  Gene	   3421	   IDH3G	   isocitrate	  dehydrogenase	  3	  (NAD(+))	  gamma	  (IDH3G)	  4191	   Entrez	  Gene	   4191	   MDH2	   malate	  dehydrogenase	  2	  (MDH2)	  4508	   Entrez	  Gene	   4508	   ATP6	   ATP	  synthase	  F0	  subunit	  6	  (ATP6)	  4509	   Entrez	  Gene	   4509	   ATP8	   ATP	  synthase	  F0	  subunit	  8	  (ATP8)	  4512	   Entrez	  Gene	   4512	   COX1	   cytochrome	  c	  oxidase	  subunit	  I	  (COX1)	  4513	   Entrez	  Gene	   4513	   COX2	   cytochrome	  c	  oxidase	  subunit	  II	  (COX2)	  4514	   Entrez	  Gene	   4514	   COX3	   cytochrome	  c	  oxidase	  III	  (COX3)	  4519	   Entrez	  Gene	   4519	   CYTB	   cytochrome	  b	  (CYTB)	  4535	   Entrez	  Gene	   4535	   ND1	   NADH	  dehydrogenase,	  subunit	  1	  (complex	  I)	  (ND1)	  4536	   Entrez	  Gene	   4536	   ND2	   MTND2	  (ND2)	  4537	   Entrez	  Gene	   4537	   ND3	   NADH	  dehydrogenase,	  subunit	  3	  (complex	  I)	  (ND3)	  4538	   Entrez	  Gene	   4538	   ND4	   NADH	  dehydrogenase,	  subunit	  4	  (complex	  I)	  (ND4)	  4539	   Entrez	  Gene	   4539	   ND4L	   NADH	  dehydrogenase,	  subunit	  4L	  (complex	  I)	  (ND4L)	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4540	   Entrez	  Gene	   4540	   ND5	   NADH	  dehydrogenase,	  subunit	  5	  (complex	  I)	  (ND5)	  4541	   Entrez	  Gene	   4541	   ND6	   NADH	  dehydrogenase,	  subunit	  6	  (complex	  I)	  (ND6)	  4694	   Entrez	  Gene	   4694	   NDUFA1	   NADH:ubiquinone	  oxidoreductase	  subunit	  A1	  (NDUFA1)	  4695	   Entrez	  Gene	   4695	   NDUFA2	   NADH:ubiquinone	  oxidoreductase	  subunit	  A2	  (NDUFA2)	  4696	   Entrez	  Gene	   4696	   NDUFA3	   NADH:ubiquinone	  oxidoreductase	  subunit	  A3	  (NDUFA3)	  4697	   Entrez	  Gene	   4697	   NDUFA4	   NDUFA4,	  mitochondrial	  complex	  associated	  (NDUFA4)	  4698	   Entrez	  Gene	   4698	   NDUFA5	   NADH:ubiquinone	  oxidoreductase	  subunit	  A5	  (NDUFA5)	  4700	   Entrez	  Gene	   4700	   NDUFA6	   NADH:ubiquinone	  oxidoreductase	  subunit	  A6	  (NDUFA6)	  4701	   Entrez	  Gene	   4701	   NDUFA7	   NADH:ubiquinone	  oxidoreductase	  subunit	  A7	  (NDUFA7)	  4702	   Entrez	  Gene	   4702	   NDUFA8	   NADH:ubiquinone	  oxidoreductase	  subunit	  A8	  (NDUFA8)	  4704	   Entrez	  Gene	   4704	   NDUFA9	   NADH:ubiquinone	  oxidoreductase	  subunit	  A9	  (NDUFA9)	  4705	   Entrez	  Gene	   4705	   NDUFA10	   NADH:ubiquinone	  oxidoreductase	  subunit	  A10	  (NDUFA10)	  4706	   Entrez	  Gene	   4706	   NDUFAB1	   NADH:ubiquinone	  oxidoreductase	  subunit	  AB1	  (NDUFAB1)	  4707	   Entrez	  Gene	   4707	   NDUFB1	   NADH:ubiquinone	  oxidoreductase	  subunit	  B1	  (NDUFB1)	  4708	   Entrez	  Gene	   4708	   NDUFB2	   NADH:ubiquinone	  oxidoreductase	  subunit	  B2	  (NDUFB2)	  4709	   Entrez	  Gene	   4709	   NDUFB3	   NADH:ubiquinone	  oxidoreductase	  subunit	  B3	  (NDUFB3)	  4710	   Entrez	  Gene	   4710	   NDUFB4	   NADH:ubiquinone	  oxidoreductase	  subunit	  B4	  (NDUFB4)	  4711	   Entrez	  Gene	   4711	   NDUFB5	   NADH:ubiquinone	  oxidoreductase	  subunit	  B5	  (NDUFB5)	  4712	   Entrez	  Gene	   4712	   NDUFB6	   NADH:ubiquinone	  oxidoreductase	  subunit	  B6	  (NDUFB6)	  4713	   Entrez	  Gene	   4713	   NDUFB7	   NADH:ubiquinone	  oxidoreductase	  subunit	  B7	  (NDUFB7)	  4714	   Entrez	  Gene	   4714	   NDUFB8	   NADH:ubiquinone	  oxidoreductase	  subunit	  B8	  (NDUFB8)	  4715	   Entrez	  Gene	   4715	   NDUFB9	   NADH:ubiquinone	  oxidoreductase	  subunit	  B9	  (NDUFB9)	  4716	   Entrez	  Gene	   4716	   NDUFB10	   NADH:ubiquinone	  oxidoreductase	  subunit	  B10	  (NDUFB10)	  4717	   Entrez	  Gene	   4717	   NDUFC1	   NADH:ubiquinone	  oxidoreductase	  subunit	  C1	  (NDUFC1)	  4718	   Entrez	  Gene	   4718	   NDUFC2	   NADH:ubiquinone	  oxidoreductase	  subunit	  C2	  (NDUFC2)	  4719	   Entrez	  Gene	   4719	   NDUFS1	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  S1	  (NDUFS1)	  4720	   Entrez	  Gene	   4720	   NDUFS2	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  S2	  (NDUFS2)	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4722	   Entrez	  Gene	   4722	   NDUFS3	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  S3	  (NDUFS3)	  4723	   Entrez	  Gene	   4723	   NDUFV1	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  V1	  (NDUFV1)	  4724	   Entrez	  Gene	   4724	   NDUFS4	   NADH:ubiquinone	  oxidoreductase	  subunit	  S4	  (NDUFS4)	  4725	   Entrez	  Gene	   4725	   NDUFS5	   NADH:ubiquinone	  oxidoreductase	  subunit	  S5	  (NDUFS5)	  4726	   Entrez	  Gene	   4726	   NDUFS6	   NADH:ubiquinone	  oxidoreductase	  subunit	  S6	  (NDUFS6)	  4728	   Entrez	  Gene	   4728	   NDUFS8	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  S8	  (NDUFS8)	  4729	   Entrez	  Gene	   4729	   NDUFV2	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  V2	  (NDUFV2)	  4731	   Entrez	  Gene	   4731	   NDUFV3	   NADH:ubiquinone	  oxidoreductase	  subunit	  V3	  (NDUFV3)	  4967	   Entrez	  Gene	   4967	   OGDH	   oxoglutarate	  dehydrogenase	  (OGDH)	  6341	   Entrez	  Gene	   6341	   SCO1	   SCO1,	  cytochrome	  c	  oxidase	  assembly	  protein	  (SCO1)	  6389	   Entrez	  Gene	   6389	   SDHA	   succinate	  dehydrogenase	  complex	  flavoprotein	  subunit	  A	  (SDHA)	  6390	   Entrez	  Gene	   6390	   SDHB	   succinate	  dehydrogenase	  complex	  iron	  sulfur	  subunit	  B	  (SDHB)	  6391	   Entrez	  Gene	   6391	   SDHC	   succinate	  dehydrogenase	  complex	  subunit	  C	  (SDHC)	  6392	   Entrez	  Gene	   6392	   SDHD	   succinate	  dehydrogenase	  complex	  subunit	  D	  (SDHD)	  6834	   Entrez	  Gene	   6834	   SURF1	   SURF1,	  cytochrome	  c	  oxidase	  assembly	  factor	  (SURF1)	  7350	   Entrez	  Gene	   7350	   UCP1	   uncoupling	  protein	  1	  (UCP1)	  7351	   Entrez	  Gene	   7351	   UCP2	   uncoupling	  protein	  2	  (UCP2)	  7352	   Entrez	  Gene	   7352	   UCP3	   uncoupling	  protein	  3	  (UCP3)	  7381	   Entrez	  Gene	   7381	   Uqcrb	   ubiquinol-­‐cytochrome	  c	  reductase	  binding	  protein	  (UQCRB)	  7384	   Entrez	  Gene	   7384	   UQCRC1	   ubiquinol-­‐cytochrome	  c	  reductase	  core	  protein	  I	  (UQCRC1)	  7385	   Entrez	  Gene	   7385	   Uqcrc2	   ubiquinol-­‐cytochrome	  c	  reductase	  core	  protein	  II	  (UQCRC2)	  7386	   Entrez	  Gene	   7386	   Uqcrfs1	   ubiquinol-­‐cytochrome	  c	  reductase,	  Rieske	  iron-­‐sulfur	  polypeptide	  1	  (UQCRFS1)	  7388	   Entrez	  Gene	   7388	   Uqcrh	   ubiquinol-­‐cytochrome	  c	  reductase	  hinge	  protein	  (UQCRH)	  8801	   Entrez	  Gene	   8801	   SUCLG2	   succinate-­‐CoA	  ligase	  GDP-­‐forming	  beta	  subunit	  (SUCLG2)	  8802	   Entrez	  Gene	   8802	   SUCLG1	   succinate-­‐CoA	  ligase	  alpha	  subunit	  (SUCLG1)	  9016	   Entrez	  Gene	   9016	   SLC25A14	   solute	  carrier	  family	  25	  member	  14	  (SLC25A14)	  9167	   Entrez	  Gene	   9167	   COX7A2L	   cytochrome	  c	  oxidase	  subunit	  7A2	  like	  (COX7A2L)	  9377	   Entrez	  Gene	   9377	   Cox5a	   cytochrome	  c	  oxidase	  subunit	  5A	  (COX5A)	  9481	   Entrez	  Gene	   9481	   SLC25A27	   solute	  carrier	  family	  25	  member	  27	  (SLC25A27)	  9551	   Entrez	  Gene	   9551	   ATP5J2	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  F2	  (ATP5J2)	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10063	   Entrez	  Gene	   10063	   COX17	   COX17,	  cytochrome	  c	  oxidase	  copper	  chaperone	  (COX17)	  10476	   Entrez	  Gene	   10476	   ATP5H	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  D	  (ATP5H)	  10632	   Entrez	  Gene	   10632	   ATP5L	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  G	  (ATP5L)	  10975	   Entrez	  Gene	   10975	   UQCR11	   ubiquinol-­‐cytochrome	  c	  reductase,	  complex	  III	  subunit	  XI	  (UQCR11)	  27089	   Entrez	  Gene	   27089	   Uqcrq	   ubiquinol-­‐cytochrome	  c	  reductase	  complex	  III	  subunit	  VII	  (UQCRQ)	  27109	   Entrez	  Gene	   27109	   ATP5S	   ATP	  synthase,	  H+	  transporting,	  mitochondrial	  Fo	  complex	  subunit	  s	  (factor	  B)	  (ATP5S)	  29796	   Entrez	  Gene	   29796	   Uqcr10	   ubiquinol-­‐cytochrome	  c	  reductase,	  complex	  III	  subunit	  X	  (UQCR10)	  55967	   Entrez	  Gene	   55967	   NDUFA12	   NADH:ubiquinone	  oxidoreductase	  subunit	  A12	  (NDUFA12)	  93974	   Entrez	  Gene	   93974	   ATPIF1	   ATPase	  inhibitory	  factor	  1	  (ATPIF1)	  374291	   Entrez	  Gene	   374291	   NDUFS7	   NADH:ubiquinone	  oxidoreductase	  core	  subunit	  S7	  (NDUFS7)	  	  	  	   Using	   the	   official	   gene	   symbols	   from	   the	   selected	   pathways,	   the	   probe	   set	   IDs	  from	   the	   RMA	   normalized	   data	   were	   selected	   (Supplements	   5.1.3).	   From	   the	   original	  table	  with	  54,676	  rows	  corresponding	  to	  the	  total	  probe	  set	  IDs	  in	  the	  Affymetrix	  U133	  array,	   we	   extracted	   three	   small	   tables	   with	   13	   probe	   sets	   for	   the	   pentose	   phosphate	  pathway,	  94	  probe	  sets	  for	  the	  glycolysis-­‐gluconeogenesis	  pathway,	  and	  218	  probe	  sets	  for	  TCA	  and	  electron	  transport	  chain.	  	  	   The	  statistical	  method	  "Presence-­‐Absence	  calls	  with	  Negative	  Probe	  sets"	  (PANP)	  was	   used	   to	   estimate	   the	   significance	   of	   the	   detection	   on	   Affymetrix	   U133	   series	  microarrays	  (Warren	  et	  al.	  2007).	  The	  probe	  sets	  in	  which	  an	  “Absence”	  value	  is	  given	  are	  the	  ones	  in	  which	  the	  expression	  level	  is	  below	  the	  threshold	  of	  detection,	  meaning	  that	  the	  expression	  level	  does	  not	  differ	  from	  zero	  significantly	  and	  that	  the	  fluorescence	  intensity	  generated	  in	  the	  sample	  occurred	  by	  unspecific	  hybridization.	  	  	   The	   PANP	   function	   runs	   in	   the	  R	   programming	   language	   and	   uses	   Affymetrix-­‐reporter	  probes	  with	  unknown	  hybridization	  partners	  to	  calculate	  the	  cutoffs	  and	  gives	  the	   p-­‐values	   for	   each	   probe	   set.	   The	   panp	   package	   (Bioconductor)	   with	   the	   PANP	  function	   (panp())	  was	   run	  with	   the	   default	   option	   for	   the	   p-­‐values	   (0.01	   and	   0.02	   as	  cutoffs,	  see	  Supplements	  5.1.4).	  “P”	  (present)	  calls	  were	  given	  to	  the	  probe	  sets	  in	  which	  the	  p-­‐value	  for	  the	  detection	  intensities	  was	  below	  0.01;	  “M”	  (marginal)	  was	  given	  to	  the	  probe	  sets	  in	  which	  the	  p-­‐value	  for	  the	  detection	  intensities	  was	  between	  0.01	  and	  0.02;	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and	   “A”	   (absence)	  was	   given	   to	   the	   probe	   sets	   in	  which	   the	   p-­‐value	   for	   the	   detection	  intensities	  was	  above	  of	  0.02.	  	  	   In	   the	   Affymetrix	   U133	   array	   the	   probe	   set	   IDs	   are	   named	   with	   a	   number	  followed	  by	  a	  letter	  suffix	  that	  indicates	  the	  probe	  set	  type:	  	  •	   “_at”	  suffix:	  predicted	  to	  perfectly	  match	  the	  antisense	  strand	  of	   the	  gene	  of	   interest.	  Just	  one	  single	  transcript	  is	  included.	  	  •	   “_a_at”	   suffix:	   at	   least	   one	   probe	   of	   the	   probe	   set	   cross-­‐hybridized	   with	   transcripts	  from	  the	  same	  gene.	  	  •	  “_s_at”	  suffix:	  at	  least	  one	  probe	  of	  the	  probe	  set	  cross-­‐hybridized	  with	  transcript	  from	  the	  same	  gene	  or	  from	  homologous	  genes.	  	  •	   “_x_at”	   suffix:	   is	   a	   mixed	   probe	   set	   that	   contains	   some	   probes	   that	   are	   identical	   or	  highly	  similar	  to	  other	  sequences.	  	  	   A	  selection	  of	  one	  probe	  set	  per	  gene	  was	  done	  based	  on	  the	  probe	  set	  suffix	  and	  on	   the	   "Presence-­‐Absence	   calls”.	   Independently	   of	   the	   "Presence-­‐Absence	   calls”,	   all	  probe	   sets	  with	  a	   _x	   suffix	  were	  deleted.	   For	   glycolysis-­‐gluconeogenesis	   together	  with	  the	  pentose	  phosphate	  pathways,	  107	  probe	  sets	  were	  reduced	  to	  51	  (51	  genes).	  From	  the	   218	   probe	   sets	   belonging	   to	   the	   TCA	   together	   with	   the	   electron	   transport	   chain	  pathways,	  104	  probe	  sets	  remained	  (104	  genes).	  Scale	  and	  center	  were	  applied	   to	   the	  expression	  values	  to	  normalize	  the	  expression	  of	  each	  gene	  in	  each	  cell	   line.	  To	  center	  the	  gene	  expression	  columns,	  the	  mean	  of	  the	  gene	  expression	  was	  calculated	  per	  each	  gene	   and	   then	   subtracted	   from	   the	   gene	   expression	   value	   in	   each	   cell	   line.	   These	  centered	   column	   values	   are	   divided	   by	   the	   column's	   standard	   deviation.	   A	   range	   to	  compare	   the	   expression	   values	   of	   each	   gene	   in	   the	   studied	   cell	   lines	   from	   –3	   (lowly	  expressed	  genes)	  to	  3	  (highly	  expressed	  genes)	  was	  obtained.	  Scaling	  and	  centering	  was	  calculated	  using	  R	  programming	  language	  function	  biscale	  from	  the	  package	  softImpute	  version	  1.4	  library	  softImpute	  (Hastie	  et	  al.	  2015)	  (Supplements	  5.1.5).	  Genes	  that	  had	  high	   or	   low	   expression	   levels	   (extreme	   values	   after	   scale	   and	   center	   >1	   or	   <–1)	   in	   at	  least	  7	  of	  the	  16	  cell	  lines	  were	  selected	  (Supplements	  5.1.5).	  A	  set	  of	  17	  genes	  out	  of	  the	  155	  remained	  for	  correlation	  analysis	  with	  the	  metabolic	  assays.	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2.3.2 Selection	   of	   Genes	   in	   the	   Total	   Probe	   Sets	   of	   the	   Affymetrix	   Array	  
with	  Extreme	  Expression	  
	  Gene	  expression	  data	  of	   the	  total	  probe	  sets	  of	   the	  Affymetrix	  array	  normalized	  with	  the	  RMA	  function	  (Experimental	  Methods	  2.3)	  were	  scaled	  and	  centered	  per	  probe	  set	  base	  in	  the	  expression	  value	  of	  the	  analyzed	  cell	  lines	  (Experimental	  Methods	  2.3.1).	  In	   the	   complete	   data	   with	   54,676	   probe	   set	   IDs	   we	   selected	   the	   extreme	   expressed	  probe	  sets	  (values	  greater	  than	  1	  and	  lower	  than	  –1)	  per	  cell	  line	  (Supplements	  5.1.5).	  A	  new	   range	   was	   done	   with	   the	   cell	   lines	   that	   presented	   the	   most	   extreme	   expressed	  probe	  set	  values.	  Probe	  sets	  were	  selected	  that	  were	  either	  highly	  or	  lowly	  expressed	  in	  at	  least	  9	  of	  the	  16	  cell	  lines.	  A	  total	  of	  202	  probe	  sets	  remained.	  The	  gene	  symbol	  of	  the	  202	  probe	  sets	  was	  added	   to	  search	  all	   the	  probe	  sets	   that	   target	   that	  gene	  symbol.	  A	  new	   list	  containing	  481	  probe	  sets	  was	  obtained.	  The	  probe	  sets	  with	  a	   _x	  suffix	  were	  deleted	  leaving	  456	  probe	  sets.	  	  	   A	   final	   selection	  was	   done	   for	   genes	  with	   consistent	   information	   through	   their	  probe	  sets.	  Genes	  with	  just	  one	  probe	  set	  were	  discarded.	  There	  remained	  36	  probe	  sets	  corresponding	  to	  17	  genes	  for	  correlation	  analysis	  with	  the	  metabolic	  assays.	  	  
2.3.3 Real-­Time	  Polymerase	  Chain	  Reaction	  (qPCR)	  
	  The	   gene	   expression	   of	   six	   genes	   belonging	   to	   the	   glycolysis-­‐gluconeogenesis	  pathway	   (GOT1,	   HK1,	   HK2,	   LDHa,	   PFKM,	   SLC2A)	  was	   estimated	   by	   quantitative	   real-­‐time	  PCR	  in	  MCF7,	  MDA-­‐MB-­‐231,	  HeLa,	  HCT	  116,	  HT-­‐29,	  Hep	  G2,	  ASPC-­‐1,	  BxPC-­‐3,	  MIA	  PaCa-­‐2,	   PANC-­‐1,	   PC-­‐3,	   and	   DU	   145	   cell	   lines.	   The	   RNA	   for	   the	   qPCR	   came	   from	   cells	  cultivated	   under	   standard	   conditions.	   The	   total	   RNA	   from	   each	   cell	   line	   was	   isolated	  with	  RNeasy	  Mini	  Kit	  (Qiagen)	  according	  to	  the	  manufacturer's	  instructions.	  The	  quality	  of	   the	   RNA	   was	   examined	   by	   electrophoresis	   in	   agarose	   gels	   and	   quantified	   by	  spectrophotometry	  (260	  nm/280	  nm)	  in	  a	  NanoDrop	  2000	  (Thermo	  Scientific).	  A	  mass	  of	  250	  ng	  of	  total	  RNA	  for	  each	  cell	   line	  was	  transcribed	  into	  cDNA	  with	  the	  RevertAid	  Reverse	  Transcriptase	  (Thermo	  Fisher).	  For	  the	  synthesis,	  oligo-­‐dT	  primers	  and	  random	  hexamer	   primers	   were	   used.	   The	   reverse	   transcription	   reaction	   program	   entailed	  incubation	  of	  10	  min	  at	  25°C,	  a	  reverse	  transcription	  of	  30	  min	  at	  48°C,	  and	  inactivation	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of	  the	  reverse	  transcriptase	  for	  5	  min	  at	  95°C.	  The	  amplification	  reactions	  contained	  1	  µl	  of	   cDNA,	   1	   µl	   SYBR	   Green	   Master	   (Qiagen),	   and	   1	   µl	   of	   the	   target	   primers	   (Eurofins	  Genomics).	   The	   primer	   sequences	   are	   listed	   in	   Table	   6.	   The	   qPCRs	   were	   performed	  using	   a	   qTOWER	   (Analytik	   Jena)	   system	  with	   the	   following	  program:	  Taq	  polymerase	  activation	  (10	  min	  at	  95°C)	  and	  40	  amplification	  cycles	  (denaturation	  at	  95°C	  for	  15	  sec	  and	  annealing/extension	  at	  58°C	  for	  1	  min).	  	   	  
Table	   6.	   List	   of	   the	   primer	   sequences	   used	   in	   real-­‐time	   PCR	   for	   estimating	   the	   expression	   of	  some	  of	  the	  genes	  involves	  in	  the	  glycolysis-­‐gluconeogenesis	  pathway	  	  
Target	  gene	   Type	  of	  primer	   Sequence	  Forward	   5’	  CAC	  TAT	  CTG	  CCA	  ATC	  CTG	  3’	  GOT1	   Reverse	   5’	  CCT	  ACC	  CGC	  TTC	  TCC	  TTG	  AG	  3’	  Forward	   5’	  GTT	  GCC	  AAC	  ATT	  CET	  AAG	  GTC	  C	  3’	  HK1	   Reverse	   5’	  CAC	  TTG	  CAC	  CCG	  CAG	  AAT	  TCG	  3’	  Forward	   5’	  GTG	  GCA	  CCC	  AGC	  TGT	  TTG	  AC	  3’	  HK2	   Reverse	   5’	  CGA	  GAA	  GGT	  AAA	  ACC	  CAG	  TGG	  3’	  Forward	   5’	  GAA	  GGG	  AGA	  GAT	  GAT	  GGA	  TCT	  C	  3’	  LDHa	   Reverse	   5’	  CTT	  ATC	  TTC	  CAA	  GCC	  ACG	  TAG	  G	  3’	  Forward	   5’	  GGT	  GGA	  GAT	  CAC	  ATC	  AAG	  GAA	  G	  3’	  PFKM	   Reverse	   5’	  CTC	  GTT	  CCC	  GAA	  AGT	  CCT	  TGC	  3’	  Forward	   5’	  CAG	  TTT	  GGC	  TAC	  AAC	  ACT	  GGA	  G	  3’	  SLC2A	   Reverse	   5’	  GCA	  GGA	  TGC	  TCT	  CCC	  CAT	  AG	  3’	  	  	  
2.4 Half	  Maximal	  Inhibitory	  Concentration	  (IC50)	  Estimations	  	  
2.4.1 IC50	  Values	   from	  the	  Genomics	  of	  Drug	  Sensitivity	   in	  Cancer	  Project	  
(GDSC)	  







Table	  7.	  IC50	  values	  in	  μM	  obtained	  from	  the	  Genomics	  of	  Drug	  Sensitivity	  in	  Cancer	  project.	  	   	  	   IC50	  μM	  
Drug	  Name	   MDA-­‐MB-­‐231	   MCF7	   HCT	  116	   HT-­‐29	   AsPC-­‐1	   BxPC-­‐3	   MIA	  PaCa-­‐2	   MDA-­‐MB-­‐435	   PC-­‐3	   LNCaP	   DU	  145	  681640	   6.86	   5.99	   28.71	   160.6	   40.21	   15.03	   29.54	   1.69	   27.16	   20.72	   0.16	  17-­‐AAG	   45.12	   0.097	   0.266	   0.033	   0.152	   0.135	   0.003	   0.079	   0.079	   0.800	   2.79	  ABT-­‐263	   121.43	   45.51	   161.9	   60.26	   19.87	   81.17	   11.32	   110.9	   157.4	   105.6	   0.90	  ABT-­‐888	   210.62	   432.9	   87.78	   680.3	   257.3	   435.3	   82.21	   373.0	   28.67	   299.5	   13.91	  AG-­‐014699	   13.77	   8.03	   7.18	   409	   31.65	   28.00	   123.3	   145.5	   106.7	   32.26	   50.49	  AICAR	   2.401	   1.894	   2.555	   17.723	   1.327	   1.376	   3.429	   2.480	   300.7	   8.310	   6.767	  AKT	  inhib.	  VIII	   103.8	   32.27	   7.76	   2.43	   48.11	   2.22	   95.78	   104.8	   10.51	   10.46	   17.69	  AMG-­‐706	   212.1	   28.86	   210.9	   75.96	   54.51	   18.64	   21.36	   38.90	   13.51	   159.8	   0.47	  AP-­‐24534	   10.21	   11.81	   0.21	   25.79	   7.29	   0.35	   1.01	   43.32	   44.43	   25.35	   1.08	  AS601245	   12.31	   1.50	   231.5	   4.27	   317.8	   1.86	   0.98	   28.42	   11.62	   73.99	   12.02	  ATRA	   71.80	   52.35	   217.1	   1.729	   997	   211.4	   425.9	   415.1	   343.2	   974	   50.55	  AUY922	   0.091	   0.003	   0.152	   0.044	   2.54	   0.043	   0.015	   0.218	   0.132	   0.082	   0.013	  Axitinib	   18.65	   46.55	   103.9	   29.30	   30.02	   74.39	   1.83	   37.16	   21.80	   34.85	   4.13	  AZD-­‐2281	   66.56	   91.79	   30.05	   241.2	   367.8	   496.9	   23.79	   493.3	   197.5	   300.4	   217.7	  AZD6244	   5.57	   243.5	   1.06	   70.39	   0.32	   4.66	   38.84	   0.04	   23.57	   395.4	   133.8	  AZD6482	   60.07	   3.35	   6.69	   29.76	   32.68	   3.45	   14.71	   20.63	   16.54	   1.52	   1.37	  AZD6482	   60.96	   468.6	   19.34	   187.9	   176.8	   39.36	   266.2	   216.8	   39.20	   2.41	   37.28	  AZD7762	   1.60	   13.24	   1.42	   0.37	   0.66	   0.26	   0.14	   0.14	   9.71	   1.44	   40.63	  AZD8055	   1.72	   0.41	   1.43	   2.33	   0.74	   0.89	   0.42	   0.47	   0.72	   0.35	   6.77	  BAY	  61-­‐3606	   547.9	   1.15	   3.98	   2.81	   432.9	   2.86	   5.40	   169.9	   418	   2.18	   7.97	  Bexarotene	   63.20	   273.9	   268.7	   108.1	   797.3	   522.9	   10.51	   53.58	   65.53	   896.1	   158.3	  BIBW2992	   28.28	   16.47	   4.41	   55.24	   19.65	   25.01	   25.21	   44.13	   21.11	   15.42	   0.45	  Bicalutamide	   106	   39.30	   59.95	   88.40	   74.47	   68.05	   77.87	   50.48	   10.28	   41.29	   98.21	  BIRB	  0796	   206.4	   768.9	   324.7	   28.19	   427.9	   263.6	   14.53	   734	   152.8	   431.7	   3.94	  Bleomycin	   0.27	   1.17	   2.88	   0.54	   82.50	   3.81	   0.11	   3.22	   13.31	   18.32	   0.82	  BMS-­‐708163	   339	   149.8	   18.80	   118.8	   60.85	   110.4	   192.4	   61.96	   78.38	   454.4	   163	  BMS-­‐754807	   2.61	   0.09	   3.21	   0.01	   18.86	   1.38	   0.25	   6.59	   1.93	   7.86	   1.93	  Bosutinib	   47.62	   135.4	   2.23	   4.61	   14.56	   62.63	   1.05	   4.49	   102.6	   147	   67.74	  Bryostatin	  1	   0.65	   0.05	   0.05	   0.47	   0.12	   0.05	   0.26	   0.01	   0.48	   0.21	   0.08	  BX-­‐795	   8.24	   35.83	   4.99	   38.55	   52.72	   10.01	   2.26	   5.22	   4.17	   30.60	   429.1	  Camptothecin	   0.010	   0.024	   0.032	   0.047	   0.168	   0.053	   0.002	   0.012	   0.007	   0.031	   2.28	  CCT007093	   519.2	   3.86	   434.3	   238	   126.1	   161.2	   687.9	   479.5	   592.1	   874.1	   759.1	  CCT018159	   2.80	   199.8	   5.77	   1.111	   90.69	   1.105	   4.42	   312.8	   9.54	   18.64	   8.22	  CEP-­‐701	   0.59	   3.20	   0.14	   0.87	   1.62	   1.01	   0.50	   0.05	   12.61	   0.35	   2.16	  CHIR-­‐99021	   200.9	   51.76	   43.21	   122.8	   152.8	   4.70	   1.76	   23.11	   99.06	   175.9	   109.95	  CI-­‐1040	   4.29	   76.60	   6.81	   1.47	   5.37	   8.39	   0.92	   0.15	   312.9	   239.6	   100.6	  Cisplatin	   31.69	   56.64	   118.4	   96.55	   20.95	   8.25	   1.48	   166.4	   49.66	   515.4	   11.12	  Cytarabine	   0.53	   1.97	   0.31	   0.57	   1.39	   4.75	   0.39	   0.58	   0.86	   1.31	   52.13	  DMOG	   367.9	   15.360	   658	   846.2	   3.924	   639.1	   139.1	   1.859	   417.6	   3.206	   824.5	  Docetaxel	   0.009	   0.002	   0.002	   0.006	   0.008	   0.004	   0.002	   0.002	   0.008	   0.001	   0.013	  Doxorubicin	   1.53	   0.012	   0.207	   0.037	   0.855	   0.211	   0.034	   0.905	   0.957	   0.204	   0.074	  EHT	  1864	   260.8	   14.76	   40.91	   700.6	   95.64	   464.0	   58.12	   297.3	   216.4	   14.35	   363.3	  Elesclomol	   0.019	   0.031	   0.040	   0.068	   0.038	   0.141	   0.005	   0.122	   0.005	   0.008	   0.500	  Embelin	   21.82	   8.35	   28.52	   7.52	   55.66	   6.41	   4.70	   11.01	   14.81	   21.92	   8.76	  Epothilone	  B	   0.025	   0.000	   0.005	   0.000	   0.144	   0.002	   0.001	   0.037	   0.023	   0.004	   0.001	  Etoposide	   9.09	   0.83	   1.01	   1.98	   302.6	   16.86	   2.66	   7.95	   61.27	   23.52	   0.59	  FH535	   14.34	   2.64	   3.72	   5.53	   22.29	   6.84	   0.60	   83.23	   8.12	   21.57	   4.69	  FTI-­‐277	   41.53	   83.08	   21.02	   3.30	   23.64	   18.84	   32.83	   65.56	   49.26	   63.89	   12.04	  
	  	   43	  
GDC-­‐0449	   65.44	   897.4	   129.1	   1.515	   38.47	   878.3	   29.67	   763.8	   609.9	   541.8	   18.32	  GDC0941	   16.71	   0.90	   30.56	   1.47	   6.75	   6.08	   0.90	   3.31	   5.92	   0.80	   151.5	  Gefitinib	   35.51	   15.81	   25.42	   40.56	   32.36	   10.97	   44.41	   25.44	   5.34	   24.02	   0.22	  Gemcitabine	   0.028	   0.000	   0.051	   0.000	   2.50	   0.037	   0.023	   0.52	   2.83	   2.65	   0.009	  GSK-­‐1904529A	   8.19	   29.27	   51.92	   33.69	   48.54	   35.82	   59.71	   49.83	   7.31	   12.90	   18.99	  GSK-­‐650394	   91.65	   1.82	   32.07	   7.27	   879.2	   28.95	   7.08	   669.2	   760.5	   1.794	   20.50	  GW	  441756	   116.2	   22.34	   55.11	   105.4	   81.74	   171.3	   8.13	   191.1	   129.4	   70.58	   4.01	  IPA-­‐3	   280.4	   2.18	   1.254	   2.562	   1.516	   367.9	   18.14	   1.947	   911.1	   47.38	   8.21	  JNJ-­‐26854165	   4.56	   17.19	   14.62	   22.51	   36.26	   14.46	   12.83	   59.18	   36.03	   1.21	   15.78	  JNK	  Inhib.	  VIII	   378.6	   279.6	   684.7	   562.9	   516	   936.5	   57.23	   238.1	   42.28	   586.7	   19.87	  JNK-­‐9L	   0.97	   0.39	   0.16	   0.36	   3.80	   0.35	   1.40	   0.34	   4.55	   0.90	   0.48	  KU-­‐55933	   462.7	   60.99	   464.7	   67.92	   87.17	   198.8	   17.13	   147.7	   43.80	   682.8	   3.27	  LAQ824	   0.07	   0.02	   0.04	   0.02	   0.05	   0.03	   0.04	   0.30	   0.07	   0.05	   0.03	  Lenalidomide	   159.8	   503	   280.9	   330.6	   224.1	   422.2	   71.12	   563.7	   219	   311.9	   336.7	  LFM-­‐A13	   81.98	   464.4	   703.1	   865.8	   344.7	   42.52	   600.8	   979.3	   583.9	   178.5	   445.2	  Methotrexate	   22.90	   16.20	   0.79	   0.16	   0.27	   4.41	   4.66	   1.94	   13.34	   9.58	   1.01	  Midostaurin	   0.28	   0.33	   0.24	   0.98	   9.86	   0.49	   20.74	   15.85	   4.67	   35.34	   0.32	  Mitomycin	  C	   3.24	   0.01	   1.02	   0.04	   2.90	   0.77	   0.28	   1.34	   4.07	   0.45	   0.01	  MK-­‐2206	   177.5	   2.86	   137.2	   9.55	   0.22	   40.57	   1.77	   23.41	   11.58	   0.61	   0.65	  Nilotinib	   54.53	   141.1	   27.43	   10.64	   105.2	   167.1	   4.98	   113.9	   40.13	   94.49	   68.00	  NSC-­‐87877	   1.911	   657.8	   441.1	   205.6	   1.559	   1.169	   542.7	   392.3	   815.5	   1.640	   1.713	  NU-­‐7441	   121.5	   80.22	   212.8	   17.62	   30.81	   100.5	   5.93	   13.03	   8.27	   17.52	   98.49	  Nutlin-­‐3a	   515.8	   5.44	   3.30	   672.8	   36.15	   468.9	   484.3	   658.3	   268.3	   2.64	   327.5	  NVP-­‐BEZ235	   0.11	   0.05	   0.13	   0.41	   0.03	   0.08	   0.04	   0.06	   0.01	   0.04	   14.51	  Obatoclax	  Mesylate	   0.80	   0.00	   0.09	   0.04	   7.49	   0.07	   0.23	   0.46	   1.75	   2.30	   0.47	  OSI-­‐906	   40.99	   5.15	   74.82	   0.24	   40.46	   52.74	   8.86	   75.53	   131.7	   38.56	   70.31	  OSU-­‐03012	   4.16	   1.06	   9.30	   3.59	   249.1	   6.36	   18.81	   7.37	   8.25	   31.05	   2.31	  PAC-­‐1	   236.5	   35.31	   97.56	   6.71	   35.14	   2.09	   191.2	   160.1	   120.3	   21.38	   195.8	  Pazopanib	   108	   28.71	   541.2	   737.9	   112.4	   111.3	   5.60	   87.92	   212.7	   12.36	   14.76	  PD-­‐0325901	   0.16	   3.86	   0.29	   0.01	   0.05	   0.39	   0.01	   0.00	   9.07	   24.43	   20.28	  PD-­‐0332991	   3.82	   2.71	   5.10	   0.86	   0.25	   6.27	   1.86	   32.98	   1.35	   13.80	   3.46	  PD-­‐173074	   43.96	   11.62	   44.99	   168.5	   144.4	   135.8	   47.70	   92.23	   112.2	   154.4	   1.58	  PF-­‐4708671	   631	   83.29	   54.03	   922.9	   125.9	   1.083	   170.1	   133.7	   214.2	   62.79	   196.3	  PF-­‐562271	   2.50	   91.71	   3.51	   9.12	   65.60	   2.35	   15.42	   164	   6.13	   37.19	   2.49	  PLX4720	   1.079	   39.86	   923.4	   2.72	   87.62	   247.2	   17.04	   0.22	   53.36	   1.174	   137	  QS11	   42.39	   2.26	   51.47	   8.45	   1.381	   56.65	   8.88	   348.7	   55.22	   13.43	   7.86	  RDEA119	   1.12	   162.5	   0.52	   0.09	   1.07	   1.60	   0.32	   0.03	   75.77	   410.8	   1.06	  RO-­‐3306	   273.7	   11.18	   19.67	   42.83	   80.39	   385.4	   10.50	   123.7	   18.00	   128.5	   209.9	  SB	  216763	   74.90	   145.9	   258.4	   27.18	   433.7	   59.73	   70.22	   751.8	   268.7	   246	   11.65	  SB590885	   29.60	   115.4	   50.88	   2.13	   7.14	   502.4	   142.4	   0.08	   196.2	   321.2	   61.53	  Shikonin	   1.02	   0.43	   0.39	   0.64	   0.62	   0.33	   0.28	   1.49	   0.86	   41.59	   0.19	  SL	  0101-­‐1	   654.5	   437	   161.8	   1.091	   79.55	   388.7	   531.5	   476.7	   239.3	   1.131	   100.3	  Temsirolimus	   0.68	   0.57	   3.41	   18.00	   1.15	   0.96	   0.10	   0.46	   0.02	   0.18	   0.56	  Thapsigargin	   0.001	   0.000	   0.001	   0.005	   1.14	   0.007	   0.003	   0.014	   0.008	   0.032	   0.009	  Tipifarnib	   5.83	   0.17	   4.88	   0.55	   72.39	   4.33	   0.32	   580	   11.29	   11.46	   8.66	  TW	  37	   0.108	   0.34	   0.053	   2.13	   0.97	   2.48	   0.48	   2.83	   0.72	   0.81	   0.052	  Vinblastine	   0.030	   0.032	   0.007	   0.050	   0.013	   0.005	   0.004	   0.009	   0.024	   0.008	   0.099	  Vinorelbine	   0.037	   0.005	   0.003	   0.003	   1.36	   0.004	   0.006	   0.021	   0.104	   0.018	   0.005	  Vorinostat	   4.70	   5.01	   1.18	   3.12	   2.71	   11.37	   0.77	   2.67	   7.71	   6.80	   748.2	  VX-­‐702	   141.9	   193.7	   78.45	   337.1	   178.6	   145.5	   40.09	   160.2	   147	   109.1	   0.15	  ZM-­‐447439	   28.49	   89.42	   1.81	   8.62	   44.97	   19.38	   2.44	   11.80	   28.46	   59.37	   125.3	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2.4.2 Drug	  IC50	  Estimations	  
	  The	   IC50	   values	   were	   determined	   for	   17-­‐AAG	   (Sigma-­‐Aldrich),	   CCT007093	  (Sigma-­‐Aldrich),	   LFM-­‐A13	   (Sigma-­‐Aldrich),	   PAC-­‐1	   (Sigma-­‐Aldrich),	   IPA-­‐3	   (Sigma-­‐Aldrich),	   AKT	   inhibitor	   VIII	   (Sigma-­‐Aldrich),	   and	   BAY	   61-­‐3606	   (Sigma-­‐Aldrich)	   in	   the	  human	   cell	   lines	  MCF7,	  MDA-­‐MB-­‐231,	   LNCaP,	  PC-­‐3,	  DU	  145,	  HT-­‐29,	  HCT	  116,	  ASPC-­‐1,	  MIA	  PaCa-­‐2,	  and	  BxPC-­‐3.	  Inhibition	  of	  the	  cell	  proliferation	  was	  monitored	  by	  means	  of	  the	  SRB	  assay	  (see	  Experimental	  Methods	  2.1.3.4).	  Cells	  were	  incubated	  for	  72	  h	  with	  a	  serial	  dilution	  (up	  to	  8	  concentrations)	  of	  each	  drug	  (Table	  8).	  Calculations	  were	  done	  using	   the	   Excel	   add-­‐in	   ED50plus	   v1.0	   development	   by	   Mario	   H.	   Vargas	   (2000).	   The	  software	  is	  a	  pharmacological	  analysis	  tool	  in	  the	  form	  of	  a	  Microsoft	  Excel	  worksheet,	  which	   allows	   creating	   and	   analyzing	   dose-­‐response	   curves.	   The	   fit	   was	   done	   using	  sigmoid	  and	  linear	  regressions.	  	  	  
Table	  8.	  Compounds	  and	  concentrations	  (μM)	  used	  for	  the	  IC50	  calculations.	  	  
Dilution	   17-­AAG	   CCT007093	   LFM-­A13	   PAC-­1	   IPA-­3	  
AKT	  
inhibitor	  VIII	   BAY	  61-­3606	  1	   10	   200	   400	   200	   400	   100	   200	  2	   5	   100	   200	   100	   200	   50	   100	  3	   2.5	   50	   100	   50	   100	   25	   50	  4	   1.25	   25	   50	   25	   50	   12.5	   25	  5	   0.625	   12.5	   25	   12.5	   25	   6.25	   12.5	  6	   0.313	   6.250	   12.500	   6.250	   12.500	   3.125	   6.250	  7	   0.156	   3.125	   6.250	   3.125	   6.250	   1.563	   3.125	  8	   0.078	   1.563	   3.125	   1.563	   3.125	   0.781	   1.563	  	  	  	  
2.5 Dependencies	   between	   Cellular	   Properties	   and	   Gene	  
Expression	  or	  Drug	  IC50s	  	  
	  The	  linear	  correlation	  value	  (r	  coefficient)	  between	  the	  metabolic	  features	  of	  the	  cell	   lines	   and	   the	   gene	   expression	   or	   drugs'	   IC50s	   were	   obtained	   with	   the	   Pearson	  algorithm	  using	  the	  Hmisc	  package	  (version	  3.17-­‐4)	  and	  the	  function	  rcorr	  (Harrell	  et	  al.	  2015)	  (Supplements	  5.1.7)	  in	  R	  programming	  language.	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2.6 Graphics	  and	  Statistics	  
	  Plots	   and	   statistics	   were	   done	   using	   R	   programming	   language	   version	   2.7.0.	  Barplot.	  boxplots	  and	  scatterplots	  were	  drawn	  using	  the	  ggplot2	  package	  version	  2.1.0	  functions	  ggplot	  and	  qplot	  (Wickham	  2009).	  For	  the	   linear	  correlation	  scatterplots	  the	  geom_smooth	   method="lm",	   se	   =	   FALSE	   was	   used.	   Heatmaps	   of	   the	   gene	   expression	  were	  constructed	  using	  the	  pheatmap	  package	  version	  1.0.8	  and	  RColorBrewer	  with	  the	  function	   colorRampPalette	   (green,	   black,	   red)	   (Kolde	   2015)	   (Supplements	   5.1.6).	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3. Results	  
	  To	  get	  a	  better	  understanding	  of	  the	  properties	  of	  cancer	  cells,	  assessment	  of	  the	  membrane	   capacitance	   and	   a	   set	   of	   metabolic	   assays	   were	   performed	   on	   different	  cancer	   cell	   lines.	   These	   parameters	   included	   the	   direct	   measurement	   of	   cellular	  capacitance	   (cell	   membrane	   properties),	   respiratory	   activity	   (O2	   consumption),	  glycolytic	   activity	   (acidification),	   energy	   metabolism	   (ATP	   level),	   intracellular	   ROS	  accumulation,	   and	  mitochondrial	   mass	   and	   proliferation	   rates	   (MTT	   and	   SRB	   assays)	  (Table	   9).	   The	   information	   obtained	   from	   the	   studied	   cell	   lines	   was	   compared	   with	  public	  gene	  expression	  data	   (Barretina	  et	  al.	  2012,	  De	  Schutter	  et	  al.	  2013)	  and	  drugs	  IC50s	  (Yang	  et	  al.	  2013)	  to	  search	  for	  correlations.	  The	  results	  revealed	  a	  set	  of	  candidate	  genes	  that	  could	  be	  involved	  in	  cell	  matrix	  adhesion	  or	  cell-­‐cell	  interactions	  and	  cancer	  metabolism,	  as	  well	  as	  new	  relations	  between	  known	  drugs	  and	  cancer	  features.	  	  	  
Table	  9.	  Mean	  value	  of	  the	  cell	  capacitance	  and	  metabolism	  features	  of	  cancer	  cell	   lines.	  Cellular	  capacitance,	  glycolytic	  and	  respiration	  activities	  were	  measured	  with	   the	  Bionas	  2500	  online	  monitoring	  system.	  Cells	  were	  seeded	  in	  chips	  containing	  IDES	  sensors	  for	  the	  estimation	  of	   the	   cellular	   capacitance.	   ISFET	   sensors	   were	   used	   to	  measure	   glycolytic	   activity	   and	   Clark	  electrodes	   for	   determining	   respiration.	   Lower	   capacitance	   indicates	   a	   stronger	   cell	   matrix	  adhesion	   and	   cell-­‐cell	   contact	   interactions.	   Higher	   respiration	   and	   glycolysis	   are	   observed	   in	  cells	  with	  greater	  pA/s	  and	  μV/s	  values,	  respectively.	  The	  ATP	  level	  was	  measured	  with	  ATPlite	  1step	   Luminescence	   ATP	   Detection	   Assay	   System	   kit	   (Perkin	   Elmer).	   The	   luminescence	   is	  proportional	   to	   the	   ATP	   concentration	   in	   the	   cells.	   The	   mitochondrial	   mass	   content	   was	  determined	   using	   MitoTracker	   Green	   (Thermo	   Fisher).	   The	   fluorescence	   intensity	   is	  proportional	   to	   the	  mitochondrial	  mass	   of	   the	   cells.	   ROS	   accumulation	   in	   cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  The	  fluorescence	  intensity	  produced	  is	  directly	  related	  to	  the	  ROS	  accumulation	   in	  the	  cells.	  The	  proliferation	  rate	  was	  estimated	  using	  the	  MTT	  and	  SRB	  assays.	  MTT	  reagent	  labels	  active	  mitochondria	  and	  its	  reduction	  produces	  a	  colored	  compound	  that	  can	  be	  measured	   by	   absorbance	   at	   595	   nm.	   The	   SRB	   dye	   is	   incorporated	   into	   fixed	   cells	   and	   the	  amount	  of	  incorporated	  dye	  is	  proportional	  to	  the	  amount	  of	  cells;	  the	  dye	  has	  an	  absorbance	  at	  510	  nm.	  SD	  =	  Standard	  deviation.	  At	   least	  three	   independent	  experiments	  with	  three	  technical	  replicates	  were	  used	  to	  calculate	  the	  means	  of	  each	  assay	  per	  cell	  line.	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3.1 Cellular	  Capacitance	  and	  Metabolism	  
	  Data	   of	   cellular	   capacitance	   and	   metabolism	   was	   obtained	   from	   cell	   lines	  belonging	   to	   breast	   (MDA-­‐MB-­‐231	   and	   MCF7),	   colon	   (HCT116,	   HT-­‐29,	   and	   LS174T),	  pancreas	   (AsPC-­‐1,	  MIA	  PaCa-­‐2,	   JoPaCa-­‐1,	   Panc-­‐1,	   and	  BxPC-­‐3),	   prostate	   (LNCaP,	   PC-­‐3,	  and	  DU145),	  skin	  (HaCaT	  and	  MDA-­‐MB-­‐435),	  cervix	  (HeLa),	   liver	  (HepG2),	  and	  central	  nervous	  system	  (1321N1)	  (Experimental	  Methods	  2.1.1,	  Table	  1).	  HaCaT	  corresponds	  to	  keratinocytes	   that	   come	   from	   normal	   tissue	   and	   is	   the	   only	   noncancerous	   cell	   line	  included	  in	  this	  study.	  For	  the	  measurements,	  all	  the	  cell	  lines	  were	  cultivated	  in	  DMEM	  media	   with	   10%	   FCS	   and	   1%	   PenStrep	   in	   a	   5%	   CO2	   incubator	   at	   37°C	   with	   95%	  humidity	   (see	   Experimental	   Methods	   2.1.1	   for	   details).	   The	   data	   were	   obtained	   from	  online	  monitoring	  (real-­‐time	  measurements)	  and	  end-­‐point	  assays.	  Cellular	  capacitance,	  glycolysis,	  and	  respiratory	  activities	  were	  estimated	  in	  real	  time	  using	  the	  Bionas	  2500	  system	  (Experimental	  Methods	  2.1.2).	  The	  Bionas	  2500	  instrument	  contains	  a	  perfusion	  system	   that	   allows	   feeding	   of	   the	   cells	   with	   a	   flow	   of	   culture	   media	   for	   4	   min	   “go”	  followed	  by	  4	  min	  “stop”	  protocol.	  In	  the	  "stop"	  phase,	  cells	  consume	  the	  nutrients	  in	  the	  media	   and	   at	   the	   same	   time	   the	   measurements	   are	   done	   (Experimental	   Methods	  2.1.2.2).	   Energy	   metabolism	   (ATP	   level),	   mitochondrial	   mass,	   ROS	   accumulation	   and	  proliferation	   rates	   of	   the	   studied	   cell	   lines	   were	   determined	   using	   end-­‐point	   assays	  (Experimental	  Methods	  2.1.3,	  Table	  9).	  	  	  
3.1.1 Cellular	  Capacitance	  
	  The	   cell	   capacitance	   was	   measured	   with	   the	   Bionas	   2500	   online	   monitoring	  system	   (Experimental	  Methods	  2.1.2,	   Fig.	   1).	   For	   each	   cell	   line	   equal	   numbers	  of	   cells	  were	  seeded	  in	  sensor	  chips	  with	  an	  IDES	  sensor	  (Experimental	  Methods	  2.1.2.1).	  In	  the	  sensor	   chips,	   an	   alternating	   current	   is	   applied	   and	   interruption	   of	   electric	   current	   is	  recorded.	  Cells	  that	  are	  seeded	  in	  the	  chip	  block	  the	  flow	  of	  electrons	  between	  the	  two	  electrodes	  of	  the	  IDES	  sensor.	  Electricity	  does	  not	  affect	  the	  viability	  of	  the	  cells,	  neither	  their	   physical	   properties	   nor	  metabolism	   (Ehret	   et	   al.	   1997).	   The	   chips	   in	   the	   Bionas	  2500	  perform	  a	  continuous	  determination	  of	  the	  cellular	  capacitance.	  The	  IDES	  sensor	  allows	   to	  detect	   changes	   in	   cellular	  morphology,	   confluence,	   cell-­‐cell	   contact,	   and	  cell-­‐
	  	   49	  






















Fig.	  2.	  Cellular	  capacitance	  per	  cell	  lines.	  The	  capacitance	  was	  measured	  on	  the	  Bionas	  2500;	  cells	  are	  seeded	  in	  chips	  with	  IDES	  sensors.	  Equal	  numbers	  of	  cells	  per	  cell	  line	  were	  seeded	  in	  sensor	  chips.	  Higher	  capacitance	  values	  indicates	  low	  cell-­‐cell	  and	  cell-­‐matrix	  adhesion.	  Box-­‐plot	  diagram	  for	  different	  cell	   lines.	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bar	  =	  standard	  deviation;	  
black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  dashed	  line	  =	  mean	  value	  for	  all	  the	  analyzed	  cell	  lines;	  black	  dots	  out	  of	  the	  box	  =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  six	  technical	  replicates.	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3.1.2 Glycolytic	  Activity	  
	  The	   extracellular	   acidification	   rate	   was	   measured	   as	   a	   proxy	   for	   the	   cell's	  glycolytic	   activity	   (Experimental	  Methods	   Fig.	   1).	   Equal	   numbers	   of	   cells	   per	   cell	   line	  were	   seeded	   in	   sensor	   chips	  with	   ISFET	   sensors	   (Experimental	  Methods	   2.1.2.1).	   The	  ISFET	   sensor	  measures	   the	   pH	   changes	   in	   the	  media	   by	   detecting	   ion	   concentrations	  (Bergveld	   1981).	   The	   chips	   are	   located	   in	   the	   Bionas	   2500	   for	   a	   continuous	   online	  monitoring	  of	  the	  acidification	  rate.	  The	  ISFET	  sensor	  allows	  to	  detect	  changes	  of	  media	  acidification	  due	  to	  lactic	  acid	  production	  by	  cells	  as	  a	  result	  of	  aerobic	  glycolysis,	  known	  to	  be	  activated	  in	  cancer	  cells	  (Warburg	  effect).	  Cell	  lines	  with	  higher	  acidification	  rate	  showed	   an	   elevated	   glycolysis	   pathway	   (Fig.	   3).	   The	   colorectal	   carcinoma	   cell	   line	  HCT116	  and	  the	  cervix	  adenocarcinoma	  HeLa	  cells	  showed	  the	  highest	  acidification	  rate	  and	   also	   displayed	   strong	   glycolytic	  metabolism	   in	   all	   the	   tested	   cell	   lines	   (Fig.	   3).	   In	  contrast,	   the	   noncancerous	   skin	   keratinocyte	   HaCaT	   showed	   the	   lowest	   glycolytic	  activity	  (Fig.	  3).	  The	  HaCaT	  and	  HT-­‐29	  cell	  lines	  show	  a	  large	  data	  dispersion,	  showing	  the	   largest	   distance	   between	   data	   in	   the	   25th	   and	   75th	   percentiles.	   Four	   and	   sixteen	  independent	  experiments	  were	  used	  to	  determine	  the	  acidification	  rates	  for	  the	  HaCaT	  and	  HT-­‐29	  cell	  lines,	  respectively	  (data	  not	  shown).	  All	  independent	  experiments	  for	  all	  cell	  lines	  are	  composed	  of	  six	  internal	  replicates.	  Selected	  data	  comes	  from	  experiments	  in	  which	  the	  culture	  and	  experimental	  conditions	  remained	  the	  same	  for	  all	  the	  cell	  lines	  (Experimental	  Methods	  2.1.2.3).	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Fig.	   3.	   Glycolytic	   activity	   per	   cell	   lines.	   The	   glycolytic	   activity	  was	  measured	   on	   the	   Bionas	  2500	   ;	   cells	   are	   seeded	   in	   chips	  with	   ISFET	  sensors.	  Equal	  numbers	  of	   cells	  per	   cell	   line	  were	  seeded	   in	  sensor	  chips.	  Higher	  acidification	  rate	   indicates	  stronger	  glycolytic	  activity.	  Box-­‐plot	  diagram	  for	  different	  cell	   lines.	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bar	  =	  standard	  deviation;	  
black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  dashed	  line	  =	  mean	  value	  for	  all	  the	  analyzed	  cell	  lines;	  black	  dots	  out	  of	  the	  box	  =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  six	  technical	  replicates.	  	  	  	  
3.1.3 Respiration	  Activity	  





















Fig.	   4.	   Respiration	   activity	   per	   cell	   line.	   The	   oxygen	   consumption	   was	   measure	   in	   Bionas	  2500;	  cells	  are	  seeded	  in	  chips	  with	  Clark	  electrodes.	  Equal	  numbers	  of	  cells	  per	  cell	   line	  were	  seeded	  in	  sensor	  chips.	  Higher	  oxygen	  consumption	  indicates	  stronger	  respiration	  rate.	  Box-­‐plot	  diagram.	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bar	  =	  standard	  deviation;	  black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  dashed	  line	  =	  mean	  value	  between	  the	  analyzed	  cell	  lines;	  black	  dots	  
out	   of	   the	   box	   =	   outliers.	   Cell	   lines	   are	   grouped	   by	   tissue	   type.	   At	   least	   three	   independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  six	  technical	  replicates.	  	  	  
3.1.4 Energy	  Metabolism	  (ATP	  Level)	  
	  The	   energy	   metabolism	   of	   the	   cells	   was	   measured	   as	   the	   amount	   of	   ATP	  produced	   by	   using	   firefly	   (Photinus	   pyralis)	   luciferase	   activity	   (see	   Experimental	  Methods	   2.1.3.1).	   In	   this	   assay,	   the	   luminescence	   produced	   is	   proportional	   to	   the	  extracellular	  ATP	  concentration	  present	   in	   the	  cell	   suspension	  (Experimental	  Methods	  2.1.3.1).	  At	   least	   three	   technical	  replicates	  and	  three	   independent	  measurements	  were	  done	  per	  cell	  line.	  The	   lowest	   levels	  of	   energy	  metabolism	  activity	   are	   found	   in	   the	   colorectal	   cell	  lines	  (the	  carcinomas	  HCT116	  and	  HT-­‐29	  and	  the	  adenocarcinoma	  LS174T).	  Also,	  one	  of	  the	  skin	  cell	   lines	  (the	  melanoma	  MDA-­‐MB-­‐435),	   the	  cervix	  adenocarcinoma	  HeLa	  and	  the	   liver	   carcinoma	  Hep	  G2)	   present	   low	   levels	   of	   energy	  metabolism	  activity.	  On	   the	  other	   hand,	   high	   levels	   of	   energy	  metabolism	   activity	   is	   found	   in	   four	   out	   of	   the	   five	  pancreatic	   cell	   lines	   (AsPC-­‐1,	   JoPaCa-­‐1,	   MIA	   PaCa-­‐2,	   and	   Panc-­‐1),	   with	   the	   remaining	  BxPC-­‐3	   having	   ATP	   levels	   corresponding	   to	   the	  mean	   of	   all	   the	   tested	   cell	   lines.	   The	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breast	  adenocarcinoma	  MCF7	  and	  the	  brain	  astrocytoma	  131N1	  are	  also	  among	  the	  cell	  lines	  with	  high	  levels	  of	  energy	  metabolism	  activity	  (Fig.	  5).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Fig.	  5.	  Energy	  metabolism	  (ATP	  level)	  per	  cell	  line.	  The	  ATP	  production	  of	  the	  cell	  lines	  was	  measured	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  The	  luminescent	  counts	  are	  proportional	  to	  the	  ATP	  concentration.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	   percentiles;	  error	   bars	   =	   standard	  deviation;	  black	  dot	   inside	   the	  box	   =	  mean;	  black	   line	   =	  median;	  dashed	   line	   =	  mean	  value	  between	   the	   analyzed	   cell	   lines;	  black	   dots	   out	   of	   the	   box	   =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  three	  technical	  replicates.	  	  	  	  
3.1.5 Total	  Mitochondrial	  Mass	  
	  The	   mitochondrial	   mass	   of	   the	   different	   cell	   lines	   was	   estimated	   using	  MitoTracker	   Green	   compound	   that	   permeates	   cell	   membranes	   and	   labels	   active	  mitochondria	   (see	   Experimental	   Methods	   2.1.3.2).	   At	   least	   three	   independent	  measurements	   with	   three	   technical	   replicates	   were	   carried	   out	   per	   cell	   line.	   High	  fluorescence	  intensity	  is	  proportional	  to	  the	  mitochondrial	  mass	  in	  the	  cells.	  The	  highest	  levels	  of	  mitochondrial	  mass	  were	  found	  in	  the	  cervix	  HeLa	  cell	  line.	  This	  cell	  line	  shows	  higher	  levels	  than	  all	  the	  other	  studied	  cell	  lines.	  It	  is	  followed	  in	  intensity	  by	  two	  of	  the	  three	  colorectal	  cell	  lines,	  the	  carcinomas	  HCT116	  and	  HT-­‐29.	  These	  two	  colorectal	  cell	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lines	  present	   a	  high	  data	  dispersion,	   showing	  higher	  values	  of	   standard	  deviation	  and	  25th-­‐to-­‐75th	   percentil	   distances.	   The	   cell	   lines	   with	   the	   lowest	   levels	   of	   active	  mitochondria	   are	   the	   breast	   adenocarcinoma	   MDA-­‐MB-­‐231,	   the	   colorectal	  adenocarcinoma	   LS174T,	   and	   noncancerous	   skin	   cell	   line	   HaCaT	   (Fig.	   6).	   The	   breast,	  pancreatic,	  and	  prostate	  cell	  lines	  appear	  together	  around	  the	  mean	  of	  the	  total	  cell	  lines	  used	  for	  the	  analysis	  (Fig.	  6).	  	  	  	  
	  
Fig.	   6.	   Total	  mitochondrial	  mass	   per	   cell	   line.	   The	  mitochondrial	  mass	   content	   of	   the	   cells	  was	  determining	  using	  MitoTracker	  Green	  (Thermo	  Fisher).	  Cell	  lines	  with	  higher	  fluorescence	  intensity	  contain	  higher	  mitochondrial	  mass.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	  percentiles;	  
error	  bars	  =	  standard	  deviation;	  black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  dashed	  line	  =	  mean	  value	  between	  the	  analyzed	  cell	  lines;	  black	  dots	  out	  of	  the	  box	  =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  three	  technical	  replicates.	  	  
3.1.6 Reactive	  Oxygen	  Species	  (ROS)	  Accumulation	  
	  Reactive	  oxygen	  species	   (ROS)	   formation	  was	  measured	  using	  dihydroethidium	  (DHE)	  in	  the	  studied	  cell	  lines.	  DHE	  permeates	  into	  cell	  membranes	  and	  diffuses	  into	  the	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cytosol,	  where	  it	  is	  oxidized	  by	  superoxide	  resulting	  in	  the	  emission	  of	  red	  fluorescence	  (Experimental	  Methods	   2.1.3.3).	   At	   least	   three	   independent	  measurements	  with	   three	  technical	  replicates	  were	  done	  per	  cell	  line.	  The	  cell	  line	  with	  the	  highest	  levels	  of	  ROS	  is	  the	  pancreatic	  carcinoma	  Panc-­‐1	  followed	  by	  the	  breast	  adenocarcinoma	  MDA-­‐MB-­‐231	  (Fig.	  7).	  The	  lowest	  level	  of	  ROS	  accumulation	  is	  found	  in	  the	  colorectal	  HT-­‐29	  cell	  line.	  Its	  tissue	  type	  pairs,	  HCT116	  and	  LS174T,	  also	  show	  low	  ROS,	  with	  its	  levels	  being	  under	  the	  mean	  for	  all	  cell	  lines	  tested	  (Fig.	  7).	  	  	  
Fig.	  7.	  Reactive	  oxygen	  species	  (ROS)	  formation	  per	  cell	  line.	  ROS	  accumulation	  in	  cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  Cell	  lines	  with	  higher	  fluorescence	  intensity	  present	  a	  higher	  ROS	  formation.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bars	  =	  standard	  deviation;	   black	   dot	   inside	   the	   box	   =	   mean;	   black	   line	   =	   median;	   dashed	   line	   =	   mean	   value	  between	   the	   analyzed	   cell	   lines;	  black	   dots	   out	   of	   the	   box	   =	   outliers.	   Cell	   lines	   are	   grouped	  by	  tissue	  type.	  At	   least	   three	   independent	  experiments	  were	  done	  per	  cell	   line	  and	  each	  one	  with	  three	  technical	  replicates.	  	  	  
3.1.7 Cell	  Proliferation	  Rate	  
	  	  	   The	   cell	   proliferation	   rate	   for	   different	   cell	   lines	   was	   estimated	   using	   two	  different	   approaches:	   i)	   metabolic	   activity	   measured	   by	   MTT	   assay	   and	   ii)	   the	   total	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protein	  content	  of	  the	  cells	  using	  SRB	  assay.	  The	  MTT	  reagent	  diffuses	  into	  the	  cells	  and	  labels	   active	   mitochondria	   and	   therefore	   is	   an	   indirect	   measurement	   for	   cell	  proliferation.	  However,	   the	  SRB	  assay	  stains	   total	  proteins	  of	   fixed	  cells,	  after	  washing	  out	  the	  dead	  cells,	  which	  then	  is	  directly	  proportional	  to	  cell	  number	  and	  proliferation	  rate	  (Vichai	  &	  Kanyawim	  2006)	  (Experimental	  Methods	  2.1.3.4).	  For	  each	  cell	  line,	  equal	  numbers	  of	  cells	  were	  seeded	  and	  the	  cells	  were	  left	  growing	  for	  72	  h	  before	  performing	  the	   measurements.	   At	   least	   three	   independent	   measurements	   with	   three	   technical	  replicates	   were	   done	   per	   cell	   line	   and	   assay.	   The	  MTT	   and	   SRB	   assays	   proved	   to	   be	  reliable	  methods	  to	  compare	  proliferation	  rates	   in	  the	  different	  cell	   lines.	  Both	  yielded	  the	   same	   results	   for	   almost	   all	   tested	   cell	   lines	   (Figs.	   8	   and	  9).	  Only	  HeLa	   and	  HepG2	  cells	   showed	   contradictory	   information	   between	   the	   assays,	   being	   the	   MTT	  measurement	   in	  HeLa	   cells	   the	  one	  with	   the	  highest	  proliferation	   rate	   and	  HepG2	   the	  one	  with	  the	  lowest.	  Besides,	   in	  SRB,	  both	  cell	   lines	  remain	  around	  the	  mean	  of	  all	   the	  tested	  cells	  (Figs.	  8	  and	  9).	  In	  both	  assays,	  at	  the	  tissue-­‐type	  level,	  the	  colorectal	  cell	  lines	  show	   the	   fastest	   proliferation	   and	   the	   breast	   cell	   lines	   the	   slowest	   proliferation	   rate	  (Figs.	   8	   and	   9).	   In	   the	   three	   tissue	   types	   where	   the	   assays	   were	   tested,	   cell	   lines	  belonging	   to	   the	   same	   tissue	   type	   showed	   similar	  proliferation	   rates,	   i.e.,	   "within	   cell-­‐type”.	   The	   prostate	   tissue	   type	   was	   only	   measured	   for	   the	   adenocarcinoma	   PC-­‐3,	  therefore	  no	  "within	  cell-­‐type"	  comparisons	  were	  possible	  (Figs.	  8	  and	  9).	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Fig.	   8.	   Proliferation	   rate	  measured	   as	  metabolic	   activity	   (MTT	   assay)	   per	   cell	   line.	   The	  MTT	   reagent	   is	   reduced	   by	   active	   mitochondria	   producing	   a	   purple-­‐colored	   product	   with	   an	  absorbance	  at	  595	  nm.	  Cells	  with	  higher	  absorbance	  present	  a	  higher	  metabolic	  activity	  that	  is	  used	  as	  an	  estimation	  of	  the	  proliferation	  rate.	  Equal	  low	  cell	  numbers	  per	  cell	  line	  were	  seeded	  in	  96-­‐well	  plates,	  the	  absorbance	  was	  measure	  after	  72	  h.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bars	  =	  standard	  deviation;	  black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  
dashed	  line	  =	  mean	  value	  between	  the	  analyzed	  cell	  lines;	  black	  dots	  out	  of	  the	  box	  =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  three	  technical	  replicates.	  	  	  	  	  
	  
Fig.	  9.	  Proliferation	  rate	  measured	  as	  total	  protein	  content	  (SRB	  assay)	  per	  cell	  line.	  In	  the	  SRB	   assay	   a	   dye	   is	   incorporated	   into	   fixed	   cells	   and	   the	   amount	   of	   incorporated	   dye	   is	  proportional	  to	  the	  amount	  of	  cells.	  Cells	  with	  higher	  absorbance	  have	  a	  higher	  protein	  content	  that	  is	  used	  as	  an	  estimation	  of	  the	  proliferation	  rate.	  Equal	  low	  cell	  numbers	  per	  cell	  line	  were	  seeded	  in	  96-­‐well	  plates,	  the	  absorbance	  was	  measured	  after	  72	  h.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bars	  =	  standard	  deviation;	  black	  dot	  inside	  the	  box	  =	  mean;	  black	  line	  =	  median;	  dashed	   line	   =	  mean	  value	  between	   the	   analyzed	   cell	   lines;	  black	   dots	   out	   of	   the	   box	   =	  outliers.	  Cell	  lines	  are	  grouped	  by	  tissue	  type.	  At	  least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  three	  technical	  replicates.	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3.2 Cellular	   Properties	   of	   the	   Cancer	   Cell	   Lines	   by	   Tissue	   Type.	  
Summary	  Figure	  and	  Cluster	  Dendrograms	  
	  The	   basal	   metabolic	   profile	   and	   the	   cellular	   capacitance	   of	   the	   18	   cell	   lines	  belonging	  to	  different	  tissue	  types	  are	  shown	  in	  Fig.	  10;	  this	  summarizes	  all	  the	  different	  features	  of	  the	  studied	  cell	  lines	  done	  before	  (Figs.	  2	  to	  9).	  	   The	   broad	   overview	   of	   the	   cellular	   properties	   in	   the	   studied	   cell	   lines	   allows	  comparisons	   of	   the	   cellular	   capacitance,	   the	   O2	   consumption	   (respiratory	   activity),	  media	   acidification	   (glycolytic	   activity),	   ATP	   levels	   (energy	   metabolism),	   intracellular	  ROS	   accumulation,	  mitochondrial	  mass,	   and	  proliferation	   rates	   (MTT	  and	   SRB	  assays)	  (Table	  9)	  by	  cell	  lines	  and	  tissue	  type.	  	  	   The	  two	  adenocarcinoma	  breast	  cancer	  cell	  lines	  differ	  in	  their	  capacitance	  and	  in	  their	   energy	   metabolism	   (ATP	   level)	   but	   present	   similar	   respiratory	   activity,	   ROS	  accumulation,	  and	  proliferation	  rates	  (Fig.	  10).	  Hierarchical	  clustering	  performed	  on	  the	  data	   for	   the	   different	   assays	   (with	   measurements	   in	   each	   cell	   line)	   show	   the	   two	  adenocarcinoma	  breast	  cell	  lines	  in	  the	  same	  branch	  for	  the	  MTT	  proliferation	  assay	  and	  in	  proximal	  branches	  in	  the	  ROS	  formation	  and	  in	  the	  SRB	  proliferation	  assay	  (Fig.	  11).	  However,	  respiration	  activity	  does	  not	  appear	  neither	  in	  the	  same	  or	  close	  branches,	  in	  fact,	   energy	   metabolism	   shows	   a	   closer	   distance	   between	   the	   two	   cell	   lines	   in	   the	  dendrogram	   (Fig.	   11).	   By	   comparing	   the	  breast	   cancer	   cell	   lines	  with	   the	   other	   tissue	  types,	   it	   is	   possible	   to	   say	   that	   these	   cells	   present	   high	   ATP	   and	   ROS	   levels	   and	   low	  proliferation	  rates	  (Figs.	  5,	  7,	  8,	  9,	  and	  10).	  	  	   The	  two	  colorectal	  carcinoma	  cancer	  cell	   lines	  HCT116	  and	  HT-­‐29	  show	  similar	  membrane	   capacitance,	   glycolysis	   activity	   (acidification),	   and	   mitochondrial	   mass,	  indicating	  discrepancies	  with	   their	   the	  adenocarcinoma	  LS174T	   (Fig.	  10).	  Hierarchical	  clustering	   locates	   these	   two	   carcinoma	   cells	   in	   near	   branches	   and	   far	   away	   from	   the	  adenocarcinoma	  LS174T	  for	  cell	  capacitance,	  glycolysis,	  and	  mitochondrial	  mass	  assays	  (Fig.	  11).	  The	  three	  cancer	  cell	   lines	  share	  similar	  levels	  in	  ATP,	  ROS,	  and	  proliferation	  rates	   (Fig.	   10).	   Dendrograms	   of	   the	   mentioned	   assays	   confirm	   these	   observations,	  grouping	   the	   three	   cell	   lines	   in	   near	   branches	   for	   energy	   metabolism	   and	   ROS	  accumulation,	  and	   in	   the	  same	  branch	   for	   the	  proliferation	  assays	  (Fig.	  11).	  Regarding	  the	   respiratory	   activity,	   the	   hierarchical	   clustering	   grouped	   LS174T	   and	   HCT	   116	  together	  in	  the	  same	  branch	  (Fig.	  11).	  In	  contrast,	  for	  the	  breast	  and	  pancreas	  cancer	  cell	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lines,	   cells	   of	   the	   colorectal	   tissue	   type	   present	   low	   ATP	   and	   ROS	   levels	   (Figs.	   5,	   7,	  and	  10)	  and	  the	  highest	  proliferation	  rate	  among	  all	  the	  tissue	  types	  analyzed	  (Figs.	  8,	  9,	  and	  10).	  	   The	  pancreatic	  cells	  do	  not	  seem	  to	  show	  similarities	  between	  the	  type	  of	  disease	  (or	   type	  of	   tumor)	  and	   their	  cell	  properties,	   like	   the	  colorectal	   line	  does,	  with	   the	   two	  adenocarcinomas	   AsPC-­‐1	   and	   BxPC-­‐3	   or	   the	   three	   carcinomas	   MIA	   PaCa-­‐2,	   JoPaCa-­‐1,	  and	  Panc-­‐1	  having	  no	   similar	   features.	  The	  data	   for	   the	  O2	   consumption	   in	  pancreatic	  cells	  spreads	  in	  a	  wide	  range	  within	  this	  tissue	  type	  presenting	  the	  highest	  (Panc-­‐1)	  and	  the	   lowest	   (JoPaCa-­‐1)	   respiration	   activities	   in	   all	   tested	   cell	   lines	   (Fig.	   10).	   Glycolysis	  activity,	  energy	  metabolism,	  and	  proliferation	  locate	  the	  pancreas	  cells	  roughly	  together,	  the	  measurements	  showing	  similar	  means	  (Fig.	  10).	  The	  hierarchical	  cluster	  for	  the	  MTT	  proliferation	   assay	   locates	   the	   pancreas	   tissue	   type	   cells	   together	   in	   one	   group	   apart	  from	  the	  rest	  of	  the	  cell	   lines.	  Such	  a	  strong	  match	  is	  not	  displayed	  in	  the	  dendrogram	  for	   the	   SRB	  proliferation	   assay;	   clusters	   spread	   the	  pancreas	   cells	   in	   two	  of	   the	   three	  branches	  (Fig.	  11).	  The	  dendrogram	  for	  energy	  metabolism	  shows	   the	  pancreas	   tissue	  type	   in	  close	  branches.	  Comparing	   the	  pancreas	   tissue	   type	  with	  breast	  and	  colorectal	  tissue	   types	   makes	   possible	   to	   observe	   that	   pancreas	   cells	   behave	   like	   breast	   cells	  showing	   relative	   high	  ATP	   and	   low	  proliferation.	   The	  ROS	   accumulation	  differs	   in	   the	  five	  pancreas	  cell	  lines	  (Figs.	  5,	  7,	  8,	  9,	  and	  10).	  	   The	   prostate	   cell	   lines	   PC-­‐3	   (adenocarcinoma)	   and	   DU145	   (carcinoma)	   show	  almost	   equal	   respiration	   and	   glycolysis	   activities	   as	   well	   as	   mitochondrial	   mass	   and	  seems	   to	   differ	   from	   the	   adenocarcinoma	   LNCaP	   (Fig.	   10).	   Hierarchical	   clustering	   for	  glycolysis	  and	  mitochondrial	  mass	  support	  the	  observations,	  showing	  the	  three	  cell	  lines	  in	  different	  branches	  but	  near	  the	  PC-­‐3	  to	  the	  DU	  145.	  Dendrograms	  of	  the	  respiration	  activity	   present	   PC-­‐3	   and	   DU	   145	   in	   the	   same	   branch	   and	   far	   away	   of	   the	   LNCaP	  (Fig.	  11).	  The	  highest	  and	   the	   lowest	  membrane	  capacitance	  of	  all	   the	   tested	  cell	   lines	  are	  present	  in	  the	  prostate	  cells	  being	  LNCaP	  that	  exhibits	  a	  weaker	  cell-­‐cell	  contact	  and	  cell-­‐matrix	  binding	  (high	  cell	  capacitance)	  and	  DU	  145	  with	  stronger	  cell	  adhesion	  and	  cell	  bindings	  (low	  cell	  capacitance).	  	  The	  last	  tissue	  type	  group	  in	  which	  the	  data	  was	  collected	  was	  the	  skin	  cell	   line	  HaCaT,	  a	  noncancerous	  cell	   line,	  and	  the	  melanoma	  MDA-­‐MB-­‐435.	  These	  two	  cell	   lines	  were	  plotted	  together	  with	  the	  cervix	  HeLa,	  the	  liver	  HepG2,	  and	  the	  brain	  1321N1.	  The	  mean	  value	  of	  the	  two	  skin	  cell	  lines	  seem	  to	  be	  similar	  for	  the	  cellular	  capacitance,	  O2	  consumption,	   acidification	   rate	   and	   ROS	   accumulation	   measurements	   (Fig.	   10).	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Hierarchical	  clusters	  build	  with	  the	  cell	  capacitance	  data	  show	  the	  two	  skin	  cell	  lines	  in	  different	  branches	  but	  together	  in	  one	  of	  the	  two	  main	  tails	  of	  the	  tree.	  In	  the	  glycolysis	  and	  respiration	  dendrograms,	  HaCaT	  and	  MDA-­‐MB-­‐435	  are	   far	  away	   from	  each	  other;	  they	   cluster	   in	   separated	   branches.	   For	   the	   ROS	   accumulation,	   hierarchical	   clustering	  located	  the	  cells	  for	  the	  skin	  tissue	  type	  in	  different	  branches	  (Fig.	  11).	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Fig.	   10.	   Summary	  of	   cell	   capacitance	   and	  metabolic	   features	  of	   cell	   lines	  by	   tissue	   type.	  Cellular	  capacitance,	  glycolytic	  activity	  (acidification),	  and	  respiratory	  activity	  (O2	  consumption)	  were	   measured	   on	   the	   Bionas	   2500	   online	   monitoring	   system.	   Cells	   were	   seeded	   in	   chips	  containing	  IDES	  sensors	  for	  the	  estimation	  of	  the	  cellular	  capacitance,	  ISFET	  sensors	  to	  measure	  the	   acidification	   rate,	   and	   Clark-­‐type	   electrodes	   for	   determining	   oxygen	   consumption.	   Lower	  capacitance	   indicates	   a	   stronger	   cell	   matrix	   adhesion	   and	   cell-­‐cell	   contact	   interactions.	   A	  stronger	   acidification	   rate	   indicates	   a	   higher	   glycolysis	   level.	   Higher	   oxygen	   consumption	  indicates	   stronger	   respiration	   rate.	   The	   energy	   metabolism	   (ATP	   level)	   was	   measured	   with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  The	  luminescence	  is	   proportional	   to	   the	   ATP	   concentration	   in	   the	   cells.	   The	   mitochondrial	   mass	   content	   was	  determined	   using	   MitoTracker	   Green	   (Thermo	   Fisher).	   The	   fluorescence	   intensity	   is	  proportional	   to	   the	  mitochondrial	  mass	   of	   the	   cells.	   ROS	   accumulation	   in	   cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  The	  fluorescence	  intensity	  produced	  is	  directly	  related	  to	  the	  ROS	  accumulation	  in	  the	  cells.	  The	  proliferation	  rate	  was	  estimated	  using	  MTT	  and	  SRB	  assays.	  MTT	  reagent	  labels	  active	  mitochondria	  and	  its	  reduction	  produces	  a	  colored	  compound	  that	  can	  be	  measured	   with	   absorbance	   at	   595	   nm.	   The	   SRB	   dye	   is	   incorporated	   into	   fixed	   cells	   and	   the	  amount	  of	  incorporated	  dye	  is	  proportional	  to	  the	  amount	  of	  cells,	  the	  dye	  has	  an	  absorbance	  at	  510	  nm.	  Box-­‐plot	  diagram:	  Box	  =	  25th	  and	  75th	  percentiles;	  error	  bars	  =	  standard	  deviation;	  black	  
dot	   inside	   the	   box	   =	   mean;	   black	   line	   =	   median;	   dashed	   line	   =	   mean	   value	   between	   the	   total	  analyzed	  cell	   lines;	  black	  dots	  out	  of	  the	  box	  =	  outliers.	  At	   least	  three	  independent	  experiments	  were	  done	  per	  cell	  line	  and	  each	  one	  with	  three	  technical	  replicates.	  	  	  	  	   The	   cervix	   adenocarcinoma	   cell	   line	   HeLa	   shows	   a	  much	   higher	  mitochondrial	  mass	   than	   the	   rest	   of	   the	   studied	   cell	   lines	   (Figs.	   6	   and	   10).	   Hierarchical	   clustering	  corroborates	   this	   observation	   localizing	   HeLa	   in	   the	   mitochondrial	   mass	   content	  dendrogram	  alone	  in	  a	  branch	  separate	  from	  the	  others.	  Looking	  deeper	  into	  the	  cellular	  property	   clusters,	   it	   is	   remarkable	   that	   in	   several	   of	   the	   metabolic	   assays	   HeLa	   cells	  appears	   closer	   to	   the	   colorectal	   cell	   lines,	   sharing	   with	   the	   three	   of	   them	   the	   same	  branch	   in	  the	  MTT	  proliferation	  assay	  dendrogram	  and	  being	  closer	  to	  the	  ones	   in	  the	  respiration	   activity	   and	   energy	   metabolism	   clusters.	   Moreover,	   in	   ROS	   formation	  dendrogram	  it	  shares	  the	  same	  branch	  with	  HT-­‐29	  and	  with	  HCT	  116	  in	  the	  glycolysis	  activity	  dendrogram	  (Fig.	  11).	  	  	   The	  liver	  carcinoma	  cell	   line	  Hep	  G2	  seems	  to	  not	  share	  features	  with	  other	  cell	  lines	   except	   for	   cellular	   capacitance	   and	   glycolysis	   activity	   where,	   in	   the	   hierarchical	  clustering,	  it	  shares	  the	  same	  branches	  with	  pancreas	  carcinoma	  Panc-­‐1	  (Fig.	  11).	  	  	   The	   central	   nervous	   system	   astrocytoma	   1321N1	   cell	   line	   in	   the	   hierarchical	  clusters	  of	  the	  metabolic	  assay	  measurements	  appears	  near	  the	  pancreas	  cells	  JoPaCa-­‐1	  and	  Panc-­‐1.	  The	  brain	  cell	   line	   localizes	   in	  the	  same	  branches	  with	  JoPaCa-­‐1	  regarding	  its	   respiratory	   activity	   and	   in	   the	   ROS	   accumulation	   dendrograms.	   Notice	   also	   that	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Fig.	   11.	   Hierarchical	   clustering	   of	   cellular	   capacitance	   and	  metabolic	   features.	   Cell	   lines	  were	  grouped	  based	  on	  their	  electrical	  and	  metabolic	  properties.	  Cellular	  capacitance,	  glycolytic	  and	  respiratory	  activities	  were	  measured	  on	  the	  Bionas	  2500	  online	  monitoring	  system.	  Energy	  metabolism	   (ATP	   level)	  was	  measured	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	   (Perkin	   Elmer).	   The	   mitochondrial	   mass	   content	   was	   determined	   using	   MitoTracker	  Green	  (Thermo	  Fisher).	  ROS	  accumulation	   in	  cells	  was	  measured	  using	  DHE.	  The	  proliferation	  rate	   was	   estimated	   using	   MTT	   and	   SRB	   assays.	   The	   clustering	   calculations	   were	   done	   via	  
R	  programming	   language	   and	   Euclidean	   distance	   approach.	   Cell	   lines	   belonging	   to	   the	   same	  tissue	   type	   share	   the	   same	   color.	   The	   height	   in	   the	   y-­‐axis	   gives	   the	   values	   of	   the	   respective	  metabolism	  assay	  tested.	  The	  mean	  of	  at	  least	  three	  independent	  experiments	  per	  assay	  and	  per	  cell	  line	  was	  used	  for	  the	  cluster	  analysis.	  	  	  
3.3 Linear	   Relations	   between	   the	   Cellular	   Properties	   of	   the	  
Studied	  Cell	  Lines	  
	  The	  data	  collected	   for	   the	  cellular	  properties	  of	   the	  studied	  cell	   lines	  (Figs.	  2	   to	  10)	   was	   used	   to	   calculate	   a	   Pearson	   product	   moment	   correlation	   (see	   Experimental	  Methods	   2.5)	   in	   order	   to	   search	   for	   linear	   relationships	   within	   the	   different	   cellular	  features.	  The	  Pearson	  correlation	  coefficient	  (r	  coefficient)	  indicates	  whether	  there	  is	  a	  linear	  relationship	  between	  two	  variables	  and	  how	  the	  two	  sets	  of	  data	  are	  related,	  i.e.,	  whether	  a	  positive	   linear	   relation	   (0	  <	   r	  <	  1)	  or	  a	  negative	   linear	   relation	   (–1	  <	  r	  <	  0)	  exists,	  with	  r	  being	  the	  correlation	  coefficient.	  An	  r	  value	  equal	  to	  1	  indicates	  a	  perfect	  positive	  correlation	  between	  the	  two	  variables,	  and	  –1	  is	  a	  perfect	  negative	  correlation.	  Zero	   indicates	   no	   linear	   correlation.	   Table	   10	   shows	   the	   r	   and	   its	   associated	   p-­‐values	  obtained	  for	  the	  calculation	  of	  the	  Pearson	  product	  moment	  with	  the	  cellular	  properties	  data	  in	  the	  studied	  cell	  lines.	  The	  obtained	  significant	  (p-­‐values	  <	  0.05)	  relationships	  are	  plotted	  in	  Fig.	  12.	  	  	   The	   proliferation	   rate	   measured	   as	   metabolic	   activity	   by	   MTT	   and	   the	  proliferation	   rate	   measured	   as	   total	   protein	   content	   by	   SRB	   present	   a	   positive	  correlation	  (r	  =	  0.69)	  (Fig.	  12A).	  In	  the	  dependency	  graph	  it	  is	  possible	  to	  observe	  that	  the	  three	  colorectal	  cell	   lines	  have	  high	  proliferation	  rates	  for	  both	  measurements	  and	  localize	   near	   one	   another;	   the	   pancreatic	   cells	   present	   a	   low	   proliferation	   rate	   and	  localize	  together.	  The	  breast	  cancer	  cell	  lines	  exhibit	  an	  even	  lower	  proliferation	  rate.	  	   A	  significant	  (p-­‐value	  <	  0.01)	  positive	  relation	  is	  also	  recorded	  for	  the	  glycolytic	  activity	  and	  the	  proliferation	  rate	  MTT	  assay	  (r	  =	  0.71)	  (Fig.	  12B),	  meaning	  that	  the	  cell	  lines	   that	   proliferate	   most,	   also	   possess	   a	   strong	   glycolytic	   activity.	   Similarly	   to	   the	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proliferation	  rate	  assay	  dependency,	  colorectal	  cell	  lines	  display	  the	  highest	  acidification	  and	  proliferation	  rate	  values	  in	  the	  three	  tissue	  types	  tested,	  the	  breast	  tissue	  type	  cells	  show	   the	   lowest,	   and	   the	   pancreatic	   tissue	   type	   cell	   lines	  with	  moderate	   values.	   Cells	  belonging	   to	   the	   colorectal	   tissue	   type	  do	  not	  appear	   together	   in	   the	  plot	  due	   to	   their	  differences	   in	   the	   acidification	   rate.	   On	   the	   other	   hand,	   cells	  with	   a	   high	   proliferation	  rate	   accumulate	   less	   ROS	   (r	   =	   –0.68)	   (Figs.	   12C	   and	   D).	   Notice	   that	   for	   this	   negative	  dependency	  the	  colorectal	  tissue	  type	  with	  its	  faster	  proliferation	  shows	  the	  lowest	  ROS	  formation.	  The	  opposite	  is	  the	  case	  in	  the	  breast	  cancer	  cell	  lines	  with	  high	  ROS	  and	  low	  proliferation.	  	  	   It	  is	  remarkable	  that	  ROS	  accumulation	  negatively	  correlates	  with	  both	  MTT	  and	  SRB	  proliferation	  assays,	  having	  a	  significant	  (p-­‐value	  <	  0.05)	  inverse	  relationship	  with	  the	  metabolic	  activity	  as	  well	  as	  with	  the	  total	  protein	  content	  of	   the	  studied	  cell	   lines	  (Fig.	   12C	   and	  D	   and	  Table	   10).	  Moreover,	   ROS	   accumulation	   exhibits	   a	   significant	   (p-­‐value	   <	   0.01)	   positive	   relation	   with	   the	   energy	   metabolism	   (r	   =	   0.64)	   (Fig.	   12E).	  Pancreatic	  and	  breast	  tissue	  type	  cells	  show	  higher	  ROS	  and	  ATP	  levels	   in	  comparison	  with	  the	  colorectal	  ones	  which	  localize	  at	  the	  lower	  end	  in	  the	  correlation	  plot,	  showing	  low	  ROS	   accumulation	   and	   low	   energy	  metabolism	   (Fig.	   12E).	   The	   last	   significant	   (p-­‐value	  <	  0.05)	  linear	  dependency	  found	  among	  the	  cellular	  properties	  of	  the	  studied	  cell	  lines	   is	   the	   negative	   relation	   between	   energy	   metabolism	   (ATP	   formation)	   and	  proliferation	   rate	   measured	   as	   total	   protein	   content	   in	   the	   SRB	   assay	   (r	   =	   –0.64)	  (Fig.	  12F).	   Due	   to	   the	   positive	   dependency	   found	   between	   ATP	   level	   and	   ROS	  accumulation	  in	  cells,	  the	  negative	  relation	  between	  ATP	  and	  the	  SRB	  assay	  supports	  the	  dependency	  of	  ROS	  formation	  and	  proliferation	  rate	  in	  the	  studied	  cell	  lines.	  	  
	  
	  
Table	  10.	  r	  coefficients	  and	  p	  values	  of	  the	  linear	  dependencies	  between	  the	  electrical	  and	  
metabolic	  properties	  of	   the	  studies	   cell	   lines.	  A	  Pearson	   comparison	  between	   the	  different	  assays	  was	  used	  to	  search	  for	  correlations.	  The	  calculation	  was	  done	  using	  the	  mean	  of	  at	  least	  three	   independent	  experiments.	  Cellular	  capacitance,	  glycolytic	  and	  respiratory	  activities	  were	  measured	   on	   the	   Bionas	   2500	   online	   monitoring	   system.	   The	   ATP	   level	   was	   measured	   with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  The	  mitochondrial	  mass	   (mitomass)	   content	   was	   determined	   using	   MitoTracker	   Green	   (Thermo	   Fisher).	   ROS	  accumulation	  in	  cells	  was	  measured	  using	  DHE.	  The	  proliferation	  rate	  was	  estimated	  using	  MTT	  and	  SRB	  assays.	  The	  Pearson	  comparison	  calculation	  was	  done	  using	  R	  programming	  language	  package	  Hmisc	  function	  rcorr.	  In	  yellow	  the	  significant	  correlations	  (p	  -­‐values	  <	  0.05).	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r	  coefficients	   Capacitance	   Respiration	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	  
Capacitance	   1	   	   	   	   	   	   	  
Respiration	   0.28	   1	   	   	   	   	   	  
Glycolysis	   0.36	   0.44	   1	   	   	   	   	  
ATP	   0.14	   0.11	   -­‐0.32	   1	   	   	   	  
Mitomass	   -­‐0.002	   0.06	   0.45	   -­‐0.21	   1	   	   	  
ROS	   -­‐0.11	   0.24	   -­‐0.31	   0.64	   -­‐0.24	   1	   	  
SRB	   0.12	   0.26	   0.55	   -­‐0.64	   0.21	   -­‐0.68	   1.00	  
MTT	   0.42	   0.42	   0.71	   -­‐0.55	   0.53	   -­‐0.68	   0.69	  
	  
p	  -­values	   Capacitance	   Respiration	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	  
Respiration	   0.2561	   	  	   	  	   	  	   	  	   	  	   	  	  
Glycolysis	   0.1387	   0.0700	   	  	   	  	   	  	   	  	   	  	  
ATP	   0.5970	   0.6650	   0.2115	   	  	   	  	   	  	   	  	  
Mitomass	   0.9932	   0.8096	   0.0627	   0.4180	   	  	   	  	   	  	  
ROS	   0.6655	   0.3468	   0.2221	   0.0072	   0.3476	   	  	   	  	  
SRB	   0.7092	   0.4055	   0.0630	   0.0263	   0.5220	   0.0147	   	  	  
MTT	   0.1696	   0.1765	   0.0100	   0.0654	   0.0767	   0.0154	   0.0127	  	  	  
3.4 Cellular	  Properties	  and	  Affymetrix	  Gene	  Expression	  	  
	  Gene	   expression	   data	   was	   obtained	   from	   public	   repository	   files	   in	   GEO,	   NCBI	   (De	  Schutter	  et	  al.	  2013,	  Barretina	  et	  al.	  2012).	  Public	  accession	  numbers	  and	  cell	   lines	  are	  listed	  in	  Table	  2.	  The	  data	  comes	  from	  experiments	  done	  in	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Arrays.	  To	  avoid	  introducing	  extra	  variability	  between	  the	  data	  obtained	  for	   the	   electrical	   and	   metabolic	   parameters	   with	   the	   Affymetrix	   arrays,	   all	   the	   gene	  expression	  data	  collected	  comes	  from	  cell	  lines	  cultivated	  in	  DMEM	  supplemented	  with	  10%	  FCS	   in	  a	  5%	  CO2	   incubator	  at	  37°C,	   the	  same	  conditions	  set	   for	  the	  acquisition	  of	  the	  electrical	  and	  metabolism	  features.	  Gene	  expression	  data	  were	  obtained	  for	  16	  of	  the	  18	   cell	   lines	   used	   in	   this	   work.	   The	   cell	   lines	   were:	   MDA-­‐MB-­‐231	   and	   MCF7	   (breast	  tissue	   type),	  HCT	  116	  and	  HT-­‐29	  (colorectal	   tissue	   type),	  AsPC-­‐1,	  MIA	  PaCa-­‐2,	  Panc-­‐1,	  and	   BxPC-­‐3	   (pancreas	   tissue	   type),	   LNCaP,	   PC-­‐3,	   and	   DU	   145	   (prostate	   tissue	   type),	  HaCaT	   and	   MDA-­‐MB-­‐435	   (skin	   tissue	   type),	   HeLa	   (cervix	   tissue	   type),	   Hep	   G2	   (liver	  tissue	  type),	  and	  1321N1	  (central	  nervous	  system	  tissue	  type)	  (Experimental	  Methods,	  Table1).	   The	   raw	   data	   of	   the	   16	   cell	   lines	   collected	   from	   Affymetrix	   arrays	   was	  preprocessed	   using	   Bioconductor	   in	   R	  programming	   language	   and	   the	   Robust	   Multi-­‐array	   Average	   (RMA)	   normalization	  method	   (Irizarry	   et	   al.	   2003,	   Gautier	   et	   al.	   2004)	  (Experimental	  Methods	  2.3,	  Supplements	  5.1.2).	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Fig.	  12.	  Significant	  dependencies	  between	  the	  cellular	  features	  of	  the	  analyzed	  cell	  lines.	  Linear	   correlation	   coefficients	   between	   the	   cellular	   properties	   of	   the	   studied	   cell	   lines	   were	  obtained	  using	   the	  Pearson	  algorithm.	  Only	   the	   significant	  dependencies	   (p-­‐values	  <	  0.05)	  are	  shown.	   The	   proliferation	   rate	   was	   estimated	   using	   MTT	   and	   SRB	   assays.	   MTT	   reagent	   labels	  active	  mitochondria	  and	   its	   reduction	  produces	  a	   colored	  compound	   that	   can	  be	  measured	  by	  absorbance	   at	   595	   nm.	   The	   SRB	   dye	   is	   incorporated	   into	   fixed	   cells	   and	   the	   amount	   of	  incorporated	  dye	   is	  proportional	  to	  the	  amount	  of	  cells,	   the	  dye	  has	  an	  absorbance	  at	  510	  nm.	  The	  glycolytic	  activity	  (acidification	  rate)	  was	  measured	  on	  the	  Bionas	  2500;	  cells	  were	  seeded	  in	   chips	   containing	   ISFET	   sensors.	   A	   stronger	   acidification	   rate	   indicates	   a	   higher	   glycolysis	  level.	  ROS	  accumulation	  in	  cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  The	  fluorescence	  intensity	  produced	  is	  directly	  related	  to	  the	  ROS	  accumulation	  in	  cells.	  Energy	  metabolism	  (ATP	  level)	  was	  measured	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  Luminescence	  is	  proportional	  to	  ATP	  concentrations	  in	  cells.	  Pearson	  coefficients	  were	  calculated	   using	   the	   mean	   of	   at	   least	   three	   independent	   experiments	   per	   cell	   line	   and	   per	  metabolic	  assay.	  The	  calculations	  were	  done	  using	  R	  programming	  language	  package	  Hmisc	  and	  rcorr	  function.	  The	  shape	  of	  the	  dots	  gives	  the	  tissue	  types	  and	  the	  color	  indicates	  cell	  lines.	  The	  
black	  lines	  represent	  the	  linear	  regressions.	  For	  each	  dependency	  the	  r	  correlation	  coefficient	  is	  shown;	  asterisks	  represent	   level	  of	  significance	  (p-­‐values	  <	  0.05*	  and	  p-­‐values	  <	  0.01**).	  Error	  
bars	   =	   standard	   error	   (se).	   Linear	   correlations	   of:	   A.	   SRB	   and	   MTT	   proliferation	   assays.	   B.	  Glycolysis	   activity	   and	   MTT	   proliferation	   assay.	   C.	   ROS	   accumulation	   and	   SRB	   proliferation	  assay.	   D.	   ROS	   accumulation	   and	   MTT	   proliferation	   assay.	   E.	   Energy	   metabolism	   and	   ROS	  accumulation.	  F.	  Energy	  metabolism	  and	  SRB	  proliferation	  assay.	  	  	  	  	   Entrez	   genes	   and	   gene	   symbols	   belonging	   to	   the	  metabolism-­‐related	   pathways	  glycolysis,	   gluconeogenesis,	   pentose	  phosphate	  pathways,	  TCA,	   and	  electron	   transport	  chain	  were	  gathered	  using	  Wikipathways	  (Kelder	  et	  al.	  2012)	  and	  DAVID	  (Huang	  et	  al.	  2009)(Experimental	   Methods	   2.3.1,	   Tables	   3,	   4,	   and	   5	   and	   Supplements	   5.1.3).	   A	  selection	  of	  probe	  set	  IDs	  was	  done	  using	  the	  statistical	  method	  "Presence-­‐Absence	  calls	  with	   Negative	   Probe	   sets"	   to	   estimate	   the	   significance	   of	   the	   detection	   on	   Affymetrix	  U133	   series	  microarrays	   and	   to	   exclude	   the	   probe	   sets	   that	   could	   show	  an	  unspecific	  hybridization	   (Warren	  et	   al.	   2007).	  The	  Presence-­‐Absence	   call	   calculations	  were	  done	  using	   R	  programming	   language	   and	   Bioconductor	   (Experimental	   Methods	   2.3.1	   and	  Supplements	  5.1.4).	  Additionally,	  all	  the	  probe	  sets	  with	  a	  _x	  suffix	  (mixed	  probe	  set	  that	  contains	   some	   probes	   that	   are	   identical	   or	   highly	   similar	   to	   other	   sequences)	   were	  deleted.	   For	   the	   glycolysis-­‐gluconeogenesis	   together	   with	   the	   pentose	   phosphate	  pathways,	   the	  original	   107	  probe	   sets	  were	   reduced	   to	  51	   and	   just	   one	  probe	   set	  per	  gene	   was	   selected.	   From	   the	   218	   probe	   sets	   belonging	   to	   the	   TCA	   together	   with	   the	  electron	   transport	  chain	  pathways,	  104	  probe	  sets	   remained,	  with	  also	   just	  one	  probe	  set	  per	  gene.	  In	  order	  to	  search	  for	  possible	  relations	  with	  the	  metabolism	  properties	  of	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the	  studied	  cell	   lines	  (Figs.	  2	  to	  10)	  and	  their	  gene	  expression	  level	   in	  metabolism,	  the	  selected	   metabolism-­‐related	   pathways	   were	   split	   in	   two;	   the	   nutrient-­‐uptake	   related	  pathways	   (glycolysis-­‐gluconeogenesis	   and	   pentose	   phosphate	   pathways)	   and	   the	  oxidative	   phosphorylation	   (OXPHOS)	   related	   pathways	   (TCA	   cycle	   and	   electron	  transport	  chain).	  	  	   	  
Table	  11.	  Affymetric	  gene	  expression	  means	  of	  selected	  pathways	  by	  cell	   line.	  Affymetric	  Human	  Genome	  U133	  Plus	  2.0	  Array	  gene	  expression	  raw	  data	  were	  obtained	  from	  GEO,	  NCBI.	  Public	   accession	   numbers	   of	   the	   cell	   lines	   are	   listed	   in	   Experimental	   Methods	   2.3,	   Table	   2.	  Preprocessing	  was	   done	   using	   Robust	  Multi-­‐array	   Average	   (RMA)	   normalization	  method.	   The	  normalized	   expression	   mean	   of	   the	   genes	   belonging	   to	   the	   glycolysis-­‐gluconeogenesys	   plus	  pentose	  phosphate	  pathway	  (left	  side	  of	  the	  table)	  and	  TCA	  cycle	  plus	  electron	  transport	  chain	  (right	   side	   of	   the	   table)	  were	  used	   to	  determine	   three	   categories:	   low,	  medium,	  and	  high	   total	  gene	  expression	  per	  cell	  line.	  	  	  
Glycolysis-­gluconeogenesis	  and	  pentose	  
phosphate	  pathways	  










level	  Panc1	   6.83	   low	   1321N1	   10.06	   low	  DU145	   7.00	   low	   AsPC1	   10.14	   low	  HaCaT	   7.00	   low	   HaCaT	   10.17	   low	  MDAMB435S	   7.02	   low	   MDAMB231	   10.24	   low	  1321N1	   7.07	   low	   HepG2	   10.26	   low	  AsPC1	   7.14	   medium	   HeLa	   10.26	   medium	  HCT116	   7.16	   medium	   Panc1	   10.29	   medium	  PC3	   7.20	   medium	   PC3	   10.31	   medium	  BxPC3	   7.21	   medium	   MDAMB435S	   10.32	   medium	  MiaPaCa2	   7.22	   medium	   DU145	   10.33	   medium	  MCF7	   7.28	   medium	   BxPC3	   10.38	   medium	  HeLa	   7.29	   high	   HCT116	   10.39	   high	  LNCaP	   7.34	   high	   MiaPaCa2	   10.42	   high	  HT29	   7.41	   high	   HT29	   10.51	   high	  MDAMB231	   7.42	   high	   MCF7	   10.55	   high	  HepG2	   7.66	   high	   LNCaP	   10.66	   high	  	  The	  mean	  value	  of	  the	  total	  gene	  expression	  of	  the	  nutrient-­‐uptake	  related	  pathways	  per	  cell	   line	  was	  used	  to	  determine	   three	  expressions	   levels	   (Table	  11):	   low,	  medium,	  and	  high	  total	  gene	  expression.	  The	  same	  was	  done	  for	  the	  OXPHOS	  pathways.	  The	  cell	  lines	  were	   sorted	   by	   their	   expression	   level	   in	   the	   nutrient-­‐uptake	   related	   pathways	   and	  OXPHOS	   related	   pathways	   and	   plotted	   against	   their	   cellular	   properties	   (data	   not	  shown).	   For	   all	   the	   generated	   plots,	   the	   one	   with	   the	   glycolysis-­‐gluconeogenesis	   and	  pentose	   phosphate	   pathways	   against	   the	   cell	   capacitance	   (Fig.	   2)	   suggests	   a	   positive	  correlation	   between	   the	   two	  mentioned	   variables	   in	   the	   studied	   cell	   lines	   (Fig.	   13A).	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Cells	  with	  high	  expression	   levels	  appear	   to	  have	  high	  cell-­‐capacitance	  values	  and	  cells	  with	   low	   expression	   values	   a	   low	   capacitance.	   However,	   Pearson	   product	   moment	  correlation	   gives	   a	   nonsignificant	   (p-­‐values	   >	   0.05)	   and	   low	   dependency	   (r	   =	   0.3)	  (Fig.	  13A).	   Additionally,	   the	   plot	   generated	  with	   the	   expression	   level	   in	   the	   TCA	   cycle	  together	  with	  the	  electron	  transport	  chain	  versus	  respiration	  activity	  (O2	  consumption)	  (Fig.	  4)	  seems	  also	  to	  show	  a	  positive	  correlation	  between	  the	  cell	  lines	  (Fig.	  13B).	  Cells	  with	   low	   expression	   level	   in	   the	   OXPHOS	   related	   pathways	   appear	   to	   have	   a	   low	   O2	  consumption	   and	   the	   ones	   that	   show	   high	   expression	   of	   the	   genes	   related	   to	   the	  OXPHOS	   pathways	   a	   high	   respiration	   activity.	   Nevertheless,	   Pearson	   correlation	  calculation	  shows	  a	  nonsignificant	  (p-­‐values	  >	  0.05)	  moderately	  positive	  dependency	  (r	  =	  0.44)	  (Fig.	  13B).	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Fig.	   13.	   Relation	   of	   cellular	   capacitance	   and	   respiration	   activity	   with	   Affymetrix	   gene	  
expression	  level	  of	  selected	  metabolism	  pathways.	  The	  cell	  capacitance	  and	  the	  respiration	  activity	   were	   measured	   on	   the	   Bionas	   2500	   online	   monitoring	   system.	   Cells	   were	   seeded	   in	  chips	  containing	  IDES	  and	  Clark	  electrodes.	  Lower	  capacitance	  (nF	  values)	  indicates	  a	  stronger	  cell-­‐matrix	   adhesion	   and	   cell-­‐cell	   contact	   interactions.	  Higher	  oxygen	   consumption	   indicates	   a	  stronger	  respiration	  activity.	  Equal	  numbers	  of	  cells	  per	  cell	  line	  were	  seeded	  in	  the	  chips	  and	  at	  least	   three	   independent	   experiments	   were	   done	   per	   cell	   line,	   each	   one	   with	   six	   technical	  replicates.	   Affymetrix	   Human	   Genome	   U133	   Plus	   2.0	   Array	   gene	   expression	   raw	   data	   were	  obtained	  from	  GEO,	  NCBI.	  Public	  accession	  numbers	  of	  the	  cell	   lines	  are	   listed	  in	  Experimental	  Methods,	   Table	   2.	   Preprocessing	   was	   done	   using	   Robust	   Multi-­‐array	   Average	   (RMA)	  normalization	   method.	   The	   normalized	   expression	   mean	   of	   genes	   belongs	   to	   the	   glycolysis-­‐	  gluconeogenesis	  and	  pentose	  phosphate	  pathways	  together	  (A)	  and	  TCA	  cycle	  together	  with	  the	  electron	   transport	   chain	   (B)	  were	  used	   to	  determine	   three	   categories:	   low,	  medium,	   and	  high	  total	   gene	   expression	   per	   cell	   line.	  Dashed	   line	   indicates	   the	  mean	   between	   the	   analyzed	   cell	  lines.	  Black	  dot	  indicates	  the	  mean	  for	  the	  corresponding	  cell	  line.	  Linear	  correlation	  coefficients	  between	  the	  variables	  were	  obtained	  using	  Pearson	  algorithm.	  r	  coefficients	  and	  p-­‐values	  for	  the	  dependencies	   are	   shown.	   Nonsignificant	   dependencies	   (p-­‐value	   >	   0.05)	   were	   found.	   No	   data	  shows	  the	  cell	  lines	  in	  which	  no	  Affymetrix	  gene	  expression	  is	  given.	  Linear	  correlation	  and	  RMA	  normalization	   were	   done	   using	   R	   programming	   language	  with	   the	   package	   Hmisc	   and	   rcorr	  function	  and	  Bioconductor	  package	  affy.	  
	  	  
3.4.1 Selection	  of	  Genes	  Belonging	  to	  the	  Selected	  Metabolism	  Pathways	  
	  A	   selection	   of	   genes	   belonging	   to	   the	   glycolysis-­‐gluconeogenesis	   pathway,	  pentose	   phosphate	   pathway,	   TCA	   cycle,	   and	   electron	   transport	   chain	   was	   obtained	  based	  on	  the	  expression	  values	  of	   the	  genes	   in	  the	  studied	  cell	   lines.	  For	  the	  selection,	  the	  expression	  of	  each	  gene	  was	  normalized	  across	  the	  cell	   lines.	  Scale	  and	  center	  was	  applied	  to	  normalize	  the	  gene	  expression	  relative	  to	  the	  set	  of	  cell	  lines	  used.	  A	  range	  to	  compare	   the	   expression	   values	   of	   each	   gene	   in	   the	   studied	   cell	   lines	   from	   –3	   (lowly	  expressed	   genes)	   to	   3	   (highly	   expressed	   genes)	   was	   obtained	   (Figs.	   14A	   and	   15A)	  (Experimental	   Methods	   2.3.1).	   Scaling	   and	   centering	   was	   calculated	   using	   R	  
programming	   language	   package	   softImpute	   (Hastie	   et	   al.	   2015)	   (Supplements	   5.1.5).	  Normalized	  extreme	  expression	  values	  were	  the	  ones	  greater	  than	  1	  and	  lower	  than	  –1	  (Supplements	  5.1.5).	  A	  set	  of	  17	  genes	  out	  of	  the	  155	  remained	  for	  correlation	  analysis	  with	  the	  capacitance	  and	  metabolic	  assays	  (Figs.	  14	  and	  15).	  In	  the	  metabolism-­‐related	  glycolysis-­‐gluconeogenesis	   and	   pentose	   phosphate	   pathways	   the	   selected	   genes	   were	  the	   ones	   that	   present,	   after	   scaling	   and	   being	   centered,	   the	   highest	   or	   the	   lowest	  expression	  levels	  in	  at	  least	  7	  of	  the	  16	  cell	  lines	  (Fig.	  14B).	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Fig.	   14.	   Selection	   of	   genes	   related	   to	   the	   glycolysis-­gluconeogenesis	   and	   pentose	  
phosphate	   pathways.	   Affymetrix	   Human	   Genome	   U133	   Plus	   2.0	   Array	   gene	   expression	   raw	  data	  (.CEL	   files)	  were	  obtained	   from	  GEO,	  NCBI.	  Public	  accession	  numbers	  of	   the	  cell	   lines	  are	  listed	   in	   Experimental	   Methods	   2.3,	   Table	   2.	   Preprocessing	   of	   the	   .CEL	   files	   was	   done	   using	  Robust	   Multi-­‐array	   Average	   (RMA)	   normalization	   method.	   The	   normalized	   expression	   was	  scaled	   and	   centered	   to	   compare	   the	   expression	   levels	   of	   each	   gene	   in	   the	   studied	   cell	   lines.	  A	  
Heatmap of genes involved in 




















































































Heatmap of genes involved in 





















































































#" Cell Line/Gene DLD GOT1 GOT2 PC PDHB PGLS RPE SLC2A1 SLC2A5 
MDA-MB-231 -1.15  -0.02  -0.58  1.28  1.04  0.44  0.38  1.78  0.40  
MCF7 1.36  0.52  -0.75  1.37  -0.30  -0.46  -1.05  -0.54  0.93  
HCT 116 0.33  1.38  0.70  -1.24  -0.42  -1.33  0.05  0.91  -0.53  
HT-29 0.37  -0.46  0.25  0.11  -0.85  0.30  -0.21  0.52  -1.42  
AsPC-1 -0.25  -0.40  -1.73  -1.00  -0.55  1.69  0.87  0.43  -0.07  
MIA PaCa-2 -0.73  -0.15  1.24  0.09  -1.46  1.61  2.06  -1.10  -1.08  
Panc-1 -1.58  0.80  -1.28  -1.40  0.19  -1.69  -0.25  -1.72  1.31  
BxPC-3 0.61  1.07  1.19  0.45  -0.73  -0.06  -0.38  1.35  0.36  
LNCaP 1.31  0.72  0.73  0.37  1.33  -0.33  0.35  -1.01  -0.49  
PC-3 0.64  -1.39  -0.24  -0.70  0.85  1.22  -0.58  0.28  0.46  
DU 145 -0.31  0.86  1.12  -1.61  -1.09  -1.17  0.59  0.38  -1.87  
HaCaT -1.59  -1.10  -0.65  0.28  -1.71  1.19  -1.53  -0.23  1.62  
MDA-MB-435 0.76  -1.37  1.12  -0.58  1.11  0.06  1.22  -0.45  -0.35  
HeLa 0.37  -1.39  -0.13  1.22  0.09  -0.94  -1.53  -1.16  1.24  
Hep G2 -1.42  1.69  0.70  1.61  1.20  -0.28  -1.11  1.34  0.54  
1321N1 1.28  -0.76  -1.71  -0.26  1.30  -0.26  1.13  -0.78  -1.06  
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range	   from	   –3	   (lowly	   expressed	   genes	   in	   green)	   to	   3	   (highly	   expressed	   genes	   in	   red)	   was	  calculated.	  Genes	  with	  extreme	  expression	  values	  in	  at	  least	  7	  of	  the	  16	  cell	  lines	  were	  selected.	  Extreme	  expression	  values	  were	  the	  ones	  greater	  than	  1	  and	  lower	  than	  –1.	  A.	  Heatmap	  of	  the	  expression	   levels	   of	   genes	   belong	   to	   glycolysis-­‐gluconeogenesis	   and	   pentose	   phosphate	  pathways.	  Arrows	  show	  the	  genes	  that	  present	  extreme	  expression	  after	  scaling	  and	  centering.	  
B.	   Scale	  and	  center	  values	  of	  genes	   that	  present	  extreme	  expression	   in	   the	  analyzed	  cell	   lines.	  Scale-­‐center	   and	   RMA	   normalizations	   were	   done	   using	   R	   programming	   language	   with	   the	  package	  softImpute	  function	  biscale	  and	  Bioconductor	  package	  affy.	  	  	   From	   the	  51	   genes	   corresponding	   to	   the	  mentioned	  pathways,	   9	  were	   selected	  (Fig.	  14).	  The	  proteins	  corresponding	  to	  the	  selected	  genes	  are:	  	  1. DLD	  (dihydrolipoamide	  dehydrogenase)	  oxidizes	  dihydrolipoamide	  to	  lipoamide.	  2. GOT1	   (glutamic-­‐oxaloacetic	   transaminase	   1)	   located	   in	   the	   cytosol,	   catalyzes	   the	  reversible	  transamination	  of	  aspartate	  to	  oxaloacetate.	  3. GOT2	  (glutamic-­‐oxaloacetic	  transaminase	  2),	   located	  in	  mitochondria,	  catalyzes	  the	  reversible	  transamination	  of	  aspartate	  to	  oxaloacetate.	  4. PC	  (pyruvate	  carboxylase),	  catalyzes	  the	  carboxylation	  of	  pyruvate	  to	  oxaloacetate.	  5. PDHB	   (pyruvate	   dehydrogenase	   (lipoamide)	   beta)	   is	   one	   of	   the	   enzymes	   of	   the	  pyruvate	   dehydrogenase	   complex	   that	   catalyzes	   the	   conversion	   of	   pyruvate	   to	  acetyl-­‐CoA.	  6. PGLS	   (6-­‐phosphogluconolactonase)	   of	   pentose	   phosphate	   pathway	   catalyzes	   the	  hydrolysis	  of	  6-­‐phosphogluconolactone	  to	  6-­‐phosphogluconate.	  	  7. RPE	   (ribulose-­‐5-­‐phosphate-­‐3-­‐epimerase)	   of	   the	   pentose	   phosphate	   pathway	  catalyzes	   the	   reversible	   epimerization	   of	   D-­‐ribulose	   5-­‐phosphate	   to	   D-­‐xylulose	   5-­‐phosphate.	  	  8. SLC2A1	  (glucose	  transporter	  1,	  solute	  carrier	  family	  2	  member	  1)	  transports	  glucose	  across	  the	  plasmatic	  membrane.	  9. SLC2A5	   (solute	   carrier	   family	   2	  member	   5)	   transports	   fructose	   into	   the	   intestinal	  lumen.	  	  In	   the	  respiration-­‐related	  pathways,	   the	  selected	  genes	  were	  the	  ones	  with	  higher	  and	  lower	  expression	  levels	  in	  at	  least	  8	  of	  the	  16	  cell	   lines	  (Fig.	  15B).	  From	  the	  104	  genes	  corresponding	  to	  the	  TCA	  cycle	  and	  electron	  transport	  chain	  together,	  six	  were	  selected	  (Fig.	  15).	  The	  proteins	  corresponding	  to	  the	  selected	  genes	  are:	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  10. ATP5H	  (mitochondrial	  Fo	  complex	  subunit	  D),	  one	  of	  the	  subunits	  of	  ATP	  synthase	  that	  catalyzes	  ATP	  synthesis.	  11. ATP6AP2	   (ATPase	   H+	   transporting	   accessory	   protein	   2)	   is	   a	   proton-­‐translocating	  ATPase.	  12. COX17	   (cytochrome	   c	   oxidase	   copper	   chaperone).	   Cytochrome	   c	   oxidase	   catalyzes	  the	  electron	  transfer	  from	  cytochrome	  c	  to	  oxygen.	  13. COX5A	   (cytochrome	   c	   oxidase	   subunit	   5a),	   a	   subunit	   of	   the	   cytochrome	   c	   oxidase	  complex.	  14. COX5B	   (cytochrome	   c	   oxidase	   subunit	   5b),	   a	   subunit	   of	   the	   cytochrome	   c	   oxidase	  complex.	  15. NDUFS4	   (ubiquinone	   oxidoreductase	   subunit	   S4),	   a	   subunit	   of	   complex	   I	   that	  removes	  electrons	  from	  NADH	  to	  forward	  them	  to	  the	  electron	  acceptor	  ubiquinone.	  	  	  
3.4.1.1 Dependencies	  between	  Cellular	  Properties	  of	  the	  Studied	  Cell	  
Lines	  and	  Affymetrix	  Gene	  Expression	  of	  Pathways	  of	  Selected	  
Genes	  
	   With	  the	  aim	  of	  finding	  undiscovered	  dependencies	  among	  genes	  and	  metabolism	  or	  cell	   capacitance,	  Pearson	  product	  moment	  correlation	  was	  used	   to	  search	   for	  novel	  relationships	   within	   the	   expression	   values	   of	   the	   previous	   selected	   genes	   and	   the	  cellular	   properties	   data.	   Linear	   correlations	   were	   calculated	   between	   the	   data	   of	   the	  studied	   cell	   lines	   for	   cellular	   capacitance,	   respiratory	   activity	   (O2	   consumption),	  glycolytic	   activity	   (acidification),	   energy	   metabolism	   (ATP	   level),	   intracellular	   ROS	  accumulation,	   mitochondrial	   mass,	   and	   proliferation	   rates	   (MTT	   and	   SRB	   assays)	  (Figs.	  2	   to	   10)	   and	   the	   15	   selected	   metabolism-­‐related	   genes	   (DLD,	   GOT1,	   GOT2,	   PC,	  PDHB,	   PGLS,	   RPE,	   SLC2A1,	   SLC2A5,	   ATP5H,	   ATP6AP2,	   COX17,	   COX5A,	   COX5B,	   and	  NDUFS4)	   (Figs.	   14	   and	   15).	   The	   gene	   expression	   data	   of	   the	   15	   genes	   and	   their	   total	  probe	   sets	   in	   the	   Affymetrix	   Human	   Genome	   U133	   Plus	   2.0	   Array	   were	   used	   for	  searching	   dependencies	   with	   the	   cellular	   features.	   Only	   those	   genes	   with	   consistent	  information	  across	  their	  probe	  sets	  were	  chosen	  as	  candidate	  genes.	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Fig.	   15.	   Selection	   of	   genes	   related	   to	  TCA	   cycle	   and	   electron	   transport	   chain.	   Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  gene	  expression	  raw	  data	  (.CEL	  files)	  were	  obtained	  from	  GEO,	  NCBI.	   Public	   accession	   numbers	   of	   the	   cell	   lines	   are	   listed	   in	   Experimental	  Methods	   2.3,	  Table	   2.	   Preprocessing	   of	   the	   .CEL	   files	   was	   done	   using	   Robust	   Multi-­‐array	   Average	   (RMA)	  normalization	   method.	   The	   normalized	   expression	   was	   scaled	   and	   centered	   to	   compare	   the	  expression	  levels	  of	  each	  gene	  in	  the	  studied	  cell	  lines.	  A	  range	  from	  –3	  (lowly	  expressed	  genes	  in	  green)	   to	  3	   (highly	   expressed	   genes	   in	   red)	  was	   calculated.	  Genes	  with	   extreme	  expression	  values	  in	  at	  least	  8	  of	  the	  16	  cell	  lines	  were	  selected.	  Extreme	  expression	  values	  were	  the	  ones	  greater	  than	  1	  and	  lower	  than	  –1.	  A.	  Heatmap	  of	  the	  expression	  levels	  of	  genes	  belonging	  to	  TCA	  cycle	  and	  electron	   transport	  chain.	  Arrows	   indicate	   the	  genes	   that	  present	  extreme	  expression	  after	  scaling	  and	  centering.	  B.	  Scale	  and	  center	  values	  of	  genes	  that	  present	  extreme	  expression	  in	  the	  analyzed	  cell	  lines.	  Scale-­‐center	  and	  RMA	  normalizations	  were	  done	  using	  R	  programming	  































































































































































































































































































































































































































































































































































































































































































































































































#" Cell Line/Gene symbol ATP5H ATP6AP2 COX17 COX5A COX5B NDUFS4 
MDA-MB-231 -0.87 0.61 -0.62 -0.81 -0.29 1.28 
MCF7 1.03 0.99 1.19 1.24 1.54 0.38 
HCT 116 1.28 -1.33 0.26 0.12 -0.21 1.06 
HT-29 -0.99 -1.51 1.4 1.51 -0.2 0.09 
AsPC-1 -1.42 -1.47 -0.95 -1.16 -0.01 -1.00 
MIA PaCa-2 0.53 0.14 -1.61 -0.31 0.47 1.23 
Panc-1 1.38 -1.1 1.03 0.55 0.63 0.8 
BxPC-3 -1.09 -0.3 0.49 1.07 1.41 -0.43 
LNCaP -0.51 0.52 1.24 1.00 1.21 1.11 
PC-3 1.21 1.14 0.68 -1.53 0.16 -1.34 
DU 145 1.02 -0.58 -1.00 0.25 -1.36 0.74 
HaCaT 0.13 1.36 -0.61 -0.62 -1.52 -0.69 
MDA-MB-435 0.23 0.59 1.03 -0.68 -1.02 -0.11 
HeLa -1.76 1.09 -0.19 1.41 -1.76 -1.11 
Hep G2 0.25 -1.03 -0.88 -0.61 -0.08 0.11 
1321N1 -0.41 0.88 -1.45 -1.43 1.04 -2.11 
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   PGLS	  and	  COX5B	  are	  the	  genes	  that	  shown	  significant	  correlation	  and	  consistent	  information	   across	   their	   probe	   sets	   with	   some	   of	   the	   metabolism	   data.	   The	   cellular	  capacitance	   did	   not	   show	   any	   relation	   with	   any	   of	   the	   selected	   metabolism	   genes	  (Table	  12).	   PGLS	   (6-­‐phosphogluconolactonase)	   is	   an	   enzyme	   that	   catalyzes	   the	  hydrolysis	  of	  6-­‐phosphogluconolactone	  to	  6-­‐phosphogluconate	  in	  the	  second	  reaction	  of	  the	  pentose	  phosphate	  pathway	  oxidative	  phase.	  	   The	  PGLS	   gene	  presents	   four	   probe	   sets	   in	   the	  Affymetrix	   platform	  used,	   all	   of	  which	   show	   consistent	   information	   about	   the	   dependencies	   between	   the	   expression	  level	   and	   mitochondrial	   mass	   content,	   glycolytic	   activity,	   and	   proliferation	   rates	  measured	  as	  metabolic	  activity	  (MTT	  assay)	  and	  total	  protein	  content	  (SRB	  assay).	  The	  negative	   correlation	   observed	   with	   the	   mitochondrial	   mass	   is	   significant	   (p-­‐values	  <	  0.05)	  in	  three	  out	  of	  the	  four	  probe	  sets.	  The	  fourth	  probe	  set	  gave	  significance	  (Table	  12).	   Additionally,	   the	   same	   three	   probe	   sets	   show	   also	   a	   negative	   correlation	   with	  glycolysis	   activity	   but	   just	   one	   of	   the	   probe	   set	   reached	   significance	   (p-­‐value	   <	   0.05)	  (Table	  12).	  The	  significant	  dependency	  of	  PGLS	  with	  SRB	  assay	  is	  corroborated	  just	  for	  one	  out	  of	   the	  four	  probe	  sets,	  but	  all	  of	   them	  having	  a	  moderate	  negative	  correlation.	  Moreover,	   this	   is	  corroborated	  by	  according	  dependencies	  with	  the	  proliferation	  assay	  MTT,	   which	   presents	   a	   moderately	   negative	   correlation	   with	   the	   entire	   probe	   set	   of	  PGLS	  (Table	  12).	  The	  negative	  dependencies	  found	  indicate	  that	  cell	  lines	  with	  high	  gene	  expression	  of	  PGLS	  present	  low	  mitochondrial	  mass	  content,	  low	  glycolytic	  activity,	  and	  low	  proliferation	  rates.	  	   COX5B	   is	   a	   nuclear-­‐coded	   subunit	   of	   the	   cytochrome	   c	   oxidase	   complex	   in	   the	  electron	  transport	  chain.	  COX5B	  contains	  two	  probe	  sets	  in	  the	  Affymetrix	  platform	  used	  for	   this	  study.	  One	  of	   the	   two	  probe	  sets	  shows	  a	  significant	   (p-­‐value	  <	  0.05)	  negative	  correlation	  with	  the	  proliferation	  assay	  MTT,	  which	  is	  in	  agreement	  with	  the	  moderate	  r	  coefficient	   of	   the	   second	   probe	   set.	   The	   calculated	   dependencies	   between	   the	   two	  probe	   sets	   and	   the	   SRB	   proliferation	   assay	   validated	   these	   relations	   (Table	   12).	   The	  obtained	   correlations	   indicate	   that	   cell	   lines	   with	   high	   gene	   expression	   of	   COX5B	  present	  low	  proliferation	  rates.	  	  
Table	  12.	  r	  coefficients	  and	  p-­values	  of	  the	  significant	  dependencies	  between	  metabolism	  
features	  and	  Affymetrix	  gene	  expression	  of	  candidate	  genes	  of	  the	  selected	  pathway.	  The	  mitochondrial	   mass	   content	   of	   the	   cells	   was	   determined	   using	   MitoTracker	   Green	   (Thermo	  Fisher).	   Cell	   lines	   with	   higher	   fluorescence	   intensity	   contain	   higher	   mitochondrial	   mass.	   The	  proliferation	  rate	  measured	  as	  metabolic	  activity	   (MTT	  assay)	  estimates	   the	  reduction	  of	  MTT	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reagent	   by	   active	   mitochondria	   and	   can	   be	   measured	   by	   absorbance	   at	   595	   nm.	   Energy	  metabolism	   (ATP	   level)	  was	   estimated	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  Luminescence	  is	  proportional	  to	  ATP	  concentrations	  in	  the	  cells.	  	  A	   set	   of	   genes	  were	   selected	  based	  on	   the	   expression	  values	  of	   genes	  belonging	   to	   glycolysis-­‐gluconeogenesis,	   pentose	   phosphate,	   TCA	   cycle,	   and	   electron	   transport	   chain	   metabolic	  pathways.	   The	   gene	   expression	   raw	   data	   (.CEL	   files)	   were	   obtained	   from	   GEO,	   NCBI	   and	  correspond	  to	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array.	  Public	  accession	  numbers	  of	  the	  cell	   lines	  are	   listed	   in	  Experimental	  Methods	  Table	  2.	  Preprocessing	  of	   the	   .CEL	   files	  was	  done	  using	  Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  The	  selection	  process	  included	  scale	  and	  center	  normalization	  of	   the	  gene	  expression	   in	  the	  studied	  cell	   lines.	  The	  genes	  with	  extreme	   expression	   values	   in	   at	   least	   7	   of	   the	   16	   cell	   lines	   were	   selected	   for	   Pearson	  comparisons	   with	   the	   metabolism	   assay.	   All	   the	   probe	   sets	   of	   the	   selected	   genes	   in	   the	  Affymetrix	  array	  are	  shown.	  The	  Pearson	  coefficients	  were	  calculated	  using	  the	  mean	  of	  at	  least	  three	   independent	   experiments	   per	   cell	   line	   and	   per	   metabolic	   assay.	   Pearson	   comparisons,	  scale-­‐center,	   and	  RMA	  normalizations	  were	   obtained	  using	  R	  programming	   language	  with	   the	  packages	  Hmisc	   function	   rcorr,	   softImpute	   function	   biscale	   and	   Bioconductor	   package	   affy.	   In	  
yellow	   the	  probe	  sets	  that	  present	  a	  significant	  dependence	  with	  the	  metabolic	  assays	  (p-­‐value	  <	  0.05).	  	  	  
r	  coefficients	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	   MTT	  
PGLS.1554316_at	   0.00	   0.34	   -­‐0.39	   0.21	   -­‐0.17	   -­‐0.43	  
PGLS.218387_s_at	   -­‐0.51	   0.17	   -­‐0.58	   0.06	   -­‐0.41	   -­‐0.53	  
PGLS.218388_at	   -­‐0.47	   0.08	   -­‐0.53	   -­‐0.03	   -­‐0.32	   -­‐0.42	  
PGLS.230699_at	   -­‐0.41	   0.66	   -­‐0.68	   0.55	   -­‐0.72	   -­‐0.51	  
COX5B.213735_s_at	   -­‐0.15	   -­‐0.28	   -­‐0.13	   -­‐0.29	   -­‐0.10	   -­‐0.27	  
COX5B.213736_at	   -­‐0.18	   0.68	   -­‐0.13	   0.59	   -­‐0.36	   -­‐0.60	  
	  
	  
p-­values	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	   MTT	  
PGLS.1554316_at	   0.9977	   0.2142	   0.1385	   0.4488	   0.6135	   0.1850	  
PGLS.218387_s_at	   0.0427	   0.5457	   0.0183	   0.8218	   0.2114	   0.0923	  
PGLS.218388_at	   0.0643	   0.7776	   0.0354	   0.9149	   0.3437	   0.1995	  
PGLS.230699_at	   0.1183	   0.0072	   0.0037	   0.0330	   0.0120	   0.1061	  
COX5B.213735_s_at	   0.5912	   0.3119	   0.6363	   0.2893	   0.7676	   0.4292	  
COX5B.213736_at	   0.5133	   0.0052	   0.6202	   0.0213	   0.2819	   0.0494	  
	  
	  Figure	  16	  shows	  the	  significant	  dependencies	  (p-­‐values	  <	  0.05)	  among	  three	  out	  of	  four	  probe	   sets	   of	   PGLS	   gene	   and	   the	  mitochondrial	  mass	   content.	   The	   entire	   set	   of	   probe	  sets	  belonging	  to	  the	  PGLS	  gene	  display	  a	  negative	  relationship	  between	  the	  expression	  of	   the	   gene	   and	   the	   mitochondrial	   mass	   content	   in	   the	   cell	   lines.	   The	   probe	   set	  230699_at	   shows	   a	   strong	   correlation	   representing	   the	   highest	   r	   coefficient	   with	  mitochondrial	  mass.	   Although	   the	   probes	   in	   the	   probe-­‐sets	   230699_at	   and	   218388_at	  interrogate	   just	   one	   transcript	   (_at	   suffix),	   the	   information	   differs	   for	   some	   cell	   lines	  from	  the	  others.	  Colorectal	  cells	  PC-­‐3	  and	  DU-­‐145	  show	  more	  similar	  expression	  values	  for	  the	  PGLS	  gene	  with	  the	  data	  of	  the	  230699_at	  probe	  set	  than	  for	  the	  218387_at	  or	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Fig.	   16.	   Significant	   dependencies	   between	   mitochondrial	   mass	   content	   and	   gene	  
expression	   of	   candidate	   gene	  PGLS.	  Linear	   correlations	   of	   the	   gene	   expression	   values	   from	  probe	  sets	  belonging	  to	  the	  PGLS	  gene	  that	  presents	  significant	  dependencies	  (p-­‐values	  <	  0.05)	  with	   mitochondrial	   mass	   in	   the	   studied	   cell	   lines.	   The	   correlations	   were	   calculated	   using	  Pearson	  algorithm.	  Mitochondrial	  mass	  content	  of	   the	  cells	  was	  determined	  using	  MitoTracker	  Green	   (Thermo	   Fisher).	   Cell	   lines	   with	   higher	   fluorescence	   intensity	   contain	   higher	  mitochondrial	  mass.	  The	  Pearson	  coefficients	  were	  calculated	  using	   the	  mean	  of	  at	   least	   three	  independent	   experiments	   per	   cell	   line.	   The	   expression	   values	  were	   obtained	   from	   GEO,	   NCBI	  and	  correspond	  to	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array.	  Public	  accession	  numbers	  of	  the	   cell	   lines	   are	   listed	   in	   Experimental	  Methods,	   Table	   2.	  Preprocessing	   of	   the	   .CEL	   files	  was	  done	  using	  Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  Pearson	  comparisons	  and	  RMA	   normalizations	   were	   obtained	   using	   R	   programming	   language	  with	   the	   packages	  Hmisc	  function	  rcorr	  and	  Bioconductor	  package	  affy.	  The	  shape	  of	   the	  dots	  gives	  the	  tissue	  types	  and	  the	  color	   the	   cell	   lines.	  The	  blue	   lines	   represent	   linear	   regressions.	   For	   each	  dependency	   the	   r	  correlation	   coefficient	   is	   shown;	  asterisks	   represent	   the	   level	   of	   significance	   (p-­‐values	   <	   0.05*	  and	  <	  0.01**).	  Error	  bars	  =	  standard	  error	  (se).	  	  	  218388_s_at.	   In	   these	   last	   two	   probe	   sets,	   Panc-­‐1	   shows	   a	   similar	   expression	   level	   to	  HCT	  116,	  but	  a	  much	  higher	  one	  in	  the	  230699_at	  probe	  set.	  Indeed,	  the	  two	  "_at"	  probe	  sets	  correlate	  with	  each	  other	  with	  an	  r	  coefficient	  of	   just	  0.55.	  On	  the	  other	  hand,	  the	  218388_at	  and	  218387_s_at	  probe	  sets	  are	  highly	  correlated	  by	  an	  r	  coefficient	  of	  0.99	  (data	  not	  shown).	  	  	   	  
3.4.2 Relations	  between	  Cell	  Properties	  of	   the	   Studied	  Cell	   Lines	   and	   the	  
Extremely	  Expressed	  Probe	  Sets	  in	  Affymetrix	  Arrays	  	  
	  The	   preprocessing	   (RMA	   normalized	   data,	   Experimental	   Methods	   2.3)	   gene	  expression	  data	  of	  the	  total	  probe	  sets	  in	  the	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  for	  the	  studied	  cell	  lines	  were	  normalized	  using	  scale	  and	  center	  standardization.	  The	  expression	  of	  each	  probe	  set	  was	  standardized	  across	  the	  cell	  lines.	  Scale	  and	  center	  was	  applied	  to	  normalize	  the	  probe	  set	  expression	  relative	  to	  the	  set	  of	  cell	   lines	  used.	  From	  the	  complete	  Affymetrix	  platform	  with	  more	  than	  50,000	  entries	  we	  selected	  the	  extreme	  expressed	  probe	  sets	  per	  cell	  line	  (Supplements	  5.1.5).	  The	  choice	  was	  made	  for	  probe	  sets	   that	  were	  either	  highly	  or	   lowly	  expressed	   in	  at	   least	  9	  of	   the	  16	  cell	   lines.	  Using	  the	  gene	  symbol	  it	  was	  possible	  to	  collect	  the	  entire	  set	  of	  probe	  sets	  that	  join	  the	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extreme	   expressed	   probe	   sets	   chosen.	   A	   final	   selection	   of	   genes	   with	   consistent	  information	   through	   their	   probe	   sets	   was	   done.	   That	   final	   selection	   includes	   the	  condition	  that	  no	  pair	  of	  the	  chosen	  probe	  sets	  could	  show	  an	  extreme	  expression	  in	  less	  than	   seven	   cell	   lines.	   Genes	   with	   just	   one	   probe	   set	   were	   discarded	   (Experimental	  Methods	   2.3.1).	  With	   the	   remaining	   36	   probe	   sets,	   corresponding	   to	   17	   genes,	   linear	  relationships	  were	  searched	  with	  the	  metabolic	  properties	  of	  the	  studied	  cell	   lines	  and	  the	   probe	   set	   gene	   expression	   (Table	   13).	   The	   linear	   dependencies	   were	   calculated	  using	   Pearson	   product	   moment	   correlation	   using	   R	   programming	   language	   package	  
Hmisc	  and	  rcorr	  function.	  	  	   Three	   probe	   sets	   showed	   a	   linear	   dependency	   with	   some	   of	   the	   metabolism	  assays.	   No	   probe	   sets	   showed	   a	   significant	   dependency	   with	   cellular	   capacitance	  (Table	  13).	   The	   first	   probe	   set	   with	   a	   correlation	   to	   metabolism	   is	   the	   1552502_s_at	  belonging	   to	   the	   RHBDL2	   (rhomboid-­‐related	   protein	   2)	   gene.	   RHBDL2	   contains	   three	  probe	  sets	  in	  the	  Affymetrix	  array	  used,	  and	  the	  other	  two	  probe	  sets	  are	  consistent	  with	  1552502_s_at	   (Fig.	   17).	   It	   is	   remarkable	   that	   the	   only	   two	   probe	   sets	   of	   the	   IFI16	  (gamma-­‐interferon-­‐inducible	  protein	  16)	   gene	   (206332_s_at	   and	  208965_s_at)	   are	   the	  second	  and	  third	  probe	  sets	  that	  present	  a	  correlation	  with	  metabolism	  (Fig.	  18).	  	  The	   cell	   lines	  with	   higher	   expression	   levels	   of	   RHBDL2	   are	   the	   ones	  which	   have	   less	  glycolytic	  activity	  and	  mitochondrial	  mass	  (Fig.	  17A).	  An	  r	  coefficient	  of	  –0.53	  and	  –0.52	  was	   calculated	   for	   the	   dependencies	   between	   1552502_s_at	   probe	   set	  with	   glycolysis	  activity	   and	  mitochondrial	   mass	   content,	   respectively.	   The	   other	   two	   probe	   sets	   that	  interrogate	   the	  RHBDL2	   gene,	   the	   1554895_a_at	   and	   1554897_s_at,	   corroborate	   these	  findings	   and	   present	   a	   highly	   significant	   positive	   relation	   (p-­‐value	   <	   0.0001)	   with	  1552502_s_at	  (Fig.	  17B).	  A	  much	  higher	  expression	  of	  the	  RHBDL2	  gene	  is	  observable	  in	  the	   noncancerous	   skin	   cell	   line	   HaCaT,	   with	   the	   skin	   cell	   line	   pair	   MDA-­‐MB-­‐435	  completely	  in	  the	  bottom	  of	  the	  plot	  with	  one	  of	  the	  lowest	  expression	  values.	  Moreover,	  is	  it	  not	  possible	  to	  observe	  a	  correlation	  between	  the	  tissue	  type	  of	  the	  cell	  lines	  and	  the	  gene	   expression	   level	   of	   RHBDL2.	   Glycolysis	   activity	   and	  mitochondrial	  mass	   content	  both	  present	  a	  nonsignificant	  (p-­‐value	  >	  0.05)	  moderately	  positive	  relation	  (Table	  10).	  	  	  
Table	  13.	  r	   coefficients	   and	  p	  values	  of	   the	  extreme	  expressed	  probe	   sets	   in	  Affymetrix	  
array	   and	   the	   cell	   properties	   of	   the	   studied	   cell	   lines.	   In	   the	   total	   probe	   sets	   data	   from	  Affymetric	  Human	  Genome	  U133	  Plus	  2.0	  Array	  the	  extreme	  expressed	  probe	  sets	  were	  selected	  for	  Pearson	  comparison	  with	  the	  electrical	  and	  metabolic	  features	  of	  the	  studies	  cell	   lines.	  The	  gene	  expression	  values	  were	  obtained	  from	  GEO,	  NCBI,	  and	  public	  accession	  numbers	  of	  the	  cell	  lines	  are	  listed	  in	  Experimental	  Methods,	  Table	  2.	  Preprocessing	  of	  the	  .CEL	  files	  was	  done	  using	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Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  The	  normalized	  expressions	  per	  gene	  were	  scaled	  and	  centered	  to	  normalize	  them	  across	  the	  studied	  cell	   lines.	  A	  range	  to	  select	  the	  probe	  sets	  that	  were	  either	  highly	  or	  lowly	  expressed	  in	  at	  least	  9	  of	  the	  16	  cell	  lines	  was	  done.	  Cellular	   capacitance,	   glycolytic	   and	   respiratory	   activities	   were	   measure	   on	   the	   Bionas	   2500	  online	  monitoring	  system.	  The	  ATP	   level	  was	  measured	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	   Assay	   System	   kit	   (Perkin	   Elmer).	   The	  mitochondrial	   mass	   (mitomass)	   content	   was	  determined	  using	  MitoTracker	  Green	  (Thermo	  Fisher).	  ROS	  accumulation	  in	  cells	  was	  measured	  using	   DHE.	   The	   proliferation	   rate	   was	   estimated	   using	   MTT	   and	   SRB	   assays.	   At	   least	   three	  independent	   experiments	   per	   assay	   and	   cell	   line	   were	   used	   for	   the	   calculations.	   Pearson	  comparisons,	   scale-­‐center	   and	   RMA	   normalizations	   were	   obtained	   using	   R	   programming	  
language	  with	  the	  packages	  Hmisc	  function	  rcorr,	  softImpute	  function	  biscale	  and	  Bioconductor	  package	   affy.	   In	   yellow	   the	   two	   probe	   sets	   of	   IFI16	   gene	   (206332_s_at	   and	   208965_s_at)	   that	  show	  a	  significant	  linear	  dependency	  with	  respiration	  activity	  and	  one	  of	  the	  three	  probe	  sets	  of	  the	  RHBDL2	  gene	  that	  show	  a	  significant	  dependency	  with	  glycolysis	  and	  mitochondrial	  mass.	  	  
r	  coefficients	   Capacitance	   Respiration	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	   MTT	  
1555735_a_at	   0.17	   -­‐0.09	   0.03	   0.04	   0.00	   0.32	   -­‐0.14	   -­‐0.47	  
201419_at	   0.37	   -­‐0.16	   0.07	   -­‐0.21	   0.07	   0.09	   -­‐0.17	   0.14	  
201130_s_at	   -­‐0.06	   0.09	   -­‐0.14	   0.24	   0.04	   -­‐0.09	   0.08	   -­‐0.14	  
201131_s_at	   -­‐0.33	   0.11	   -­‐0.35	   0.27	   -­‐0.16	   0.10	   0.08	   -­‐0.30	  
201116_s_at	   0.16	   0.13	   0.21	   0.09	   0.26	   0.17	   -­‐0.12	   -­‐0.08	  
201117_s_at	   0.22	   0.19	   0.23	   0.13	   0.28	   0.16	   -­‐0.12	   -­‐0.01	  
203501_at	   0.03	   0.22	   0.09	   0.08	   0.06	   0.23	   -­‐0.23	   -­‐0.47	  
208454_s_at	   -­‐0.11	   0.21	   0.09	   -­‐0.06	   0.22	   0.20	   -­‐0.06	   -­‐0.31	  
217889_s_at	   0.18	   -­‐0.40	   0.00	   -­‐0.13	   -­‐0.11	   -­‐0.21	   -­‐0.22	   0.14	  
222453_at	   0.23	   -­‐0.27	   -­‐0.03	   -­‐0.09	   -­‐0.16	   -­‐0.24	   -­‐0.23	   0.19	  
220318_at	   0.00	   -­‐0.12	   -­‐0.27	   0.23	   -­‐0.23	   0.04	   0.05	   -­‐0.25	  
223895_s_at	   -­‐0.20	   0.03	   -­‐0.16	   0.11	   -­‐0.02	   0.04	   0.26	   -­‐0.10	  
219121_s_at	   -­‐0.19	   -­‐0.01	   -­‐0.21	   0.20	   0.00	   -­‐0.08	   0.24	   -­‐0.01	  
225846_at	   -­‐0.19	   -­‐0.07	   -­‐0.23	   0.15	   -­‐0.01	   -­‐0.16	   0.23	   -­‐0.01	  
225602_at	   0.27	   0.19	   0.43	   0.25	   0.27	   0.02	   0.26	   0.45	  
225604_s_at	   0.18	   0.04	   0.34	   0.16	   0.33	   -­‐0.03	   0.26	   0.36	  
219976_at	   -­‐0.19	   0.08	   0.10	   -­‐0.10	   0.17	   -­‐0.28	   0.49	   0.16	  
225792_at	   -­‐0.17	   0.04	   0.05	   -­‐0.16	   0.20	   -­‐0.37	   0.48	   0.25	  
206332_s_at	   -­‐0.07	   -­‐0.59	   -­‐0.42	   -­‐0.12	   -­‐0.28	   -­‐0.10	   -­‐0.58	   -­‐0.23	  
208965_s_at	   -­‐0.08	   -­‐0.57	   -­‐0.42	   -­‐0.06	   -­‐0.30	   -­‐0.06	   -­‐0.58	   -­‐0.27	  
235301_at	   0.16	   -­‐0.01	   0.02	   0.26	   0.22	   -­‐0.09	   -­‐0.10	   -­‐0.05	  
244317_at	   0.13	   0.03	   0.05	   0.32	   0.11	   -­‐0.07	   -­‐0.07	   -­‐0.14	  
218656_s_at	   -­‐0.40	   -­‐0.23	   -­‐0.40	   0.05	   -­‐0.26	   0.30	   -­‐0.42	   -­‐0.42	  
231411_at	   -­‐0.35	   -­‐0.09	   -­‐0.26	   0.02	   -­‐0.24	   0.39	   -­‐0.30	   -­‐0.28	  
233634_at	   -­‐0.21	   -­‐0.07	   -­‐0.13	   0.02	   -­‐0.21	   -­‐0.25	   0.42	   0.04	  
239148_at	   -­‐0.33	   -­‐0.14	   -­‐0.26	   -­‐0.01	   -­‐0.10	   -­‐0.21	   0.34	   -­‐0.03	  
239350_at	   -­‐0.27	   -­‐0.17	   -­‐0.19	   -­‐0.01	   -­‐0.16	   -­‐0.29	   0.44	   0.04	  
1555397_at	   -­‐0.37	   -­‐0.13	   -­‐0.33	   0.10	   -­‐0.10	   -­‐0.26	   0.06	   -­‐0.14	  
212338_at	   -­‐0.36	   -­‐0.22	   -­‐0.42	   0.01	   -­‐0.17	   -­‐0.20	   0.08	   -­‐0.20	  
205479_s_at	   -­‐0.16	   0.02	   -­‐0.45	   0.22	   -­‐0.29	   0.47	   -­‐0.33	   -­‐0.29	  
211668_s_at	   -­‐0.19	   0.03	   -­‐0.42	   0.16	   -­‐0.23	   0.49	   -­‐0.30	   -­‐0.39	  
1555579_s_at	   0.23	   -­‐0.15	   0.25	   -­‐0.15	   0.02	   -­‐0.11	   -­‐0.20	   -­‐0.04	  
203329_at	   0.33	   -­‐0.12	   0.21	   -­‐0.02	   0.04	   -­‐0.04	   -­‐0.22	   0.11	  
1552502_s_at	   -­‐0.21	   -­‐0.42	   -­‐0.53	   0.00	   -­‐0.52	   -­‐0.04	   -­‐0.19	   -­‐0.43	  
1554895_a_at	   -­‐0.22	   -­‐0.44	   -­‐0.42	   -­‐0.23	   -­‐0.39	   -­‐0.05	   -­‐0.15	   -­‐0.47	  
1554897_s_at	   -­‐0.03	   -­‐0.36	   -­‐0.41	   0.14	   -­‐0.38	   -­‐0.01	   -­‐0.20	   -­‐0.25	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205768_s_at	   -­‐0.26	   0.03	   0.10	   -­‐0.18	   0.11	   -­‐0.30	   0.53	   0.07	  
205769_at	   -­‐0.20	   0.01	   0.12	   -­‐0.07	   0.16	   -­‐0.36	   0.60	   0.28	  	  
p	  values	   Capacitance	   Respiration	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	   MTT	  
1555735_a_at	   0.54	   0.75	   0.92	   0.90	   0.99	   0.24	   0.69	   0.14	  
201419_at	   0.16	   0.55	   0.79	   0.46	   0.79	   0.75	   0.62	   0.68	  
201130_s_at	   0.82	   0.74	   0.60	   0.39	   0.89	   0.76	   0.81	   0.69	  
201131_s_at	   0.21	   0.69	   0.18	   0.32	   0.55	   0.72	   0.81	   0.36	  
201116_s_at	   0.56	   0.62	   0.45	   0.74	   0.33	   0.54	   0.73	   0.82	  
201117_s_at	   0.42	   0.47	   0.39	   0.66	   0.30	   0.56	   0.72	   0.98	  
203501_at	   0.91	   0.41	   0.74	   0.77	   0.82	   0.41	   0.50	   0.14	  
208454_s_at	   0.67	   0.43	   0.75	   0.83	   0.40	   0.49	   0.86	   0.35	  
217889_s_at	   0.50	   0.13	   0.99	   0.65	   0.67	   0.45	   0.52	   0.68	  
222453_at	   0.39	   0.31	   0.92	   0.76	   0.54	   0.40	   0.49	   0.57	  
220318_at	   0.99	   0.65	   0.32	   0.40	   0.40	   0.90	   0.89	   0.47	  
223895_s_at	   0.46	   0.93	   0.54	   0.69	   0.94	   0.89	   0.44	   0.78	  
219121_s_at	   0.47	   0.98	   0.44	   0.49	   1.00	   0.78	   0.48	   0.99	  
225846_at	   0.49	   0.81	   0.39	   0.59	   0.96	   0.58	   0.49	   0.98	  
225602_at	   0.32	   0.48	   0.10	   0.37	   0.31	   0.94	   0.43	   0.17	  
225604_s_at	   0.51	   0.87	   0.19	   0.56	   0.21	   0.92	   0.44	   0.28	  
219976_at	   0.48	   0.78	   0.72	   0.71	   0.53	   0.32	   0.12	   0.63	  
225792_at	   0.53	   0.87	   0.85	   0.58	   0.45	   0.17	   0.14	   0.46	  
206332_s_at	   0.79	   0.02	   0.10	   0.66	   0.30	   0.73	   0.06	   0.49	  
208965_s_at	   0.77	   0.02	   0.10	   0.84	   0.27	   0.84	   0.06	   0.43	  
235301_at	   0.55	   0.97	   0.93	   0.35	   0.40	   0.76	   0.77	   0.89	  
244317_at	   0.62	   0.90	   0.86	   0.25	   0.68	   0.81	   0.84	   0.68	  
218656_s_at	   0.13	   0.39	   0.13	   0.85	   0.34	   0.27	   0.20	   0.20	  
231411_at	   0.18	   0.75	   0.33	   0.95	   0.37	   0.15	   0.37	   0.41	  
233634_at	   0.43	   0.79	   0.64	   0.94	   0.43	   0.38	   0.19	   0.91	  
239148_at	   0.21	   0.61	   0.34	   0.98	   0.71	   0.45	   0.31	   0.94	  
239350_at	   0.31	   0.52	   0.47	   0.98	   0.54	   0.29	   0.17	   0.90	  
1555397_at	   0.16	   0.62	   0.21	   0.72	   0.73	   0.35	   0.86	   0.67	  
212338_at	   0.17	   0.42	   0.10	   0.98	   0.52	   0.46	   0.82	   0.55	  
205479_s_at	   0.55	   0.93	   0.08	   0.44	   0.27	   0.08	   0.33	   0.39	  
211668_s_at	   0.48	   0.90	   0.11	   0.58	   0.39	   0.06	   0.37	   0.24	  
1555579_s_at	   0.40	   0.57	   0.36	   0.60	   0.94	   0.69	   0.55	   0.90	  
203329_at	   0.22	   0.65	   0.44	   0.93	   0.88	   0.90	   0.52	   0.76	  
1552502_s_at	   0.43	   0.10	   0.04	   0.99	   0.04	   0.88	   0.58	   0.19	  
1554895_a_at	   0.42	   0.09	   0.11	   0.42	   0.14	   0.87	   0.65	   0.15	  
1554897_s_at	   0.91	   0.17	   0.12	   0.61	   0.14	   0.97	   0.55	   0.46	  
205768_s_at	   0.33	   0.90	   0.71	   0.53	   0.70	   0.27	   0.09	   0.84	  
205769_at	   0.46	   0.97	   0.66	   0.81	   0.54	   0.19	   0.05	   0.41	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Fig.	  17.	  Significant	  dependencies	  between	  glycolytic	  activity	  and	  mitochondrial	  mass	  with	  
one	   of	   the	   probe	   sets	   of	   the	   RHBDL2	   gene.	  From	   the	   total	   probe	   set	   data	   from	  Affymetrix	  Human	   Genome	   U133	   Plus	   2.0	   Array	   the	   extreme	   expressed	   probe	   sets	   were	   selected	   for	  Pearson	   comparison	  with	   the	   cellular	   features	   of	   the	   studied	   cell	   lines.	   The	   glycolytic	   activity	  was	  measured	  on	  the	  Bionas	  2500	  containing	  chips	  with	  ISFET	  sensors.	  A	  stronger	  acidification	  rate	  indicates	  a	  higher	  glycolysis	  level.	  Equal	  numbers	  of	  cells	  per	  cell	  line	  were	  seeded	  in	  sensor	  chips.	   The	  mitochondrial	   mass	   content	   of	   the	   cells	   was	   determined	   using	  MitoTracker	   Green	  (Thermo	   Fisher).	   Cell	   lines	   with	   higher	   fluorescence	   intensity	   contain	   higher	   mitochondrial	  mass.	   The	   relationships	   were	   calculated	   using	   the	   mean	   of	   at	   least	   three	   independent	  experiments	   per	   cell	   line	   and	  per	  metabolic	   assay.	  The	   gene	   expression	   values	  were	   obtained	  from	  GEO,	  NCBI,	   and	   the	  public	   accession	  numbers	  of	   the	   cell	   lines	   are	   listed	   in	  Experimental	  Methods,	   Table	   2.	   Preprocessing	   of	   the	   .CEL	   files	  was	   done	   using	  Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  The	  normalized	  expressions	  per	  gene	  were	  scaled	  and	  centered	  to	  normalize	   them	  across	   the	  studied	  cell	   lines.	  A	   range	   to	   select	   the	  probe	  sets	   that	  were	  either	  highly	  or	  lowly	  expressed	  in	  at	  least	  9	  of	  the	  16	  cell	  lines	  was	  done.	  Pearson	  comparisons,	  scale-­‐center	   and	   RMA	   normalizations	   were	   obtained	   using	   R	   programming	   language	   with	   the	  packages	  Hmisc	   function	   rcorr,	   softImpute	   function	   biscale	   and	   Bioconductor	   package	   affy.	  A.	  Linear	  dependency	   curves.	  The	   shape	  of	   the	  dots	   gives	   the	   tissue	   types	  and	   the	  colors	   the	   cell	  line.	   The	   blue	   lines	   represent	   the	   linear	   regressions.	   For	   each	   dependency,	   the	   r	   correlation	  coefficient	  is	  shown;	  asterisks	  represent	  the	  level	  of	  significance	  (p-­‐values	  <	  0.05*).	  Error	  bars	  =	  standard	   error	   (se).	   B.	   Number	   of	   cell	   lines	   with	   extreme	   expression	   of	   the	   probe	   sets,	   r	  coefficients,	  and	  p-­‐values.	  The	  RHBDL2	  gene	  has	  consistent	   information	   in	  the	  r	  coefficients	   in	  the	  three	  probe	  sets,	  but	  just	  one	  of	  them	  has	  a	  significant	  p	  score.	  	   The	   description	   of	   IFI16	   is	   “encodes	   a	   member	   of	   the	   HIN-­200	   (hematopoietic	  
interferon-­inducible	   nuclear	   antigens	   with	   200	   amino	   acid	   repeats)	   family	   of	   cytokines.	  
The	  encoded	  protein	  contains	  domains	  involved	  in	  DNA	  binding,	  transcriptional	  regulation,	  
and	   protein-­protein	   interactions.	   The	   protein	   localizes	   to	   the	   nucleoplasm	   and	   nucleoli,	  
and	  interacts	  with	  p53	  and	  retinoblastoma-­1.	  It	  modulates	  p53	  function,	  and	  inhibits	  cell	  
growth	   in	   the	   Ras/Raf	   signaling	   pathway.	   Alternatively	   spliced	   transcript	   variants	  
encoding	   different	   isoforms	   that	   have	   been	   found	   for	   this	   gene”	   (NCBI/Gene	   summary,	  Gene	  ID:	  3428).	  Our	  results	  shown	  that	  the	  two	  probe	  sets	  corresponding	  to	  IFI16	  have	  a	  significant	  negative	   correlation	   (p-­‐value	  <	  0.02)	  with	   the	   respiration	  activity	   (Fig.	  18),	  meaning	  that	  the	  cell	  lines	  that	  present	  a	  high	  expression	  of	  this	  gene	  respire	  less	  (less	  O2	  consumption).	  It	  is	  obvious	  that	  there	  is	  a	  group	  of	  cell	  lines	  that	  present	  much	  higher	  expression	   levels	   of	   IFI16,	   in	   contrast	   to	   a	   group	  with	  much	   lower	   expression	   of	   that	  gene	  (Fig.	  18A).	  Among	  the	  highest	  expressing	  cells	  are	  the	  brain	  1321N1,	  the	  two	  skin	  cell	  lines	  HaCaT	  and	  MDA-­‐MB-­‐435,	  the	  two	  adenocarcinoma	  pancreatic	  cell	  lines	  AsPC-­‐1	  and	  BxPC-­‐3	  and	  one	  of	   the	   two	  breast	   cancer	  cell	   lines	   the	  adenocarcinoma	  MDA-­‐MB-­‐231	  (Fig.	  18A).	  The	  carcinoma	  cell	   lines	  Hep	  G2	  (liver)	  and	  HT-­‐29,	  as	  well	  as	  HCT	  116	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Fig.	  18.	  Significant	  dependencies	  between	  respiratory	  activity	  and	  the	  two	  probe	  sets	  of	  
IFI16.	   In	   the	   total	   probe	   sets	   data	   from	   Affymetrix	   Human	   Genome	   U133	   Plus	   2.0	   Array	   the	  extreme	  expressed	  probe	  sets	  were	  selected	  for	  Pearson	  comparison	  with	  the	  metabolic	  features	  of	  the	  studies	  cell	   lines.	  The	  respiratory	  activity	  of	   the	  cells	  was	  measured	  on	  the	  Bionas	  2500	  containing	  chips	  with	  Clark	  electrodes.	  Higher	  oxygen	  consumption	  indicates	  higher	  respiration	  rate.	   Equal	   numbers	   of	   cells	   per	   cell	   line	  were	   seeded	   in	   sensor	   chips.	   For	   the	   calculation	   the	  mean	  of	  at	   least	   three	   independent	  experiments	  per	  cell	   line	  with	  six	   technical	  replicates	  each	  one	  was	  used.	  The	  gene	  expression	  values	  were	  obtained	  from	  GEO,	  NCBI,	  and	  public	  accession	  numbers	  of	  the	  cell	  lines	  are	  listed	  in	  Experimental	  Methods,	  Table	  2.	  Preprocessing	  of	  the	  .CEL	  files	  was	  done	  using	  Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  The	  normalized	  expressions	  per	  gene	  were	  scaled	  and	  centered	  to	  normalize	  them	  across	  the	  studied	  cell	  lines.	  A	  range	  to	  select	  the	  probe	  sets	  that	  were	  either	  highly	  or	  lowly	  expressed	  in	  at	  least	  9	  of	  the	  16	  cell	  lines	  was	  done.	  The	  IFI16	  gene	  has	  consistent	  information	  in	  the	  r	  coefficients	  and	  p-­‐values	  in	  its	  two	  probe	  sets.	  Pearson	  comparisons,	  scale-­‐center	  and	  RMA	  normalizations	  were	  obtained	  using	   R	   programming	   language	  with	   the	   packages	   Hmisc	   function	   rcorr,	   softImpute	   function	  biscale	   and	   Bioconductor	   package	   affy.	   A.	   Linear	   dependency	   curves.	   The	   shape	   of	   the	   dots	  shows	  the	  tissue	  types	  and	  the	  color	  the	  cell	  line.	  The	  blue	  lines	  represent	  linear	  regressions.	  For	  each	   dependency	   the	   r	   correlation	   coefficient	   is	   shown;	   asterisks	   represent	   the	   level	   of	  significance	   (p-­‐values	   <	   0.05*).	  Error	   bars	   =	   standard	   error	   (se).	  B.	   Number	   of	   cell	   lines	  with	  extreme	  expression	  of	  the	  probe	  sets,	  r	  coefficients,	  and	  p-­‐values.	  	  	  	   Besides,	  two	  of	  the	  seven	  cell	  lines	  with	  the	  lowest	  expression	  levels	  of	  IFI16	  are	  the	  breast	  adenocarcinoma	  MCF7	  and	  the	  prostate	  adenocarcinoma	  LS174T	  (Fig.	  18A).	  The	   probe	   sets	   206332_s_at	   and	   208965_s_at	   are	   the	   only	   ones	   that	   interrogate	   the	  IFI16	  gene	  and	  present	  an	  almost	  perfect	  positive	  correlation	  with	  each	  other,	  with	  an	  r	  coefficient	  of	  0.99	  (Fig.	  18B).	  	  
	  
3.4.3 Relationships	  between	  Cell	  Properties	  of	   the	  Studied	  Cell	  Lines	  and	  
Affymetrix	  Gene	  Expression	  of	  the	  Probe	  Sets	  with	  High	  Significance	  
	  The	  expression	  values	  of	  the	  entire	  probe	  sets	  in	  the	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  were	  used	   for	  Pearson	  product	  moment	  statistical	   tests	   to	  search	  for	  highly	  significant	  dependencies	  (p-­‐values	  <	  0.0001)	  of	  the	  cellular	  properties	  of	  the	  studied	  cell	  lines	  (Tables	  14	  and	  15).	  The	  expression	  values	  of	  the	  pair	  probe	  sets	  from	  the	   ones	   that	   present	   highly	   significant	   relations	   with	   the	   cellular	   properties	   were	  collected	   and	   their	   dependencies	   recalculated	   (Table	   16).	   From	   the	   13	   genes	   that	  present	  at	  least	  one	  probe	  set	  with	  a	  highly	  significant	  relation	  with	  the	  cellular	  features,	  four	  genes	  have	  consistent	  information	  across	  their	  set	  of	  probe	  sets	  (Table	  16).	  These	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are	   genes	   like	  LARP4	   for	  which	   one	   of	   the	   _at	   probe	   sets	   shows	   a	  moderate	   negative	  relation	  with	   the	   proliferation	   assay	   as	  metabolic	   activity	  MTT,	   and	   the	   others	   (_s_at,	  _a_at	  and	  _at)	  a	  positive	  one	  (Table	  16).	  Even	  more	  drastic	  is	  the	  situation	  with	  the	  six	  probe	  sets	  that	  interrogate	  ZNF333	  gene.	  For	  this	  gene,	  one	  of	  the	  _a_at	  probe	  sets	  gave	  a	  highly	   significant	  positive	  dependency	  with	   the	  proliferation	  assay	  SRB	   (that	  measure	  the	   total	   protein	   content	   of	   the	   cells).	   Also,	   a	   positive	   but	   moderate	   dependency	   is	  present	  with	  the	  other	  _a_at.	  However,	   the	   four	  remaining	  probe	  sets,	  all	  of	   them	  with	  the	  _at	  suffix	  show	  moderated	  negative	  dependencies	  with	  the	  mentioned	  proliferation	  assay	  (Table	  16).	  Moreover,	  from	  the	  13	  genes	  that	  present	  at	  least	  one	  probe	  set	  with	  a	  highly	   significant	   dependency	   with	   some	   of	   the	   cellular	   properties,	   all	   the	   ones	   that	  contain	  only	  one	  probe	  set	  were	  not	  taken	  into	  account.	  	  	   Figure	  19	  plots	  the	  highly	  significant	  dependencies	  among	  the	  cellular	  properties	  and	  selected	  probe	  sets	  of	  genes	  with	  consistent	  information	  across	  their	  probe	  sets.	  All	  of	  these	  genes	  contain	  more	  than	  one	  probe	  set	  on	  the	  Affymetrix	  platform	  used.	  Notice	  that	  the	  entire	  set	  of	  probe	  sets	  belonging	  to	  the	  four	  candidate	  genes,	  present	  at	  least	  a	  significant	   (p-­‐value	   <	   0.05)	   relationship	  with	   the	   proliferation	   rate	   of	   the	   studied	   cell	  lines	  (Table	  16).	  	  	  	   The	   GCN1L1	   gene	   (eIF-­‐2-­‐alpha	   kinase	   activator	   GCN1)	   with	   its	   probe	   set	  216232_s_at	   shows	   a	   highly	   positive	   significant	   dependency	   (p-­‐values	   <	   0.0001)	  with	  the	   proliferation	   rate	   measured	   as	   total	   protein	   content	   in	   the	   SRB	   assay	   (r	   =	   0.91)	  (Fig.	  19A).	   UniProtKB/Swiss-­‐Prot	   refers	   to	   GCN1L1	   as	   follows:	   “acts	   as	   a	   positive	  
activator	   of	   the	   EIF2AK4/GCN2	   protein	   kinase	   activity	   in	   response	   to	   amino	   acid	  
starvation.	   Forms	   a	   complex	   with	   EIF2AK4/GCN2	   on	   translating	   ribosomes;	   during	   this	  
process,	  GCN1	  seems	  to	  act	  as	  a	  chaperone	  to	  facilitate	  delivery	  of	  uncharged	  tRNAs	  that	  
enter	   the	   A	   site	   of	   ribosomes	   to	   the	   tRNA-­binding	   domain	   of	   EIF2AK4/GCN2,	   and	   hence	  
stimulating	  EIF2AK4/GCN2	  kinase	  activity.	  Participates	  in	  the	  repression	  of	  global	  protein	  
synthesis	   and	   in	   gene-­specific	   mRNA	   translation	   activation,	   such	   as	   the	   transcriptional	  
activator	  ATF4,	  by	  promoting	  the	  EIF2AK4/GCN2-­mediated	  phosphorylation	  of	  eukaryotic	  
translation	  initiation	  factor	  2	  (eIF-­2-­alpha/EIF2S1)	  on	  'Ser-­52',	  and	  hence	  allowing	  ATF4-­
mediated	  reprogramming	  of	  amino	  acid	  biosynthetic	  gene	  expression	  to	  alleviate	  nutrient	  
depletion”	  (UniProtKB/Swiss-­‐Prot	  accession	  number:	  Q92616).	  Furthermore,	  probe	  set	  216232_s_at	   of	   GCN1L1	   presents	   a	   significant	   (p-­‐value	   <	  0.05)	   dependency	   with	   the	  MTT	  proliferation	  assay	  (Table	  15).	  The	  second	  probe	  sets	  that	   interrogate	  GCN1L1	  in	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the	  Affymetrix	  array	  corroborate	  the	  relations	  found	  giving	  a	  significant	  (p-­‐value	  <	  0.05	  data	  not	  shown)	  correlation	  with	  both	  the	  proliferation	  assays,	  SRB	  and	  MTT	  (Table	  16).	  The	  expression	  value	  of	  this	  gene	  measured	  according	  to	  the	  probe	  set	  216232_s_at	  does	  not	  show	  much	  variation	  across	  the	  studied	  cell	  lines	  (Table	  14).	  The	  cell	  lines	  with	  the	  highest	   expression	   are	   the	   colorectal	  HT-­‐29	  and	  HCT	  116	   (relative	   expression	  of	   8.92	  and	  9.14,	   respectively)	  and	   the	   lowest	  are	   the	   skin	  cell	   lines	  HaCaT	  and	  MDA-­‐MB-­‐435	  (relative	  expression	  of	  8.04	  and	  7,	  respectively)	  (Table	  14).	  Due	  to	  the	  missing	  data	  for	  the	   proliferation	   assays	   in	   the	   skin	   cell	   lines,	   the	   lowest	   values	   shown	   in	   the	   linear	  dependency	  curve	  in	  Fig.	  19A	  are	  the	  ones	  for	  the	  breast	  cancer	  cell	  lines	  MDA-­‐MB-­‐231	  and	  MCF7.	  These	  results	   indicate	  that	   the	  cell	   lines	  that	  proliferate	  the	  most	  present	  a	  high	  expression	  of	  the	  GCN1L1	  gene	  and	  this	  is	  also	  related	  to	  the	  tissue	  type	  from	  which	  the	  cells	  are	  derived.	  	  	  
	  	   Moreover,	   the	   proliferation	   rate	   (MTT/SRB	   assays)	   shows	   significant	   positive	  dependencies	   with	   HOXA7	   (Homeobox	   7)	   (Tables	   15	   and	   16)	   for	   its	   two	   probe	   sets.	  	  NCBI	   describes	   HOXA7	   as	   follows:	   “In	   vertebrates,	   the	   genes	   encoding	   the	   class	   of	  
transcription	  factors	  called	  homeobox	  genes	  are	  found	  in	  clusters	  named	  A,	  B,	  C,	  and	  D	  on	  
four	   separate	   chromosomes.	   Expression	   of	   these	   proteins	   is	   spatially	   and	   temporally	  
regulated	  during	  embryonic	  development.	  This	  gene	  is	  part	  of	  the	  A	  cluster	  on	  chromosome	  
7	   and	   encodes	   a	   DNA-­binding	   transcription	   factor	  which	  may	   regulate	   gene	   expression,	  
morphogenesis,	   and	   differentiation.	   For	   example,	   the	   encoded	   protein	   represses	   the	  
transcription	   of	   differentiation-­specific	   genes	   during	   keratinocyte	   proliferation,	   but	   this	  
repression	   is	   then	   overcome	   by	   differentiation	   signals“	   (NCBI/Gene	   summary,	   Gene	   ID:	  3204).	  The	  expression	  values	  of	   the	   two	  probe	   sets	   that	   interrogate	  HOXA7	  showed	  a	  strong	  positive	   relation	  with	   the	  proliferation	  assay	  measured	  as	  metabolic	   activity	   in	  MTT,	  and	   is	  corroborated	  with	  a	  significant	  (p-­‐values	  <	  0.01,	  data	  not	  shown)	  positive	  relation	  found	  between	  the	  two	  probe	  sets	  and	  the	  proliferation	  assay	  SRB	  (Table	  16).	  For	  this	  gene	  it	  is	  also	  possible	  to	  observe	  a	  significant	  (p-­‐values	  <	  0.01,	  data	  not	  shown)	  negative	  dependency	  between	  the	  two	  probe	  sets	  and	  ROS	  accumulation	  in	  the	  cells.	  As	  discussed	   in	   Sect.	   3.3,	   the	   proliferation	   rate	   in	   the	   SRB	   and	   MTT	   assays	   presents	   a	  significant	   negative	   correlation	   (r	   =	   –0.68)	   (Table	   10)	   with	   ROS	   accumulation	   in	   the	  cells.	   These	   findings	   indicate	   that	   cells	   with	   high	   proliferation	   rates	   also	   express	   the	  HOXA7	  gene	  to	  a	  higher	  degree	  and	  show	  less	  ROS	  accumulation.	  The	  expression	  levels	  of	  HOXA7	  are	  low	  for	  most	  of	  the	  cell	  lines;	  the	  two	  breast	  cancer	  cell	  lines	  and	  the	  four	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pancreatic	   ones	   show	   equally	   low	   levels	   of	   the	   gene.	   In	   contrast,	   the	   two	   colorectal	  cancer	  cell	   lines	  HT-­‐29	  and	  HCT	  116	  present	  a	  much	  higher	  expression	  level	  of	  HOXA7	  (Fig.	  19B).	  Even	  higher	  is	  the	  expression	  of	  HOXA7	  in	  HaCaT	  and	  HeLa	  cells	  (Table	  14),	  being	  these	  two	  cell	  lines	  the	  ones	  with	  the	  stronger	  expression.	  The	  cell	  lines	  belonging	  to	  the	  prostate	  tissue	  type	  (LNCaP,	  PC-­‐3,	  and	  DU	  145)	  present	  a	  similarly	  low	  expression	  level	  as	  the	  pancreatic	  and	  breast	  tissue	  type	  cell	  lines	  (Table	  14).	  	   	  The	   third	   gene	   that	   presents	   a	   high	   dependency	   with	   the	   proliferation	   rate	   is	  INPP5B	   (inositol	   polyphosphate-­‐5-­‐phosphatase	  B).	  NCBI	   describes	   INPP5B	   as	   follows:	  “This	  gene	  encodes	  a	  member	  of	  a	  family	  of	  inositol	  polyphosphate-­5-­phosphatases.	  These	  
enzymes	   function	   in	   the	   regulation	   of	   calcium	   signaling	   by	   inactivating	   inositol	  
phosphates.	   The	   encoded	   protein	   is	   localized	   to	   the	   cytosol	   and	   mitochondria,	   and	  
associates	   with	   membranes	   through	   an	   isoprenyl	   modification	   near	   the	   C-­terminus“	  (NCBI/Gene	  summary,	  Gene	  ID:	  3633).	  The	  highly	  sifnificant	  (p-­‐value	  <	  0.0001)	  positive	  dependency	  found	  for	  the	  probe	  set	  213643_s_at	  of	  the	  INPP5B	  gene	  and	  the	  SRB	  assay	  is	  corroborated	  by	  the	  three	  probe	  sets	  that	  contain	  information	  for	  the	  gene,	  all	  of	  them	  having	   a	   significant	   (p-­‐value	   <	   0.01,	   data	   not	   shown)	   positive	   relation	   with	   the	   MTT	  proliferation	  assay	  (data	  not	  shown).	  The	  expression	  of	  the	  INPP5B	  gene	  behaves	  in	  the	  same	  way	  as	   the	  expression	   for	  HOXA7;	  most	  of	   the	   cell	   lines	   showed	  similar	   relative	  low	  expression	  levels	  with	  the	  two	  colorectal	  ones	  having	  together	  a	  higher	  expression	  (Fig.	  19C).	  Interestingly,	  the	  lowest	  relative	  expressions	  are	  for	  the	  breast	  and	  pancreas	  cell	  lines,	  which	  are	  around	  5.5,	  and	  the	  highest	  is	  for	  the	  brain	  1321N1	  with	  just	  7.14.	  The	  colorectal	  HT-­‐29	  and	  HCT	  116	  present	  a	   relative	  expression	  of	   around	  6.5	   (Table	  14).	   Cell	   lines	   with	   low	   expression	   levels	   of	   the	   INPP5B	   gene	   also	   present	   low	  proliferation	  rates.	  	   	  Among	   the	   highly	   significant	   positive	   dependencies	   found	   between	   the	   set	   of	  candidate	   genes	   and	   the	   proliferation	   rate	   is	   LGALS8	   (Galectin	   8),	   the	   only	   one	   that	  shows	   a	   negative	   correlation	   with	   one	   of	   the	   proliferation	   assays	   and	   also	   with	   the	  cellular	  mitochondrial	  mass	  content	  (Table	  16	  and	  Fig.	  19D).	  NCBI	  describes	  LGALS8	  as	  follows:	   “This	   gene	   encodes	   a	   member	   of	   the	   galectin	   family.	   Galectins	   are	   beta-­
galactoside-­binding	  animal	  lectins	  with	  conserved	  carbohydrate	  recognition	  domains.	  The	  
galectins	   have	   been	   implicated	   in	   many	   essential	   functions	   including	   development,	  
differentiation,	  cell-­cell	  adhesion,	  cell-­matrix	  interaction,	  growth	  regulation,	  apoptosis,	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Fig.	  19.	  Highly	  significant	  dependencies	  between	   the	  metabolic	   features	  of	   the	  analyzed	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information	   in	   all	   their	   corresponding	  probe	   sets	  were	  plotted.	  Pearson	   comparison	  and	  RMA	  normalization	  were	  obtained	  using	  R	  programming	  language	  with	  the	  packages	  Hmisc	   function	  rcorr	  and	  Bioconductor	  package	  affy.	  The	  shape	  of	  the	  dots	  gives	  the	  tissue	  types	  and	  the	  color	  the	  cell	  line.	  The	  blue	  lines	  represent	  linear	  regressions.	  For	  each	  independent	  dependency	  the	  r	  correlation	   coefficient	   is	   shown;	   asterisks	   represent	   the	   level	   of	   significance.	   Error	   bars	   =	  standard	  error	  (se).	  Linear	  correlations	  between:	  A.	  SRB	  proliferation	  assay	  and	  GCN1L1	  probe	  set	   216232_s_at.	   B.	   MTT	   proliferation	   assay	   and	   HOXA7	   probe	   set	   206847_s_at.	   C.	   SRB	  proliferation	   assay	   and	   INPP5B	   probe	   set	   213643_s_at.	   D.	   Mitochondrial	   mass	   content	   and	  LGALS8	  probe	  set	  208935_s_at.	  	  
	  
Table	   16.	   r	   coefficients	   of	   the	   highly	   significant	   dependencies	   between	   metabolism	  
features	  and	  total	  probe	  sets	  from	  Affymetrix	  Array.	  Linear	  correlation	  coefficients	  between	  the	   cellular	   features	   and	   the	   complete	  Affymetrix	  Human	  Genome	  U133	  Plus	   2.0	  Array	   probe	  sets	   were	   calculated	   using	   Pearson	   algorithm.	   Cellular	   capacitance,	   glycolytic	   activity	  (acidification),	   and	   respiratory	   activity	   (O2	   consumption)	  were	  measured	   on	   the	   Bionas	   2500	  online	  monitoring	  system.	  Cells	  were	  seeded	  in	  chips	  containing	  IDES	  sensors	  for	  the	  estimation	  of	   the	   cellular	   capacitance,	   ISFET	   sensors	   to	   measure	   the	   acidification	   rate,	   and	   Clark-­‐type	  sensor	  for	  determination	  of	  oxygen	  consumption.	  Energy	  metabolism	  (ATP	  level)	  was	  measured	  with	  ATPlite	  1step	  Luminescence	  ATP	  Detection	  Assay	  System	  kit	  (Perkin	  Elmer).	  Mitochondrial	  mass	  content	  was	  determined	  by	  MitoTracker	  Green	  (Thermo	  Fisher).	  ROS	  accumulation	  in	  cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  Gene	  expression	  values	  were	  obtained	  from	  GEO,	  NCBI,	  and	  public	  accession	  numbers	  of	  the	  cell	  lines	  are	  listed	  in	  Experimental	  Methods,	  Table	  2.	  Preprocessing	  of	  the	  .CEL	  files	  was	  done	  using	  Robust	  Multi-­‐array	  Average	  (RMA)	  normalization	  method.	  From	  more	  than	  54,000	  probe	  sets	   in	  which	  the	  r	  coefficient	  was	  calculated,	   the	  ones	  with	   the	   highest	   significant	   p-­‐values	   (<	   0.0001***)	   were	   selected.	   Genes	   with	   consistent	  information	   of	   the	   r	   coefficients	   in	   their	   total	   probe	   sets	   are	   highlighted.	   Pearson	   comparison	  and	  RMA	  normalization	  were	  obtained	  using	  R	  programming	  language	  with	  the	  packages	  Hmisc	  function	  rcorr	  and	  Bioconductor	  package	  affy.	  	  	  
Gene	  
Symbol	  	  
Probe	  set	  ID	  	   Capacitance	   Respiration	   Glycolysis	   ATP	   Mitomass	   ROS	   SRB	   MTT	  
CCL19	   210072_at	   -­‐0.39	   -­‐0.26	   -­0.78	   0.13	   -­‐0.13	   0.18	   -­‐0.70	   -­‐0.54	  
DUSP2	   204794_at	   0.38	   0.62	   0.64	   -­‐0.21	   0.50	   -­‐0.14	   0.55	   0.91	  
218912_at	   0.15	   -­‐0.02	   0.22	   -­‐0.20	   0.29	   -­‐0.31	   0.57	   0.92	  243306_s_at	   -­‐0.22	   -­‐0.16	   0.07	   -­‐0.17	   0.19	   -­‐0.26	   0.65	   0.08	  GCC1	   243437_at	   0.14	   0.04	   0.03	   0.13	   0.34	   0.01	   -­‐0.02	   0.04	  212139_at	   0.14	   0.30	   0.22	   0.15	   0.31	   0.02	   0.54	   0.73	  
GCN1L1	  
216232_s_at	   0.11	   0.24	   0.26	   0.06	   0.37	   0.00	   0.91	   0.68	  
206847_s_at	   -­‐0.08	   -­‐0.16	   0.30	   -­‐0.51	   0.37	   -­‐0.63	   0.74	   0.95	  
HOXA7	   235753_at	   -­‐0.05	   -­‐0.20	   0.22	   -­‐0.49	   0.27	   -­‐0.62	   0.63	   0.90	  1563565_at	   0.51	   0.01	   0.50	   0.15	   0.21	   -­‐0.17	   0.29	   0.71	  




217505_at	   -­‐0.19	   0.33	   -­‐0.22	   0.55	   -­‐0.22	   0.83	   -­‐0.46	   -­‐0.54	  
LARP4	   1555384_a_at	   0.26	   0.49	   0.42	   0.35	   0.01	   0.36	   0.23	   0.13	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212714_at	   0.41	   0.48	   0.51	   -­‐0.32	   0.22	   -­‐0.22	   0.66	   0.95	  214155_s_at	   0.19	   0.38	   0.38	   0.17	   0.29	   0.27	   0.11	   0.38	  238959_at	   0.13	   0.47	   0.41	   0.33	   0.08	   0.38	   0.23	   -­‐0.13	  
	  
238960_s_at	   0.14	   0.32	   0.45	   0.25	   0.09	   0.21	   0.34	   0.00	  208933_s_at	   -­‐0.20	   0.05	   -­‐0.45	   0.30	   -­‐0.76	   0.38	   -­‐0.32	   -­‐0.77	  208934_s_at	   -­‐0.35	   0.18	   -­‐0.41	   0.40	   -­‐0.67	   0.50	   -­‐0.22	   -­‐0.70	  
208935_s_at	   -­‐0.16	   0.09	   -­‐0.46	   0.46	   -­0.84	   0.45	   -­‐0.38	   -­‐0.73	  208936_x_at	   -­‐0.26	   0.19	   -­‐0.45	   0.39	   -­‐0.70	   0.50	   -­‐0.31	   -­‐0.75	  210731_s_at	   -­‐0.24	   0.01	   -­‐0.47	   0.17	   -­‐0.73	   0.35	   -­‐0.30	   -­‐0.75	  LGALS8	   210732_s_at	   -­‐0.33	   0.13	   -­‐0.41	   0.38	   -­‐0.68	   0.52	   -­‐0.23	   -­‐0.74	  
LHX8	   1569469_a_at	   0.15	   0.31	   0.53	   -­‐0.47	   0.85	   -­‐0.37	   0.56	   0.87	  
SLC39A10	   225295_at	   0.84	   0.43	   0.51	   0.14	   0.12	   0.01	   0.12	   0.48	  
WDR86	   243526_at	   -­‐0.15	   0.12	   0.09	   -­‐0.22	   0.23	   -­‐0.49	   0.54	   0.93	  1552375_at	   0.23	   0.33	   0.18	   0.60	   -­‐0.20	   0.50	   -­‐0.33	   -­‐0.41	  1559674_at	   0.19	   0.18	   0.22	   0.00	   -­‐0.10	   0.21	   -­‐0.21	   0.01	  
1563783_a_at	   0.36	   0.38	   0.53	   0.27	   0.05	   0.10	   0.92	   0.51	  1569250_at	   0.22	   -­‐0.11	   0.23	   0.29	   -­‐0.21	   0.17	   -­‐0.10	   -­‐0.07	  1569251_a_at	   0.40	   0.12	   0.30	   0.39	   -­‐0.10	   -­‐0.01	   0.13	   0.27	  ZNF333	   231369_at	   -­‐0.25	   -­‐0.11	   0.00	   0.10	   -­‐0.07	   0.23	   -­‐0.02	   -­‐0.48	  	  	  
and	  RNA	  splicing.	  This	  gene	  is	  widely	  expressed	  in	  tumoral	  tissues	  and	  seems	  to	  be	  involved	  
in	   integrin-­like	   cell	   interactions”	   (NCBI/Gene	   summary,	   Gene	   ID:	   3964).	   The	   probe	   set	  208935_s_at	   shows	   a	   highly	   significant	   (p-­‐value	   <	   0.0001)	   and	   negative	   dependency	  with	   the	  mitochondrial	  mass	  content	   (Fig.	  19D).	  The	  LGALS8	  gene	  contains	   five	  probe	  sets	   more	   and	   in	   all	   of	   them	   a	   significant	   (p-­‐value	   <	   0.01	   data	   not	   shown)	   negative	  dependency	  with	  the	  mitochondrial	  mass	  is	  found	  (Table	  16).	  In	  the	  entire	  set	  of	  probe	  sets	   that	   interrogate	   the	  LGALS8	  gene,	  a	  negative	  and	  significant	   (p-­‐value	  <	  0.01,	  data	  not	  shown)	  relation	  with	  the	  MTT	  proliferation	  assay	  is	  observable	  as	  well,	  but	  not	  for	  SRB.	  However,	  the	  dependencies	  found	  between	  the	  LGALS8	  probe	  sets	  and	  SRB	  assay	  display	  the	  same	  tendency,	  a	  negative	  correlation	  (Table	  16).	  The	  data	  obtained	  for	  the	  Pearson	  correlation	  coefficients	  indicate	  that	  the	  cell	  lines	  that	  express	  the	  higher	  level	  of	  the	  LGALS8	  gene	  are	  the	  ones	  that	  present	  the	  lowest	  proliferation	  rate	  measured	  as	  metabolic	   activity	   and	   mitochondrial	   mass.	   As	   shown	   in	   Table	   10,	   the	   mitochondrial	  mass	   content	   of	   the	   studied	   cell	   lines	   and	   the	  MTT	  proliferation	   assay	   do	   not	   show	   a	  significant	   dependency	   upon	   each	   other.	   However,	   a	  moderate	   positive	   correlation	   is	  present.	   Different	   to	   the	   expression	   pattern	   observed	   for	   the	   other	   three	   candidates	  genes,	  here,	  the	  colorectal	  cells	  HT-­‐29	  and	  HCT	  116	  are	  part	  of	  the	  ones	  that	  present	  the	  lowest	  expression	  levels	  (Fig.	  19D).	  The	  relative	  expression	  of	  the	  LGALS8	  gene	  for	  the	  breast	  and	  pancreas	  tissue	  type	  cells	  is	  high	  in	  comparison	  with	  the	  colorectal	  cell	  lines.	  The	  prostate	  cell	  lines	  differ	  in	  their	  expression	  levels	  and	  the	  same	  is	  observable	  for	  the	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skin	   cell	   lines,	   MDA-­‐MB-­‐435	   being	   one	   of	   the	   lowest	   and	   the	   noncancerous	   cell	   line	  HaCaT	  the	  highest	  in	  all	  the	  tested	  cell	  lines.	  The	  lowest	  relative	  expression	  is	  displayed	  by	  the	  cervix	  HeLa	  cell	  line	  (Fig.	  19D).	  	  
3.4.4 Affymetrix	  Gene	  Expression	  and	  qPCR	  
	  The	   relative	   gene	   expression	   of	   the	   glycolysis-­‐gluconeogenesis	   genes	   GOT1	  (glutamic-­‐oxaloacetic	  transaminase	  1),	  HK1	  (hexokinase	  1),	  HK2	  (hexokinase	  2),	  LDHA	  (lactate	   dehydrogenase	   A),	   PFKM	   (phosphofructokinase-­‐muscle),	   and	   SLC2A1	   (solute	  carrier	  family	  2	  member	  1)	  was	  estimated	  by	  qPCR.	  Real-­‐time	  PCR	  was	  performed	  in	  the	  breast	   cancer	   cell	   lines	  MDA-­‐MB-­‐231	  and	  MCF7,	   the	   colorectal	   cell	   lines	  HCT	  116	  and	  HT-­‐29,	   the	  pancreatic	   cell	   lines	  AsPC-­‐1,	  MIA	  PaCa-­‐2,	   Panc-­‐1,	   and	  BxPC-­‐3,	   the	  prostate	  cell	  lines	  PC-­‐3	  and	  DU	  145,	  the	  cervix	  HeLa,	  and	  the	  liver	  cell	  line	  Hep	  G2.	  	   The	  RNA	  for	  the	  Reverse	  Transcriptase	  PCR	  comes	  from	  cells	  cultivated	  in	  DMEM	  medium	   at	   37°C	   in	   5%	   CO2	   incubator	   with	   95%	   humidity.	   Primer	   sequences	   for	   the	  qPCR	  are	   listed	   in	  Table	  6	  (Experimental	  Methods	  2.3.3).	  The	  relative	  gene	  expression	  was	   calculated	   as	   the	  mean	   of	   three	   independent	   experiments.	   Most	   of	   the	   amplified	  genes	  are	  highly	  expressed	  in	  the	  carcinoma	  cell	  lines	  Hep	  G2	  and	  HCT	  116	  (Fig.	  20).	  In	  contrast,	  HK1	  and	  PFKM	  present	  the	  lowest	  expression	  values	  in	  all	  the	  tested	  cell	  lines	  for	  Hep	  G2.	  A	  high	  expression	  is	  also	  observed	  for	  LDHA	  in	  the	  adenocarcinomas	  AsPC-­‐1	  and	  PC-­‐3	  (Fig.	  20).	  	  Comparison	   was	   made	   between	   the	   results	   obtained	   from	   the	   qPCR	   gene	  expression	  estimations	  (Fig.	  20)	  and	  the	  data	  from	  the	  Affymetrix	  Human	  Genome	  U133	  Plus	   2.0	   Array	   obtained	   from	   public	   repositories	   files	   (Experimental	   Methods	   2.3)	  (Fig.	  21).	  The	  qPCR	  expression	  value	  of	  each	  of	  the	  six	  amplified	  genes	  was	  normalized	  across	   the	   cell	   lines.	   Scale	   and	   center	  were	   applied	   to	   normalize	   the	   gene	   expression	  relative	  to	  the	  set	  of	  cell	  lines	  used.	  A	  range	  of	  calculations	  was	  obtained	  to	  compare	  the	  expression	  values	  of	  each	  gene	  in	  the	  tested	  cell	  lines	  from	  –3	  (lowly	  expressed	  genes)	  to	  3	   (highly	   expressed	   genes)	   (Experimental	   Methods	   2.3.1).	   The	   same	   procedure	   was	  done	  regarding	   the	  gene	  expression	  of	   the	  same	  six	  genes	  obtained	   from	  the	  available	  public	   repositories	   (De	   Schutter	   et	   al.	   2013,	   Barretina	   et	   al.	   2012)	   (Experimental	  Methods	  2.3).	  For	   the	  genes	   that	  contain	  more	   than	  one	  probe	  set	   in	   the	  Affymetrix,	  a	  mean	  of	  the	  probe	  sets	  was	  used.	  Probe	  sets	  with	  a	  _x	  suffix	  were	  deleted.	  Scaling	  and	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centering	  were	  calculated	  using	  R	  programming	  language	  package	  softImpute	  (Hastie	  &	  Mazumder	  2015)	  (Supplements	  5.1.5).	  Affymetrix	   arrays	   and	   qPCR	   standardized	   relative	   expression	   values	   of	   GOT1,	  HK1,	  HK2,	  LDHA,	  PFKM,	  and	  SLC2A1	  in	  the	  12	  cell	  lines	  were	  plotted	  together	  in	  order	  to	  compare	  our	  results	  with	  the	  ones	  obtained	  by	  De	  Schutter	  et	  al.	  (2013)	  and	  Barretina	  et	  al.	  (2012)	  (Fig.	  21).	  From	  a	  total	  of	  six	  glycolytic	  genes	  in	  the	  12	  cell	  lines,	  53	  out	  of	  the	   72	   comparisons	   show	   the	   same	   tendency,	   positive	   expression	   or	   negative	  expression,	  within	  the	  set	  of	  cell	  lines	  used.	  However,	  in	  most	  of	  the	  cases,	  they	  do	  not	  share	  the	  level	  of	  expression	  between	  the	  two	  methodologies.	  An	  exception	  is	  observed	  for	   GOT1	   in	  Hep	   G2;	   HK1	   in	   DU	   145	   and	  HeLa;	   HK2	   in	  HT-­‐29,	   HCT	   116,	   Panc-­‐1,	   and	  MCF7;	   PFKM	   in	   Panc-­‐1;	   and	   SLC2A1	   in	   MCF7,	   AsPC-­‐1,	   and	   MIA	   PaCa-­‐2	   that	   showed	  relative	   similar	   expression	   values	   in	   relation	   to	   the	   cell	   lines	   used	   (Fig.	   21).	   Major	  similarities	  are	  found	  in	  the	  prostate	  cell	  line	  PC-­‐3	  and	  the	  liver	  cell	  line	  Hep	  G2,	  where	  all	   the	   amplified	   genes	   follow	   the	   same	   Affymetrix	   patterns,	   being	   similarly	   either	  upregulated	  or	  downregulated	  (Fig.	  21).	  	  
	  
Fig.	   20.	   Real-­time	   polymerase	   chain	   reaction	   (qPCR)	   in	   key	   metabolic	   genes	   of	   the	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Fig.	  21.	  Affymetrix	  Gene	  expression	  and	  qPCR	  comparison.	  Affymetrix	  Gene	  expression	  raw	  data	   (.CEL	   files)	  were	   obtained	   from	  GEO,	  NCBI	   and	   correspond	   to	   the	  Human	  Genome	  U133	  Plus	   2.0	   Array.	   Public	   accession	   numbers	   and	   cell	   lines	   are	   listed	   in	   Experimental	   Methods	  Table	  2.	   Preprocessing	   of	   the	   .CEL	   files	   was	   done	   using	   Robust	   Multi-­‐array	   Average	   (RMA)	  normalization	   method.	   Primer	   sequences	   and	   amplification	   details	   for	   the	   qPCR	   are	   given	   in	  Experimental	  Methods	  2.3.	  The	  standard	  deviation	  of	  the	  qPCR	  experiments	  is	  not	  shown	  (for	  SD	  of	  qPCR	  see	  Fig.	  19).	  Scale	  and	  center	  normalization	  were	  applied	  to	  the	  expression	  values	  of	  the	  Affymetrix	  and	  the	  qPCR	  data	  to	  normalize	  the	  expression	  of	  each	  gene	  in	  the	  set	  of	  studied	  cell	  lines.	  A	  range	  from	  –3	  (lowly	  expressed	  genes	  in	  the	  lower	  part	  of	  the	  plot)	  to	  3	  (high	  expressed	  genes	   in	  the	  upper	  part	  of	   the	  plot)	  was	  obtained.	  Expression	  values	  that	  come	  from	  qPCR	  are	  denoted	   by	   a	   “q”	   followed	   by	   the	   corresponding	   gene	   symbol.	   Scale-­‐center	   and	   RMA	  normalizations	   were	   obtained	   using	   R	   programming	   language	   package	   softImpute	   function	  biscale	  and	  Bioconductor	  package	  affy.	  	  	  
3.5 Cellular	  Properties	  and	  Drug	  IC50s	  	  
3.5.1 Relationships	  between	  Cell	  Properties	  and	  Drug	  IC50s	  of	  the	  Studied	  
Cell	  Lines	  
	  To	   reach	   a	   better	   understanding	   of	   the	   impact	   of	   drugs	   in	   relation	   to	   cancer	  metabolism	   and	   cellular	   capacitance,	   measurements	   were	   obtained	   on	   the	   cellular	  properties	   of	   the	   studied	   cell	   lines	   (Figs.	   2	   to	   10)	   and	   the	   log10	  of	   the	   IC50	   values	   for	  several	  drugs	  (Fig.	  22	  and	  Experimental	  Methods	  2.4.1,	  Table	  7)	  were	  used	  to	  search	  for	  relationships.	  Novel	  links	  between	  known	  drugs	  and	  cellular	  features	  were	  discovered.	  Pearson	  product	  moment	  correlations	  were	  used	   to	   find	   linear	  dependencies	  between	  the	   mentioned	   two	   variables.	   For	   the	   cellular	   properties,	   at	   least	   three	   independent	  experiments	  per	  assay	  and	  per	  cell	  line,	  on	  the	  average,	  were	  carried	  out.	  The	  IC50	  values	  of	   nearly	   100	   compounds	   were	   obtained	   from	   the	   Genomics	   of	   Drug	   Sensitivity	   in	  Cancer	   project	   (Yang	   et	   al.	   2013)	   (Fig.	   22	   and	   Experimental	   Methods	   2.4.1,	   Table	   7).	  Data	  for	  drug	  IC50s	  were	  found	  for	  11	  out	  of	  the	  18	  cell	  lines	  used	  in	  this	  study.	  The	  data	  collection	  was	  done	   for	   the	   following	  cell	   lines:	  MDA-­‐MB-­‐231	  and	  MCF7	  (breast);	  HCT	  116	  and	  HT-­‐29	  (colon);	  AsPC-­‐1,	  MIA	  PaCa-­‐2,	  and	  BxPC-­‐3	  (pancreas);	  LNCaP,	  PC-­‐3,	  and	  DU	  145	  (prostate);	  and	  MDA-­‐MB-­‐435	  (skin)	   (Experimental	  Methods	  1.1,	  Table	  1).	  The	  r	  coefficients	   were	   acquired	   using	   R	   programming	   language	   packages	   Hmisc	   and	   the	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Elesclomol	   is	   a	   copper	   chelator	   that	   induces	   growth	   arrest	   and	   apoptosis	   in	  cancer	   cell	   lines	   through	   the	   induction	   of	   oxidative	   stress	   and	   an	   increase	   in	   ROS	  production	   (Rae	   &	   Mairs	   2017,	   Krishner	   et	   al.	   2008).	   Preclinical	   studies	   showed	   an	  efficacy	   against	   acute	   myeloid	   leukemia	   (Hedley	   et	   al.	   2016).	   Our	   results	   indicate	   a	  negative	   correlation	   of	   elesclomol	   with	   cellular	   capacitance,	   indicating	   stronger	   cell-­‐matrix	   and	   cell-­‐cell	   contacts	   of	   the	   prostate	  DU	  145	   and	   the	   pancreas	   cancer	   cell	   line	  BxPC-­‐3	  that	  may	  make	  them	  more	  resistant	  to	  the	  compound	  (Fig.	  23).	  	  	  
	  	  
Fig.	  23.	  Elesclomol	  -­	  significant	  dependencies	  between	  cellular	  capacitance	  and	  the	  log10	  

































































Fig.	  24.	  Nutlin	  3a	  and	  PF	  4708671	  –	  significant	  dependencies	  between	  respiration	  activity	  
and	   the	   log10	   IC50	   of	   Nutlin	  3a	   (A)	   and	   PF	   4708671	   (B).	   The	   respiration	   activity	   was	  measured	  with	  the	  Bionas	  2500	  online	  monitoring	  system.	  Cells	  were	  seeded	  in	  chips	  containing	  Clark	   electrodes.	   Higher	   oxygen	   consumption	   indicates	   stronger	   respiration	   rate.	   The	   mean	  value	   of	   at	   least	   three	   independent	   experiments	   per	   cell	   line	   was	   used	   for	   the	   Pearson	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correlation.	  IC50	  values	  were	  obtained	  from	  the	  Genomics	  of	  Drug	  Sensitivity	  in	  Cancer	  project.	  The	   Pearson	   calculations	   were	   done	   using	   R	  programming	   language	   package	   Hmisc	   function	  rcorr.	   The	   shape	   of	   the	   dots	   gives	   the	   tissue	   types	   and	   the	   color	   the	   cell	   lines.	   The	   blue	   lines	  represent	  the	  linear	  regressions.	  For	  each	  independent	  dependency	  the	  r	  correlation	  coefficient	  is	  shown;	  asterisks	  represent	  the	  level	  of	  significance	  (p-­‐values	  <	  0.01**).	  Error	  bars	  =	  standard	  error	  (se).	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Fig.	   25.	   EHT	   1864,	   IPA3,	   and	   RDEA119	   –	   significant	   dependencies	   between	   energy	  





Fig.	   26.	   Methotrexate	   –	   significant	   dependencies	   between	   ROS	   accumulation	   and	   the	  
log10	   IC50	  of	  methotrexate.	   ROS	   accumulation	   in	   cells	  was	  measured	  using	  dihydroethidium	  (DHE).	  The	  mean	  value	  of	  at	  least	  three	  independent	  experiments	  per	  cell	  line	  was	  used	  for	  the	  Pearson	  correlation.	  IC50	  values	  were	  obtained	  from	  the	  Genomics	  of	  Drug	  Sensitivity	  in	  Cancer	  project.	   The	   Pearson	   calculations	   were	   done	   using	   R	   programming	   language	   package	   Hmisc	  function	  rcorr.	  The	  shape	  of	  the	  dots	  gives	  the	  tissue	  types	  and	  the	  color	  the	  cell	  lines.	  The	  blue	  
lines	   represent	   the	   linear	   regressions.	   For	   each	   independent	   dependency	   the	   r	   correlation	  coefficient	  is	  shown;	  asterisks	  represent	  the	  level	  of	  significance	  (p-­‐values	  <	  0.001***).	  Error	  bars	  =	  standard	  error	  (se).	  
	  
3.5.2 Drug	  Sensitivity	  (IC50)	  of	  the	  Cell	  Lines	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IC50	   values	   obtained	   from	   the	   GDSC	   (Yang	   et	   al.	   2013)	   (Experimental	   Methods	   2.4.2,	  Table	  8).	  The	  obtained	  absorbencies	  were	  fitted	  to	  sigmoid	  and	   linear	  regressions	  and	  the	   best	   fit	   was	   chosen	   (r	   coefficient	   near	   to	   –1).	   At	   least	   three	   independent	  measurements,	  with	   three	   technical	   replicates	   each,	  were	  done	  per	  drug	  and	   cell	   line.	  Fittings	   and	   IC50	   calculations	   were	   performed	   using	   the	   Excel	   add-­‐in	   ED50plus	   v1.0	  developed	  by	  Mario	  H.	  Vargas	  (2000).	  	  	   The	  results	  obtained	  from	  the	  GDSC	  project	  for	  the	  IC50	  values	  of	  drugs	  (Yang	  et	  al.	  2013)	  (Fig.	  22	  and	  Experimental	  Methods	  2.4.1,	  Table	  7)	  differ	   in	  most	  of	   the	  cases	  from	   the	   estimations	   done	   by	   us.	   Furthermore,	   it	   is	   possible	   to	   observe	   one	   order	   of	  magnitude	   difference	   between	   the	   two	   calculations	   for	   CCT007093	   in	  MCF7,	   PAC1	   in	  MDA-­‐MB-­‐231,	   AKT1/2	   kinase	   inhibitor	   in	   HT-­‐29,	   for	   BAY61-­‐3606	   in	   MCF7	   and	   MIA	  PaCa-­‐2,	  and	  for	  IPA3	  in	  HCT	  116	  and	  HT-­‐29	  (Table	  17).	  Similarly,	   the	  cases	  where	  the	  IC50	   from	   the	   database	   and	   our	   estimations	   differed	   in	   less	   than	   25%	  were	   the	   ones	  calculated	   for	   CCT007093	   in	   HCT	   116,	   HT-­‐29	   and	  MDA-­‐MB-­‐435,	   LFM-­‐A13	   in	   AsPC-­‐1,	  PAC1	  in	  AsPC-­‐1,	  and	  BAY61-­‐3606	  in	  HCT	  116	  (Table	  17)	  	  
Table	  17.	  Database	  drug	  IC50s	  compared	  with	  own	  estimations	  in	  our	  cell	  lines.	  Drug	  IC50	  values	  were	  obtained	  from	  the	  Genomics	  of	  Drug	  Sensitivity	  in	  Cancer	  (GDSC)	  project.	  From	  the	  total	   of	   drugs	   in	   the	   database,	   seven	  were	   used	   for	   our	   IC50	   estimations.	   The	   IC50	   calculations	  were	   done	   based	   on	   the	   inhibition	   of	   cell	   proliferation	   in	   ten	   cell	   lines.	   Cell	   proliferation	  was	  monitored	  by	  means	  of	  the	  SRB	  assay.	  Cells	  were	  incubated	  for	  72	  h	  with	  a	  serial	  dilution	  (up	  to	  eight	  concentrations)	  of	  each	  drug	  (Experimental	  Methods,	  Table	  8).	  At	  least	  three	  independent	  measurements	   with	   three	   internal	   replicates	   were	   done	   per	   drug	   and	   cell	   line.	   The	   fit	   was	  adjusted	  to	  sigmoid	  and	  linear	  regressions.	  Based	  on	  the	  r	  coefficients,	  the	  best	  fit	  was	  selected.	  IC50	  GDSC	  =	  IC50	  Genomics	  of	  Drug	  Sensitivity	  in	  Cancer	  project;	  IC50	  =	  our	  IC50	  estimation;	  SD	  =	  standard	  deviation	  of	  our	  IC50	  estimations;	  fit	  r	  coefficient	  =	  r	  coefficient	  between	  the	  estimation	  done	  by	  the	  data	  and	  the	  sigmoid	  or	  linear	  regressions	  to	  the	  fit	  model.	  	  
Drug	   Cell	  line	   IC50	  GDSC	  
(μM)	  
IC50	  (μM)	   SD	  (μM)	   fit	  r	  coefficient	  MDA-­‐MB-­‐231	   45.12	   6.14	   1.04	   -­‐0.78	  
17-­AAG	   LNCaP	   0.80	   1.29	   0.53	   -­‐0.95	  MCF7	   3.86	   158	   51.03	   -­‐0.80	  HCT	  116	   434.3	   435.3	   227.5	   -­‐0.46	  HT-­‐29	   238	   187.4	   51.54	   -­‐0.55	  MIA	  PaCa-­‐2	   687.9	   258.3	   64.57	   -­‐0.61	  LNCaP	   874.1	   311.5	   70.41	   -­‐0.58	  DU	  145	   759.1	   406.1	   46.31	   -­‐0.64	  CCT007093	   MDA-­‐MB-­‐435	   479.5	   415.2	   73.93	   -­‐0.72	  MDA-­‐MB-­‐231	   81.9	   348.9	   34.63	   -­‐0.94	  MCF7	   464.4	   196.5	   20.06	   -­‐0.95	  LFM-­A13	   HCT	  116	   703.1	   189.4	   20.40	   -­‐0.96	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HT-­‐29	   865.8	   189.3	   22.21	   -­‐0.86	  AsPC-­‐1	   344.6	   293.1	   25.34	   -­‐0.94	  MIA	  PaCa-­‐2	   600.7	   212.6	   13.07	   -­‐0.94	  LNCaP	   178.5	   240.3	   43.59	   -­‐0.91	  PC-­‐3	   583.9	   219.2	   34.46	   -­‐0.96	  
	  
DU145	   445.2	   231.2	   18.59	   -­‐0.98	  MDA-­‐MB-­‐231	   236.5	   4.01	   1.42	   -­‐0.81	  AsPC-­‐1	   35.14	   43.67	   25.21	   -­‐0.59	  MIA	  PaCa-­‐2	   191.2	   106.3	   23.56	   -­‐0.65	  PAC1	   MDA-­‐MB-­‐435	   160.1	   105.1	   34.70	   -­‐0.68	  MDA-­‐MB-­‐231	   103.8	   24.80	   1.01	   -­‐0.92	  HCT	  116	   7.76	   33.92	   3.90	   -­‐0.82	  HT-­‐29	   2.43	   44.96	   12.50	   -­‐0.89	  AKT1/2	  kinase	  inhibitor	   MDA-­‐MB-­‐435	   105	   35.27	   3.29	   -­‐0.84	  MCF7	   1.15	   11.76	   1.52	   -­‐0.88	  HCT	  116	   3.98	   3.06	   1.38	   -­‐0.94	  MIA	  PaCa-­‐2	   5.40	   368	   55.39	   -­‐0.65	  LNCaP	   2.18	   12.07	   3.12	   -­‐0.74	  BAY61-­3606	   DU	  145	   7.97	   26.18	   6.11	   -­‐0.72	  HCT	  116	   1,254	   37.58	   10.38	   -­‐0.58	  HT-­‐29	   2,562	   50.60	   9.70	   -­‐0.59	  IPA3	   LNCap	   47.38	   77.12	   13.21	   -­‐0.64	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4. Discussion	  
	  
4.1 Cellular	  Properties	  	   The	  cellular	  features	  of	  18	  human	  cell	  lines	  were	  studied.	  The	  electrical	  (cellular	  capacitance)	   and	   metabolic	   properties	   (glycolysis	   and	   respiration	   activities,	   energy	  metabolism,	  mitochondrial	  mass	   content,	   levels	   of	   intracellular	   ROS	   and	   proliferation	  rates)	  were	  used	  to	  characterize	  the	  cell	  lines	  based	  on	  their	  tissue	  type	  source.	  	  	   Although	  the	  histological	  subtype	  of	  each	  cell	   line	  was	  not	  in	  focus	  in	  this	  work,	  we	  could	  observe	  a	  difference	  between	  the	  colorectal	  carcinoma	  cells	  HCT	  116	  and	  HT-­‐29	  and	  their	  counterpart	  pair	  the	  adenocarcinoma	  LS174T	  for	  the	  cellular	  capacitance,	  glycolitic	   activity,	   and	   the	  mitochondrial	  mass	   content.	   The	   two	   carcinoma	   cells	   show	  stronger	   cell-­‐matrix	   adhesion	   and	   cell-­‐cell	   contact	   binding	   (low	   capacitance)	   and	  elevated	   glycolysis	   and	   mitochondrial	   mass	   content	   in	   comparison	   with	   the	  adenocarcinoma	  (Results,	  Fig.	  10).	  Evidence	  points	  to	  differences	  among	  the	  molecular	  profile	   and	  metabolism	   between	   the	   histological	   subtype	   of	   tumors	   in	   some	   lung	   and	  cervix	   cancers	   (Meijer	   et	   al.	   2012,	  Wright	   et	   al.	   2013).	   In	   lung	   cancer,	   the	   carcinoma	  subtype	  displays	  a	  higher	  expression	  of	   glucose	   transporter	  1	   (GLUT1)	   in	   comparison	  with	   the	   adenocarcinoma	   subtype	   (Meijer	   et	   al.	   2012).	   In	   colorectal	   cancer	   cell	   lines	  GLUT1	  was	   found	   to	  be	  upregulated	   in	  cells	  with	  KRAS	  or	  BRAF	  mutations	   (Yun	  et	  al.	  2009).	   The	   mutated	   cell	   lines	   present	   also	   higher	   glucose	   incorporation	   and	   higher	  glycolysis	  levels	  than	  the	  wild-­‐type	  cells	  (Yun	  et	  al.	  2009).	  In	  patients	  with	  cervix	  cancer,	  KRAS	  mutations	  were	  found	  only	  in	  adenocarcinomas	  subtype	  tumors	  and	  not	  in	  other	  carcinoma	  types	  (Wright	  et	  al.	  2013).	  The	  limited	  number	  of	  colorectal	  cancer	  cell	  lines	  studied	   in	   this	   work	   impedes	   to	   draw	   a	   conclusion.	   However,	   the	   observation	   that	  carcinoma	   cells	   behave	   differently	   in	   glycolysis,	   and	   the	   varying	   amount	   of	   active	  mitochondria	   and	   different	   levels	   of	   capacitance	   in	   comparison	  with	   adenocarcinoma	  cells,	  may	  serve	  as	  a	  lead	  for	  attempting	  to	  improve	  colorectal	  cancer	  treatment.	  	  	   On	   the	  other	  hand,	  cluster	  dendograms	   localize	   in	   the	  same	  branch	  or	   in	  closer	  ones	   the	   colorectal	   cell	   lines	   HCT116	   and	   the	   LS174T	   for	   respiration	   activity,	   energy	  metabolism,	  and	  ROS	  formation	  (Results,	  Fig.	  11).	  Both	  cell	   lines	  share	  the	  presence	  of	  KRAS	  mutations	  (Little	  et	  al.	  2011,	  Lee	  et	  al.	  2011)	  differing	  from	  HT-­‐29	  that	  carries	  a	  B-­‐RAFV600E	  mutation	  (Makrodouli	  et	  al.	  2011).	  
	  108	  
	   B-­‐RAF	  protein	  kinases	  regulate	  the	  MAP	  kinase/ERKs	  signaling	  pathway	  affecting	  cell	   division,	   differentiation,	   and	   secretion.	   Mutations	   in	   this	   pathway	   are	   associated	  with	  various	  cancers,	   inducing	  cellular	  proliferation	  (Cicenas	  et	  al.	  2017).	  On	  the	  other	  hand,	   RAS	   genes	   are	   a	   family	   of	   small	   GTPase	   in	   which	   a	   mutation	   causes	   different	  malignancies,	  including	  lung,	  pancreatic,	  and	  colorectal	  carcinomas.	  Oncogenic	  forms	  of	  the	  RAS	  genes	  are	  prevalent	   in	  pancreatic	   carcinomas	   (>80%),	   colon	  carcinomas	   (40–50%),	  and	  lung	  carcinomas	  (30–50%)	  but	  are	  rare	  in	  human	  breast	  cancers	  (Jančík	  et	  al.	  2010,	   Niemitz	   2013).	   RAS,	   as	   B-­‐RAF	   mutations,	   result	   in	   an	   increase	   in	   cellular	  proliferation	  (Cicenas	  et	  al.	  2017).	  	   Comparing	  the	  cell	  lines	  belonging	  to	  the	  colorectal	  tissue	  type	  with	  the	  cell	  lines	  belonging	  to	  others	  tissue	  types	  as	  studied	  in	  this	  work	  (breast,	  pancreas,	  prostate,	  and	  skin)	   reveals	   that	   the	   colorectal	   cells	   present	   the	   highest	   proliferation	   rate	   and	   the	  lowest	  energy	  metabolism	  and	  ROS	  accumulation	  (Results,	  Fig.	  10).	  Furthermore,	  breast	  cancer	   cell	   lines,	   normally	   wt	   RAS	   (Niemitz	   2013),	   show	   an	   inversed	   behavior	   with	  higher	  ATP	  and	  ROS	   levels	  and	  a	   low	  proliferation	  rate	  (Results,	  Fig.	  10).	  Between	  the	  two	  breast	  cancer	  cell	  lines	  used	  in	  this	  study,	  MCF7	  does	  not	  present	  mutations,	  neither	  in	  KRAS	  nor	  in	  B-­‐RAF,	  in	  contrast	  to	  MDA-­‐MB-­‐231	  that	  has	  mutations	  in	  both	  oncogenes	  (Forbes	   et	   al.	   2016).	   The	   calculated	   Pearson	   correlation	   coefficient	   for	   energy	  metabolism,	   ROS	   accumulation,	   and	   proliferation	   rates	   corroborate	   these	   findings,	  indicating	   that	   cells	   with	   high	   ATP	   levels	   also	   have	   higher	   ROS	   levels	   (r	   =	   0.64**)	  (Results,	  Fig.	  12E).	  Also,	  an	  inverse	  correlation	  is	  found	  between	  ROS	  and	  proliferation	  (r	  =	  –0.68*)	  and	  ATP	  with	  proliferation	  (r	  =	  –0.64*)	  (Results,	  Fig.	  12C,	  D,	  and	  F).	  	  	   Pearson	  correlation	  shows	  the	  glycolytic	  activity	  of	  the	  cells	  and	  the	  proliferation	  rate	   as	   a	   strongly	   positive	   related	   (r	   =	   0.71**)	   (Results,	   Fig.	   12B).	   These	   correlations	  could	  indicate	  that	  cells	  that	  have	  more	  active	  glycolysis	  and	  proliferate	  more	  have	  less	  pyruvate	  to	  enter	   into	  the	  mitochondria	  for	  the	  TCA	  cycle	  and	  therefore	  less	  oxygen	  is	  consumed	  and	   less	  ROS	   is	  produced.	  Furthermore,	  glycolysis	  produces	   less	  ATP	  and	  a	  moderate	  nonsignificant	  negative	  relation	  is	  found	  between	  these	  two	  variables	  (Results	  3.3,	  Table	  10).	  	  	   It	   has	   been	   shown	   that	   glycolysis	   contributes	   to	   the	   generation	   of	   biomass	   in	  providing	   the	   necessary	   building	   blocks	   for	   new	   cells;	   therefore,	   an	   increase	   in	  glycolysis	   is	   observed	   in	   proliferating	   cells	   (Lunt	   &	   Vander	   Heiden	   2011).	   A	   positive	  correlation	  seems	  exist	  between	  glycolysis	  and	  cell	  proliferation.	  As	  was	  discussed	  in	  the	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Introduction,	  some	  enzymes	  belonging	  to	  the	  glycolysis	  pathway	  display	  non-­‐glycolytic	  functions	  crucial	  for	  cell	  proliferation	  (Lincet	  &	  Icard	  2015).	  	   Pearson	   correlation	   was	   applied	   in	   a	   study	   that	   could	   show	   a	   strong	   positive	  relation	  between	  cell	  proliferation	  and	  the	  glycolytic	  efficiency	  in	  cancer	  cells	  (r	  =	  0.82,	  p-­‐value	  =	   0.04)	   (De	  Preter	   et	   al.	   2016).	   In	   the	   same	   study,	   nonsignificant	   correlations	  were	  found	  between	  glycolysis	  and	  ATP	  levels	  and	  also	  not	  for	  the	  oxygen	  consumption	  with	  ATP	  nor	  with	  proliferation	  rate	  (De	  Preter	  et	  al.	  2016).	  	  
4.2 Gene	  Expression	  and	  Metabolism	  	   Data	   of	   gene	   expression	   from	   the	   public	   repository	   GEO,	   NCBI	   obtained	   using	  Affymetrix	  Human	  Genome	  U133	  Plus	  2.0	  Array	  platform	  (De	  Schutter	  et	  al.	  2013	  and	  Barretina	  et	  al.	  2012.	  Experimental	  Methods	  2.3,	  Table	  2)	  were	  used	  to	  search	  for	  linear	  relationships	  with	  the	  cellular	  properties	  of	  cancer	  cell	   lines.	  Pearson	  product	  moment	  correlations	   show	   that	   the	   expression	   levels	   of	   eight	   genes	   are	   correlated	   with	   the	  metabolism	   features	  of	   cancer	   cells.	   These	   eight	   genes	  provide	   consistent	   information	  through	   their	   corresponding	   probe	   sets.	   The	   metabolism-­‐related	   candidate	   genes	  encode	  the	  following	  proteins:	  PGLS	  (6-­‐phosphogluconolactonase),	  COX5B	  (cytochrome	  
c	  oxidase	  subunit	  5b),	  RHBDL2	  (rhomboid-­‐related	  protein	  2),	  IFI16	  (gamma-­‐interferon-­‐inducible	  protein	  16),	  GCN1L1	  (eIF-­‐2-­‐alpha	  kinase	  activator	  GCN1),	  HOXA7	  (Homeobox	  7),	  INPP5B	  (inositol	  polyphosphate-­‐5-­‐phosphatase	  B)	  and	  LGALS8	  (galectin	  8).	  	   The	  PGLS	  gene	  is	  interrogated	  by	  four	  probe	  sets	  in	  the	  Affymetrix	  platform	  used	  for	  this	  study.	  Among	  all	   the	  candidate	  genes	  PGLS	   is	   the	  one	  that	  displays	  the	  highest	  number	   of	   relations	   with	   metabolism	   with	   all	   of	   the	   probe	   sets	   of	   this	   gene	   having	  inverse	   congruent	   correlation	   with	   the	   mitochondrial	   mass	   content,	   the	   glycolytic	  activity,	   and	   the	   proliferation	   rates	   measured	   as	   metabolic	   activity	   (MTT	   assay)	   and	  total	   protein	   content	   (SRB	   assay)	   (Results	   3.4.1.1,	   Table	   12	   and	   Fig.	   16).	   It	   is	   not	  surprising	   that	   PGLS	   appears	   to	   be	   related	   with	   glycolysis	   and	   cellular	   proliferation	  because	   PGLS	   is	   the	   second	   enzyme	   in	   the	   pentose	   phosphate	   pathway	   (PPP)	   and	  catalyzes	   the	   conversion	  of	   6-­‐phosphonoglucono-­‐delta-­‐lactone	   to	   6-­‐phosphogluconate.	  The	  PPP	  produces	  ribose	  and	  NADPH	  and	  is	  a	  metabolic	  pathway	  parallel	  and	  directly	  related	   to	   glycolysis	   (Cha,	   Jung	   &	   Koo	   2017).	   Proliferating	   and	   cancer	   cells	   show	   an	  increase	   in	  glycolysis	  as	  well	  as	   in	  PPP	  (Jin	  et	  al.	  2017,	  Cha,	   Jung	  &	  Koo	  2017).	  Cancer	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cells	   need	   pentose	   phosphate	   and	  NADPH	   for	   the	   synthesis	   of	   lipids	   and	   cell	   survival	  under	  stress,	  repairing	  ROS	  damage	  produced	  by	  the	  accelerated	  proliferation	  (Cha,	  Jung	  &	   Koo	   2017,	   Jin	   et	   al.	   2017).	   Lower	   rates	   of	   the	   PPP	   in	   cancer	   cells	   through	   siRNA	  against	  the	  first	  enzyme	  in	  the	  pathway,	  glucose-­‐6-­‐phosphate	  dehydrogenase,	  leads	  to	  a	  reduction	   in	   the	  proliferation	  rate	  of	   the	  cells	   (De	  Preter	  et	  al.	  2016).	   In	  breast	   tissue,	  PGLS	   protein	   has	   been	   reported	   to	   be	   overexpressed	   in	   98%	   of	   the	   tumors	   in	  comparison	   with	   normal	   tissue	   and	   thus	   has	   been	   identified	   as	   a	   breast	   cancer	  biomarker	  (Ou	  et	  al.	  2008).	  Here,	  we	  present	  that,	  among	  cancer	  cells,	  the	  cell	  lines	  with	  high	   expression	   levels	   of	   PGLS	   present	   low	   glycolysis	   and	   low	   proliferation	   rates	  (Results	   3.4.1.1,	   Table	   12	   and	   Fig.	   16).	   No	   literature	   was	   found	   that	   could	   indicate	   a	  possible	  relation	  between	  PGLS	  and	  mitochondrial	  mass.	  	   COX5B	   and	   its	   two	   probe	   sets	   in	   the	   Affymetrix	   platform	   show	   negative	  correlations	   with	   the	   proliferation	   assay	   MTT	   and	   that	   is	   in	   agreement	   with	   the	  moderate	   r	   coefficient	   between	   the	   two	   probe	   sets	   and	   the	   proliferation	   assay	   SRB	  (Results	  3.4.1.1,	  Table	  12).	  The	  obtained	  correlations	   indicate	   that	   cell	   lines	  with	  high	  gene	  expression	  of	  COX5B	  present	  low	  proliferation	  rates.	  COX5B	  is	  a	  nuclear	  encoded	  protein	  part	  of	  the	  cytochrome	  c	  oxidase	  complex	  and	  it	  has	  been	  shown	  that	  depletion	  of	   COX5B	   leads	   to	   a	   diminution	   of	   the	   cytochrome	   c	   oxidase	   activity,	   suggesting	   a	  regulatory	  activity	  of	   this	  gene	  (Galati	  et	  al.	  2009).	  No	  much	  evidence	  has	  been	  shown	  about	   a	   possible	   relation	   between	   COX5B	   and	   cancer	   metabolism.	   In	   patients	   with	  breast	   cancer	   an	   upregulation	   of	   COX5B	   in	   comparison	   with	   the	   normal	   tissue	   is	  exhibited	   (Gao	   et	   al.	   2015).	   Contrary	   to	   our	   findings,	   the	   same	   study	   reported	   that	   a	  downregulation	   of	   COX5B	   in	   the	   breast	   cancer	   cell	   lines	   MDA-­‐MB-­‐231,	   MDA-­‐MB-­‐468	  and	  MCF-­‐7	   leads	   to	  an	   inhibition	  of	  cell	  proliferation.	  The	  same	  group	  has	  shown	  that	  cells	  with	   a	   COX5B	  knock-­‐down	  also	   exert	   low	  migration	   activity,	   low	  ATP	   formation,	  and	  an	  increase	  in	  ROS	  production	  (Gao	  et	  al.	  2015).	  	   RHBDL2	   contains	   three	   probe	   sets	   in	   the	   Affymetrix	   array	   used,	   and	   three	   of	  them	   show	   a	   middle	   to	   moderate	   negative	   correlation	   with	   glycolysis	   activity	   and	  mitochondrial	  mass	  content	  (Results	  3.4.2,	  Fig.	  17).	  The	  Rhomboids	  are	  a	  relatively	  new	  discovered	  family	  of	  intramembrane	  serine	  proteasess.	  RHBDL2	  is	  one	  of	  the	  members	  of	  this	  family	  that	  has	  been	  implicated	  in	  wound	  healing	  of	  keratinocytes	  by	  the	  cleavage	  of	   thrombomodulin,	   a	   protein	   involved	   in	   cell	   adhesion	   and	  migration	   during	  wound	  healing	  (Etheridge	  et	  al.	  2013,	  Cheng	  et	  al.	  2014).	  In	  keratinocytes,	  an	  overexpression	  of	  RHBDL2	   increases	  cell	  proliferation,	  reduces	  cell	  adhesion	  and	  supports	   the	  overcome	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of	   anoikis	   (Cheng	   et	   al.	   2014).	   The	   other	   two	   substrates	   that	   have	   been	   attributed	   to	  RHBDL2	   in	   humans	   are	   the	   EGF	   ligand	   and	   the	   members	   of	   the	   EphrinB	   family	  (Etheridge	   et	   al.	   2013).	   All	   of	   the	   three	   recognized	   substrates	   contain	   an	   EGF-­‐like	  domain	  (Etheridge	  et	  al.	  2013).	  RHBDL2	  cleaves	  the	  EGF	  ligand	  inducing	  the	  activation	  of	  the	  epithelial	  growth	  factor	  receptor	  (EGFR)	  (Cheng	  et	  al.	  2014).	  Limited	  information	  is	   available	   on	   the	   function	   of	   RHBDL2	   and	   its	   relation	   to	   cancer	   is	   largely	   unknown.	  Here	  we	  show	  that	  cancer	  cells	  with	  high	  expression	  of	  RHBDL2	  present	  low	  glycolysis	  activity	  and	  low	  mitochondrial	  mass	  suggesting	  a	  possible	  involvement	  of	  this	  protein	  in	  cancer	  metabolism	  (Results	  3.4.2,	  Fig.	  17).	  	  	   The	   two	  probe	  sets	  of	   the	   IFI16	  gene	  presented	  a	  negative	  correlation	  with	   the	  respiration	  activity	  at	  almost	  0.6	  (Results	  3.4.2,	  Fig.	  18).	  No	  information	  about	  a	  relation	  between	   cellular	   oxygen	   consumption	   and	   the	   IFI16	   gene	  have	   been	   found.	   IFI16	   is	   a	  transcriptional	  regulator	  that	  has	  a	  function	  in	  the	  inflammatory	  process	  (Shi	  et	  al.	  2014,	  Ansari	   et	   al.	   2015),	   in	   immune	   response	   (Ansari	   et	   al.	   2015),	   in	   autophagy	   and	   cell	  survival	   under	   glucose	   depletion	   (Duan	   et	   al.	   2011),	   and	   in	   cellular	   senescence	  associated	   with	   cell	   growth	   arrest	   (Alimirah	   et	   al.	   2007).	   Its	   function	   in	   the	  inflammatory	  process	  and	  in	  immune	  responses	  are	  widely	  studied	  (Johnson	  et	  al.	  2014,	  Ansari	  et	  al.	  2015).	  IFI16	  is	  a	  pathogen	  DNA	  sensor	  that	  acts	  by	  inducing	  the	  production	  of	  inflammatory	  cytokines	  (Ansari	  et	  al.	  2015).	  The	  tumor	  suppressor	  p53	  is	  one	  of	  the	  main	   regulators	  of	   IFI16	  activity	   (Shi	   et	   al.	   2014).	   In	  human	  diploid	   fibroblasts	   it	  was	  shown	   that	   the	   IFI16	   protein	   is	   necessary	   for	   the	   activation	   of	   the	   ATM/AMPK/p53	  pathway	   for	  autophagy	  upon	  glucose	  restriction	  and	   in	   low	  glucose	  microenviroments	  the	  expression	  of	  IFI16	  is	  increased	  (Duan	  et	  al.	  2011).	  Noncancerous	  prostate	  cells	  with	  an	  elevated	  expression	  of	  IFI16	  protein	  show	  cellular	  senescence	  and	  cell	  growth	  arrest	  (Alimirah	   et	   al.	   2007).	   In	   cancer	  prostate	   cell	   lines,	   IFI16	  protein	   is	  not	  present	  or	   its	  amount	   is	   very	   low	   (Alimirah	   et	   al.	   2007)	   being	   an	   advantage	   for	   the	   cancer	   cells	  exposed	   to	   an	   energetic	   stress	   (Duan	   et	   al.	   2011).	   An	   overexpression	   of	   IFI16	   in	   the	  prostate	   cancer	   cell	   lines	   LNCaP	   and	   DU	   145	   leads	   to	   an	   inhibition	   of	   proliferation	  (Alimirah	   et	   al.	   2007).	   In	   contrast	   to	   the	   prostate	   cells,	   in	   liver	   cancer	   cells	   the	   IFI16	  protein	  is	  expressed,	  but	  not	  in	  healthy	  adults	  hepatocytes	  (Shi	  et	  al.	  2014).	  In	  our	  study	  the	  prostate	  cancer	  cell	  lines	  DU	  145	  and	  PC-­‐3	  showed	  a	  mid-­‐to-­‐high	  expression	  of	  the	  IFI16	   gene	   in	   comparison	   with	   the	   other	   cell	   lines	   studied.	   On	   the	   other	   side,	   the	  prostate	  LNCaP	  and	  liver	  HepG2	  showed	  low	  gene	  expressions	  (Results	  3.4.2,	  Fig.	  18).	  It	  is	  known	   that	   the	  expression	  of	   the	   IFI16	  gene	   is	  well	   regulated	  at	   the	   transcriptional	  
	  112	  
and	  posttranscriptional	  levels	  (Shi	  et	  al.	  2014)	  suggesting	  that	  the	  protein	  levels	  of	  IFI16	  is	  not	  necessarily	  reflected	  by	  the	  gene	  expression	  levels.	  	   The	   GCN1L1	   gene	   with	   one	   of	   its	   two	   probe	   sets	   shows	   a	   significant,	   highly	  positive	  correlation	  with	  the	  proliferation	  rate	  measured	  by	  total	  protein	  content	  of	  the	  SRB	  assay	  (r	  =	  0.91	  and	  p-­‐values	  <	  0.0001)	  (Results	  3.4.3,	  Fig.	  19A).	  The	  second	  probe	  set	   that	   interrogates	   GCN1L1	   also	   shows	   a	   significant	   dependency	   with	   SRB.	   The	  relation	  with	   the	   proliferation	   is	   corroborated	   by	   both	   probe	   sets	   that	   present	   also	   a	  significant	  relation	  with	   the	  MTT	  assay	  (Results	  3.4.3,	  Table	  15).	   It	   is	  well	  known	  that	  GCN1L1	  in	  Saccharomyces	  cerevisiae	  growing	  in	  amino	  acid	  reduced	  media	  is	  involved	  in	  the	  activation	  of	  the	  eukaryotic	  initiation	  factor	  2α	  that	  represses	  the	  synthesis	  of	  the	  GCN4	   transcription	   factor	   which	   induces	   the	   expression	   of	   the	   genes	   necessary	   for	  amino	  acid	  biosynthesis	   (Kubota	   et	   al.	   2001).	  Years	   later,	   it	  was	   found	  out	   in	  humans	  that	  GCN1L1	  is	  one	  of	  the	  factors	  that	  is	  associated	  with	  the	  CDK8	  complex	  (Knuesel	  et	  al.	   2009).	   CDK8	   is	   an	   oncogene	   that	   presents	   a	   kinase	   activity	   necessary	   for	   the	  regulation	  of	   β-­‐catenin	   activity	   (Firestein	   et	   al.	   2008).	   Colon	   cancer	   cells	   present	  high	  levels	   of	   CDK8	   and	   Wnt/β-­‐catenin	   hyperactivity	   (Firestein	   et	   al.	   2008).	   In	   renal	  carcinogenesis,	  mutations	  were	   identified	   in	  members	   of	   the	  CDK8	   complex	   including	  GCN1L1	   that	   could	   participate	   in	   the	   dysregulation	   of	   the	   Wnt/β-­‐catenin	   pathway	  inducing	  cancer	  transformation	  (Arai	  et	  al.	  2014).	  It	  has	  also	  been	  well	  documented	  that	  hyperactivity	   of	   the	   Wnt/β-­‐catenin	   pathway	   induces	   cell	   proliferation	   (MacDonald,	  Tamai	  &	  He	  2009).	  We	  found	  that	  the	  gene	  expression	  of	  GCN1L1	  is	  directly	  related	  to	  the	  proliferation	  of	  cancer	  cells	  and	  the	  cell	  lines	  that	  express	  more	  GCN1L1	  show	  a	  high	  proliferation	  rate.	  	   Both	   proliferation	   assays	   (MTT	   and	   SRB)	   show	   significantly	   positive	  dependencies	  on	  HOXA7	  for	  its	  two	  probe	  sets.	  The	  expression	  values	  of	  the	  two	  probe	  sets	   that	   interrogate	   HOXA7	   showed	   a	   strong	   positive	   relation	   with	   the	   proliferation	  assay	   measured	   as	   metabolic	   activity	   MTT	   (r	   =	   0.95	   and	   0.90,	   p-­‐values	   <	   0.0001)	  (Results	  3.4.3,	  Tables	  15	  and	  16),	  and	  is	  corroborated	  with	  a	  significant	  (p-­‐values	  <	  0.01	  data	   not	   shown)	   positive	   relation	   between	   the	   two	   probe	   sets	   and	   the	   proliferation	  assay	   SRB	   (Results	   3.4.3,	   Table	   16).	   For	   this	   gene	   it	   is	   also	   possible	   to	   observe	   a	  significant	  negative	  dependency	  between	   the	   two	  probe	  sets	  and	  ROS	  accumulation	   in	  cells	   (p-­‐values	   <	   0.01,	   data	   not	   shown).	   The	   proliferation	   rate	   SRB	   and	   MTT	   assays	  present	   a	   significant	  negative	   correlation	   (r	  =	  –0.68)	   (Results	  3.3,	  Table	  10)	  with	  ROS	  accumulation	  in	  cells.	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   HOX	  genes	  are	  transcriptional	  factors	  involved	  in	  morphogenesis,	  organogenesis,	  differentiation,	   cell	   migration,	   and	   proliferation	   (Zhang	   et	   al.	   2013,	   Li	   et	   al.	   2015).	  Several	   studies	   have	   shown	   a	   direct	   function	   of	   HOXA7	   in	   the	   positive	   regulation	   of	  cellular	  proliferation	   in	   cancer	   cells.	  Knockdown	  of	  HOXA7	   in	  human	  precursor	  B-­‐cell	  leukemia	  MCF7,	  HepG2,	   and	  QGY-­‐7703	   cells	   reduces	   cell	   proliferation	   (Orlovsky	   et	   al.	  2011,	  Zhang	  et	  al.	  2013,	  Li	  et	  al.	  2015).	  Our	  findings	  corroborate	  the	  relation	  of	  HOXA7	  and	   proliferation	   indicating	   that	   cells	  with	   high	   proliferation	   rates	   also	   have	   a	   higher	  expression	   of	   the	   HOXA7	   gene	   giving	   a	   novel	   insight	   on	   the	   function	   of	   this	  transcriptional	  factor	  and	  ROS	  accumulation	  in	  cancer	  cells.	  	   The	  expression	  of	   the	   INPP5B	  gene	  presents	  a	  highly	  positive	  dependency	  with	  the	  SRB	  assay	  (r	  =	  0.92,	  p-­‐value	  <	  0.0001)	  that	  is	  corroborated	  by	  the	  three	  probe	  sets	  that	  contain	  information	  on	  the	  gene,	  all	  of	  them	  having	  a	  significantly	  positive	  relation	  also	  with	  the	  proliferation	  assay	  MTT	  (p-­‐value	  <	  0.01	  data	  not	  shown).	  A	  deficiency	   in	  the	  complementation	  of	  Ocrl’s	  functionality	  by	  INPP5B	  in	  humans,	  and	  not	  in	  mouse,	  is	  responsible	   for	   the	   development	   of	   Lowe	   syndrome,	   an	   oculocerebrorenal	   X-­‐linked	  genetic	   disorder	   (Bothwell	   et	   al.	   2010).	   There	   is	   no	   evidence	   that	   links	   INPP5B	  with	  cancer.	  We	   show	   that	   cancer	   cell	   lines	  with	   low	  expression	   levels	  of	   the	   INPP5B	  gene	  also	  present	   low	  proliferation	  rates,	  being	   the	   first	   time	  that	   this	  gene	   is	   implicated	   in	  cancer	  metabolism.	  	   LGALS8	  shows	  a	  high	  negative	  correlation	  with	   the	  cellular	  mitochondrial	  mass	  content	   (r	  =	  –0.84,	  p-­‐value	  <	  0.0001)	  and	  also	  with	   the	  MTT	  proliferation	  assay	  (r	  =	  –0.73	  p-­‐value	  <	  0.01)	  (Results	  3.4.3,	  Table	  16	  and	  Fig.	  19D).	  The	  LGALS8	  gene	  contains	  five	  probe	   sets	  more	   and	   in	   all	   of	   them	  a	   significant	   (p-­‐value	  <	  0.01,	   data	  not	   shown)	  negative	  dependency	  with	  the	  mitochondrial	  mass	  and	  the	  MTT	  proliferation	  assay	  are	  observable	   (Results	   3.4.3,	   Table	   16).	   The	   dependencies	   found	   between	   the	   LGALS8	  probe	  sets	  and	  the	  SRB	  assay	  display	  the	  same	  tendency,	  a	  negative	  correlation	  (Results	  3.4.3,	   Table	   16).	   LGALS8	   is	   part	   of	   the	   galectin	   family	   of	   secreted	   proteins	   that	   bind	  glycoproteins	  of	   the	  cell	   surface	  and	  the	  extracellular	  matrix.	  Galectins	  are	   involved	   in	  cell-­‐cell	   and	   cell-­‐matrix	   interactions,	   cell-­‐cell	   communication,	  migration,	   proliferation,	  apoptosis,	  and	  angiogenesis	  (Delgado	  et	  al.	  2011,	  Metz	  et	  al.	  2016).	  In	  glioblastoma	  U87	  cells	  a	  reduction	  of	  LGALS8	  by	  shRNA	  leads	  to	  a	  decrease	   in	  the	  proliferation	  rate	  and	  induces	  apoptosis	  (Metz	  et	  al.	  2016).	  On	  the	  other	  hand,	   in	  colorectal	  cancer	  cell	   lines,	  LGALS8	   was	   inversely	   correlated	   to	   tumor	   growth	   and	   migration	   rates	   (Nagy	   et	   al.	  2002).	  In	  our	  study,	  the	  data	  obtained	  with	  the	  Pearson	  correlation	  coefficients	  indicates	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that	   the	   cell	   lines	   that	   express	   a	   higher	   level	   of	   the	   LGALS8	   gene	   are	   the	   ones	   that	  present	  the	  lowest	  proliferation	  rate.	  No	  evidence	  was	  found	  that	  relate	  LGALS8	  activity	  and	  the	  mitochondrial	  mass	  content	  of	  the	  cells.	  	  	   The	  estimation	  of	  changes	  in	  gene	  expression	  levels	  in	  many	  cases	  assumes	  that	  these	  changes	  will	  be	  propagated	  to	  protein	  expression	  and	  several	  studies	  take	  as	  a	  fact	  that	   the	  gene	  expression	   is	   informative	   in	  predicting	  protein	   levels	   (Kern	  et	  al.	  2003).	  Regrettably,	   incongruences	   have	   been	   found	   in	   studies	   that	   calculate	   the	   correlation	  between	  gene	  expression	  and	  protein	  levels	  (Guo	  et	  al.	  2008,	  Maier,	  Güell	  and	  Serrano	  2009).	   In	   patients	  with	   acute	  myeloma	   leukemia,	   congruent	   results	   were	   obtained	   in	  correlating	  the	  mRNA	  of	  39	  specific	  genes	  and	  their	  protein	  abundances	  in	  samples	  from	  more	   than	   100	   patients	   (Kern	   et	   al.	   2003).	   However,	   mRNA	   expression	   of	   freshly	  isolated	  human	  monocytes	  correlated	  with	   their	  protein	  expression	   levels	  shows	  huge	  variations	   in	   the	   different	   investigated	   genes	   and	   between	   different	   individuals.	   That	  part	   of	   the	   studied	   genes	   presents	   a	   significant	   positive	   correlation	   with	   protein	  expression	  (Maier,	  Güell	  &	  Serrano	  2009).	  Nevertheless,	  an	  overall	  congruence	  is	  found	  indicating	  a	  general	  concordance	  between	  the	  abundance	  of	  mRNA	  and	  proteins	  (Maier,	  Güell	  &	   Serrano	   2009).	   This	   indicates	   the	   necessity	   to	   corroborate	   the	   relation	   of	   the	  candidate	  genes	  found	  and	  cancer	  metabolism	  before	  drawing	  any	  conclusions	  from	  our	  findings.	  	  
4.3 Drug	  Sensitivity	  and	  Cellular	  Properties	  of	  Cancer	  Cell	  Lines	  	   The	   IC50	   values	   of	   99	   compounds	   were	   obtained	   from	   the	   Genomics	   of	   Drug	  Sensitivity	  in	  Cancer	  project	  (Yang	  et	  al.	  2013)	  (Results	  3.5.1,	  Fig.	  22	  and	  Experimental	  Methods	   2.4.1,	   Table	   7)	   and	   were	   used	   for	   Pearson	   correlation	   calculations	   with	   the	  cellular	  properties	  of	  cancer	  cell	   lines	  to	  search	  for	   linear	  relations	  between	  these	  two	  variables.	  Pearson	  product	  moments	   show	   that	   the	   sensitivity	  of	   seven	  of	   these	  drugs	  present	  a	  correlation	  with	  some	  of	  the	  cellular	  features	  of	  cancer	  cells.	  The	  compounds	  that	  correlate	  with	  the	  cellular	  properties	  are:	  elesclomol,	  Nutlin	  3a,	  PF	  4708671,	  EHT	  1864,	  IPA3,	  RDEA119,	  and	  methotrexate.	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   Elesclomol	   is	   a	   copper	   chelator	   that	   transports	   the	   copper	   ions	   into	  mitochondria	   inducing	   ROS	   production	   and,	   as	   a	   consequence,	   growth	   arrest	   and	  apoptosis	  in	  cancer	  cell	  lines	  (Krishner	  et	  al.	  2008,	  McCarty	  and	  Contreras	  2014,	  Rae	  and	  Mairs	   2017).	   A	   study	   done	   in	   patients	  with	  melanoma	   treated	  with	   elesclomol	   shows	  that	  the	  compound	  is	  more	  effective	  in	  the	  individuals	  with	  low	  lactate	  dehydrogenase	  (LDH)	   levels	   in	   the	   serum	   (McCarty	   and	  Contreras	   2014).	   Patients	  with	   elevated	  LDH	  show	   cancer	   with	   a	   Warburg	   effect	   phenotype,	   meaning	   high	   glycolysis	   and	   less	  oxidative	  phosphorylations	   in	  mitochondria,	  which	  can	  be	  the	  reason	  for	  the	  observed	  low	   activity	   of	   the	   drug	   (McCarty	   and	   Contreras	   2014).	   Our	   findings	   show	   that	  elesclomol	   is	   negatively	   correlated	   with	   the	   cellular	   capacitance	   (r	   =	   –0.76	   p-­‐value	   <	  0.01),	   indicating	   that	   the	   cancer	   cell	   lines	  presenting	   stronger	   cell-­‐matrix	   and	   cell-­‐cell	  contacts	  are	  more	  resistant	  to	  the	  compound	  (Results	  3.5.1,	  Fig.	  22).	  	  	   Nutlin	  3a	   is	   an	   indirect	   activator	   of	  wild-­‐type	   p53.	   The	   compound	   inhibits	   the	  interaction	  between	  MDM2,	  an	  ubiquitin	   ligase,	  and	  negative	   regulator	  of	  p53	  and	   the	  tumor	   suppressor	   p53	   (Kojima	   et	   al.	   2006).	   p53	   is	   a	   tumor	   suppressor	   involved	   in	  genomic	  stability	  and	  in	  the	  regulation	  of	  the	  cell	  cycle,	  senescence,	  and	  apoptosis	  (Lago	  et	   al.	   2011).	   It	   has	   also	   been	   shown	   to	   be	   involved	   in	   the	   promotion	   of	   oxidative	  phosphorilation	  stimulating	  mitochondrial	  respiration	  and	  inhibiting	  glycolysis	  and	  that	  mutated	  p53	  contributes	  to	  the	  Warburg	  effect	  phenotype	  in	  cancer	  (Lago	  et	  al.	  2011).	  We	  show	  that	  cancer	  cells	  that	  are	  more	  sensitive	  to	  Nutlin	  3a	  present	  a	  high	  respiration	  rate	  (r	  =	  –0.74,	  p-­‐value	  <	  0.01)	  (Results	  3.5.1,	  Fig.	  24A).	  	  	  	   PF	  4708671	  is	  an	  inhibitor	  of	  the	  p70	  ribosomal	  S6	  kinase	  1	  (p70S6K1)	  (Pearce	  et	   al.	   2010).	   P70S6K1	   is	   involved	   in	   the	   regulation	   of	   protein	   synthesis,	   proliferation,	  growth,	   survival,	  motility,	   longevity,	   and	  chemotherapy	  drug	  resistance	   in	   cancer	  cells	  (Pearce	  et	  al.	  2010,	  Qiu	  et	  al.	  2016).	  Cells	  treated	  with	  PF	  4708671	  show	  cell	  cycle	  arrest	  and	  a	   reduction	   in	   the	  proliferation	   rate	  and	   invasion	   (Qiu	  et	  al.	  2016).	  We	  show	   that	  cancer	   cell	   lines	   with	   high	   oxygen	   consumption	   are	   more	   sensitive	   to	   PF	   4708671,	  indicating	   that	   the	   inhibitor	   of	   p70S6K1	   has	   a	   negative	   effect	   on	   respiration	   activity	  (r	  =	  –	  0.74,	  p-­‐value<0.01)	  (Results	  3.5.1,	  Fig.	  24B).	  	  	   EHT	  1864,	   as	  discussed	   in	  more	  detail	   in	  3.5.1,	   is	  a	  Rac	   inhibitor	   (Onesto	  et	  al.	  2008).	   Rac	   proteins	   are	   directly	   involved	   in	   proliferation,	   invasion,	   and	  metastasis	   in	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cancer	   cells	   (Onesto	   et	   al.	   2008).	  We	   show	   that	   EHT	   1864	   correlates	   negatively	  with	  energy	  metabolism	  (r	  =	  –0.77,	  p-­‐value	  <	  0.01)	  (Results	  3.5.1,	  Fig.	  25A).	  	  	   IPA3	   is	   a	   small	   molecule	   inhibitor	   of	   p21-­‐activated	   protein	   kinase	   1	   (PAK1)	  (Singhal	  and	  Kandel	  2012).	  PAKs	  promote	  tumor	  cell	  proliferation	  (Liu	  et	  al.	  2016).	   In	  colon	   carcinoma	   and	   melanoma	   cell	   lines	   with	   mutations	   either	   in	   BRAF	   or	   in	   RAS	  (NRAS	  or	  KRAS)	  genes,	  treatment	  of	  cells	  with	  RAS	  mutations	  with	  IPA3	  appears	  to	  be	  more	  effective	  (Singhal	  and	  Kandel	  2012).	  RAS	  and	  specifically	  KRAS	  mutant	  cells	  show	  high	  nucleotide	  biosynthesis,	  glycolysis,	  and	  PPP	  activity	  (Lv	  et	  al.	  2016).	  In	  the	  mouse	  model,	  mutant	  KRAS	   increased	   glucose	   and	   glutamine	  uptake	   and,	   on	   the	   other	   hand,	  cancer	  cells	  cultivated	  under	  low	  glucose	  conditions	  acquired	  KRAS	  mutations	  (Lv	  et	  al.	  2016).	  Here	  we	  show	  that	  there	  is	  a	  negative	  correlation	  between	  energy	  metabolism	  in	  cells	  and	  the	  IC50	  of	   IPA3	  meaning	  that	   the	  cell	   lines	   that	  produce	  more	  ATP	  are	  more	  sensitive	  to	  this	  compound	  (r	  =	  –0.77,	  p-­‐value	  <	  0.01)	  (Results	  3.5.1,	  Fig.	  25B).	  This	  data	  provides	   further	   insight	   into	   treatment	   strategies	   of	   cancers	   with	   BRAF	   or	   RAS	  mutations	  using	  IPA3	  and	  targeting	  metabolism.	  	  	   RDEA119	  is	  a	  highly	  selective	  allosteric	  inhibitor	  of	  MEK1/2	  enzymes	  (Iverson	  et	  al.	  2009).	  Crystallization	  of	  the	  MEK-­‐RDEA119	  complex	  indicates	  that	  the	  drug	  binds	  on	  the	   adjacent	   side	   of	   the	  Mg-­‐ATP	   binding	   region	   interacting	   with	   ATP,	   preventing	   the	  binding	  and	  phosphorilation	  of	  the	  MEK	  substrate	  ERK	  (Iverson	  et	  al.	  2009).	  MEKs	  are	  downstream	   of	   BRAF	   in	   the	   RAS-­‐RAF-­‐MEK-­‐ERK	   pathway	   implicated	   in	   cellular	  proliferation	  (Iverson	  et	  al.	  2009).	  RDEA119	  that	  has	  shown	  to	  act	  in	  xenograft	  models	  of	  melanoma,	   colon	   and	   epidermal	   carcinomas,	   and	   pancreatic	   cancers	   (Iverson	   et	   al.	  2009)	   is	  now	  in	  phase	  II	  clinical	  studies	  (Caunt	  et	  al.	  2015).	  Our	  results	  show	  a	  highly	  positive	  relation	  between	  the	  cellular	  tolerance	  to	  RDEA119	  and	  energy	  metabolism	  (r	  =	  0.84,	  p-­‐value	  <	  0.01)	  (Results	  3.5.1,	  Fig.	  25C).	  	  	   Methotrexate,	  as	  elaborated	  in	  Sect.	  3.5.1,	  is	  an	  approved	  drug	  for	  use	  in	  several	  conditions	   including	   breast	   cancer,	   acute	   lymphatic	   leukemia,	   osteogenic	   sarcoma,	  choriocarcinoma,	   lung	   cancer,	   bladder	   carcinoma,	   brain	   medulloblastoma,	   primary	  central	   nervous	   system	   lymphoma,	   and	   chronic	   myeloid	   leukemia	   (Abolmaali	   et	   al.	  2013)	  and	  is	  the	  most	  used	  drug	  in	  the	  treatment	  of	  rheumatoid	  arthritis	  (Phillips	  et	  al.	  2003,	  Abolmaali	  et	  al.	  2013,	  Bianchi	  et	  al.	  2016).	  Methotrexate	  has	  been	  widely	  studied	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in	  the	  context	  of	  its	  synthesis	  as	  an	  analog	  of	  folic	  acid.	  It	  is	  an	  inhibitor	  of	  dihydrofolate	  reductase,	  an	  enzyme	  that	  is	  necessary	  for	  purine	  and	  pyrimidine	  syntheses.	  Due	  to	  its	  effect	  of	  disrupting	  DNA	  synthesis,	  methotrexate	  has	  an	  antiproliferative	  effect	  (Phillips	  et	   al.	   2003,	  Abolmaali	   et	   al.	   2013,	  Thomas	  et	   al.	   2015).	  Here	  we	   show	   that	   the	   IC50	  of	  cells	  to	  methotrexate	  displays	  a	  highly	  significant	  and	  strongly	  positive	  correlation	  with	  ROS	  accumulation	  in	  cancer	  cells	  (r	  =	  0.93,	  p-­‐value	  <	  0.001)	  (Results	  3.5.1,	  Fig.	  26).	  	  	  	   In	   conclusion,	   the	   detailed	   metabolic	   and	   electrochemical	   characterization	   of	  several	   cancer	   cell	   lines	   presented	   in	   this	   work	   demonstrates	   a	   wide	   variability	  regarding	   metabolic	   activity	   and	   morphological	   properties	   of	   cancer	   cells.	   The	   data	  obtained	   provide	   an	   overview	   of	   various	   growth	   parameters	   including	   proliferation	  rates,	   energy	   metabolism,	   measured	   as	   glycolytic	   and	   respiration	   rates,	   formation	   of	  reactive	  oxygen	   species	   (ROS),	  mitochondrial	  mass,	   as	  well	   as	   cell-­‐cell	   and	   cell-­‐matrix	  interactions,	  which	  can	  be	  taken	  as	  a	  cell-­‐specific	  footprint	  of	  the	  cancer	  cells	  analyzed.	  With	   the	   large	  data	   sets	  obtained	   for	   these	   complementary	  metabolic	   and	   cell	   growth	  parameters	   it	   became	   possible	   to	   calculate	   correlations	   between	   the	   analyzed	  parameters	   and	   further	   available	   gene	   expression	   and	   drug	   sensitivity	   data	   sets	   in	   a	  detailed	   computational	   analysis.	   Using	   a	   robust	   statistical	   analysis,	   based	   on	   Pearson	  correlation	   coefficient	   calculation,	   several	   significant	   correlations	   could	   be	   identified.	  The	  results	  support	  among	  others	  the	  relevance	  of	  HOXA7	  as	  a	  potential	  drug	  target	  and	  link	  the	  efficacy	  of	  known	  and	  potential	  anticancer	  drugs	  with	  metabolic	  properties.	  	  	  	   	  The	   results	   obtained	   confirm	   in	   particular	   the	   efficacy	   of	   drugs	   aimed	   at	   the	  control	   of	   cell	   metabolism	   and	   provides	   hints	   to	   specific	   metabolic	   markers	   and	  metabolism-­‐associated	  expressed	  genes	  indicating	  that	  metabolic	  parameters	  of	  cancer	  cells	  could	  provide	  valuable	  additional	  information	  to	  optimize	  drug	  selection	  and	  adjust	  patient-­‐specific	   therapy	   by	   combining	   drugs	   targeting	   both	   metabolism	   and	  proliferation.	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5. Supplements	  	  
5.1 R	  Scripts	  	   The	   data	   collection,	   calculations,	   statistics	   and	   plotting	   for	   this	   study	   were	   done	  using	   RStudio	   versions	   0.98.1103	   and	   0.99.473.	   RStudio	   is	   an	   open-­‐source	   integrated	  development	   environment	   used	   as	   an	   interface	   for	   R	   programming	   language	   for	  statistical	  computing	  and	  graphics	  (Team,	  R.	  Core.	  2015).	  The	  R	  versions	  2.7.0	  and	  3.2.1	  were	  used.	  	  	  
5.1.1 Bionas	  Data	  Collection	  path	  <-­‐	  "/Users/admin/Documents/PhD/basal	  levels	  Results/human1"	  	  ##	  Get	  all	  the	  ANALYZER	  folders	  from	  the	  different	  cell	  line	  	  folders1	  <-­‐	  list.files(path=path)	  	  folders2	  <-­‐	  list.dirs(folders1)	  	  file	  <-­‐	  list.files(folders2,	  full.names=TRUE,	  pattern="*ANALYZER_DATA.dat",include.dirs	  =	  TRUE)	  	  write.csv(file,	  file="path.csv",	  row.names=TRUE)	  	  out.file<-­‐""	  	  for(i	  in	  1:length(file)){	  	  	  read	  <-­‐	  readLines(file[i])	  	  	  out.file	  <-­‐	  rbind(out.file,	  read)	  }	  write.csv(out.file,	  file="raw	  data	  all	  cell	  lines.csv",	  row.names=TRUE)	  	  class(out.file)	  #matrix	  	  read2<-­‐	  out.file[,c(11,42,72)]	  #	  read	  just	  ides,	  o2	  and	  isfet.	  Columns	  11,	  42	  y	  72	  colnames(read2)	  <-­‐	  c("IDES	  DATA	  in	  norming	  distance	  per	  BM	  (nF)",	  "ELECTRODES	  DATA	  in	  norming	  distance	  per	  BM	  (pA/s)",	  "FET	  DATA	  in	  norming	  distance	  per	  BM	  (uV/s)")	  	  write.csv(read2,	  file="raw	  data	  IDES,O2	  and	  FET	  all	  cell	  lines.csv",	  row.names=TRUE)	  	  ###	  IDES	  	  IDES	  <-­‐	  read2[,1]	  #to	  have	  just	  the	  column	  with	  IDES	  data	  View(IDES)	  class(IDES)	  #character	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  IDES1	  <-­‐	  as.numeric(unlist(strsplit(gsub(",",	  ".",	  IDES),	  "\t")))	  #	  write	  dots	  and	  splitt	  the	  experiments	  with	  comas	  	  View(IDES1)	  class(IDES1)	  #numeric	  	  IDES2	  <-­‐	  matrix(IDES1,	  ncol=6,	  byrow=TRUE)	  #	  make	  a	  matrix	  with	  the	  6	  columns,	  one	  per	  each	  biomodul	  	  write.csv(IDES2,	  file="raw	  data	  IDES	  all	  cell	  lines.csv",	  row.names=TRUE)	  	  ####	  O2	  	  O2	  <-­‐	  read2[,2]	  #just	  the	  column	  with	  O2	  data	  View(O2)	  	  O2a	  <-­‐	  as.numeric(unlist(strsplit(gsub(",",	  ".",	  O2),	  "\t")))	  	  View(O2a)	  	  O2b	  <-­‐	  matrix(O2a,	  ncol=6,	  byrow=TRUE)	  	  	  write.csv(O2b,	  file="raw	  data	  O2	  all	  cell	  lines.csv",	  row.names=TRUE)	  	  ####	  FET	  	  FET	  <-­‐	  read2[,3]	  #just	  the	  column	  with	  ISFET	  data	  View(FET)	  	  FET1	  <-­‐	  as.numeric(unlist(strsplit(gsub(",",	  ".",	  FET),	  "\t")))	  	  View(FET1)	  	  FET2	  <-­‐	  matrix(FET1,	  ncol=6,	  byrow=TRUE)	  	  	  write.csv(FET2,	  file="raw	  data	  FET	  all	  cell	  lines.csv",	  row.names=TRUE)	  
	  
5.1.2 Robust	  Multi-­Array	  Average	  (RMA)	  	  source("http://bioconductor.org/biocLite.R")	  	  biocLite("affy")	  #The	  package	  contains	  functions	  for	  exploratory	  oligonucleotide	  array	  analysis	  library(affy)	  	  biocLite("pd.ht.hg.u133.plus.pm")	  #Annotation	  package	  for	  pd.ht.hg.u133.plus.pm	  built	  with	  pdInfoBuilder.	  Data<-­‐ReadAffy()	  	  #Robust	  Multi-­‐array	  Average	  preprocessing	  methodology.	  This	  strategy	  allows	  background	  subtraction,	  quantile	  normalization	  and	  summarization	  (via	  median-­‐polish).	  The	  generated	  data	  are	  stored	  as	  ExpressionSet	  class	  in	  the	  'eset'	  object	  	  	  eset<-­‐rma(Data).	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  write.exprs(eset,	  file="Data.txt",	  sep="\t")	  #	  Writes	  expression	  values	  to	  text	  file	  in	  working	  directory.	  	  summarized	  <-­‐	  rma(eset)	  show(summarized)	  	  HeLa<-­‐rowMeans(hela,	  na.rm=TRUE)	  View(HeLa)	  	  write.table(HeLa,	  file="HeLamean.txt",sep	  =	  "	  ",row.names	  =	  FALSE,	  col.names	  =	  "Mean")	  	  HaCaT<-­‐rowMeans(Hacat,	  na.rm=TRUE)	  View(HaCaT)	  	  write.table(HaCaT,	  file="HaCaTmean.txt",sep	  =	  "	  ",row.names	  =	  FALSE,	  col.names	  =	  "Mean")	  	  	  
5.1.3 Pathways	  Gene	  Selection	  	  ggenes	  <-­‐	  HGU133plusna34plus16celllines	  #	  file	  with	  all	  probes	  sets	  and	  their	  gene	  symbol	  colnames(ggenes)[3]<-­‐"1321N1"	  #to	  have	  the	  column	  for	  1321N1	  without	  X	  (X1321N1)	  View(ggenes)	  	  ###	  Genes	  for	  the	  Glycolysis/Gluconeogenesys,	  TCA	  cycle	  and	  Pentose	  phosphate	  pathways	  were	  downloaded	  from	  The	  Database	  for	  Annotation,	  Visualization	  and	  Integrated	  Discovery	  (DAVID	  6.7).	  	  #	  SELECTION	  OF	  PROBES	  AGAINS	  GLYCOLYSIS	  GENES	  	  gly.sub	  <-­‐	  ggenes[ggenes$Gene.Symbol	  %in%	  c("ALDOA","ALDOB",	  "ALDOC",	  "DLAT",	  "DLD",	  "ENO1",	  "ENO2",	  "ENO3",	  "FBP1",	  "G6PC",	  "GAPDHL6",	  "GCK",	  "GOT1",	  "GOT2",	  "GPI",	  "HK1",	  "HK2",	  "HK3",	  "LDHB",	  "LDHC",	  "MDH1",	  "MDH2",	  "PC",	  "PCK1",	  "PDHA1",	  "PDHA2",	  "PDHB",	  "PFKL",	  "PFKM",	  "PFKP","PGAM2","PGK1",	  "PGK2",	  "PKLR",	  "PKM2",	  "SLC2A1",	  "SLC2A2",	  "SLC2A3","SLC2A4","SLC2A5","TPI1","PDHX","FBP2","MPC2","GAPDHS","MPC1","HKDC1","ADPGK","LDHAL6B"),	  ]	  gly.sub	  write.csv(gly.sub,	  file="glycolysis	  genes.csv")	  #,	  sep	  =	  "	  ",row.names	  =	  TRUE,	  col.names	  =	  TRUE)	  	  #	  SELECTION	  OF	  PROBES	  AGAINS	  TCA	  GENES	  tca.sub	  <-­‐	  ggenes[ggenes$Gene.Symbol	  %in%	  c("AC02","SLC25A4","SLC25A5","SLC25A6","ATP5A1","ATP5B","ATP5C1","ATP5D","ATP5E","ATP5F1","ATP5G1","ATP5G2","ATP5G3","ATP5I","ATP5J","ATP6AP1","ATP5O","COX4I1","COX5B","COX6A1","COX6A2","COX6B1","COX6C","COX7A1","COX7A2","COX7B","COX7C","COX8A","COX11","COX15","CS","DLD",	  "DLST","FH","IDH2","IDH3A","IDH3B","IDH3G","MDH2","COX3","ATP6",	  "COX1","COX2","ATP6","CYTB","ND1","ND2","ND3","ND4","ND5","ND6","NDUFA1","NDUFA2",	  "NDUFA3",	  "NDUFA4","NDUFA5","NDUFA6",	  "NDUFA7","NDUFA8","NDUFA9","NDUFA10",	  "NDUFAB1","NDUFB1","NDUFB2","NDUFB3","NDUFB4","NDUFB5","NDUFB6","NDUFB7","NDUFB8","NDUFB9","NDUFB10","NDUFC1","NDUFC2","NDUFS1","NDUFS2","NDUFS3","NDUFV1","NDUFS4","NDUFS5","NDUFS6","NDUFS8","NDUFV2","NDUFV3","OGDH","SCO1","SDHA","SDHB","SDHC","SDHD","SURF1","UCP1","UCP2","UCP3",	  "UQCRB","UQCRC1","UQCRC2","UQCRFSL1",	  "UQCRHL","SUCLG2","SUCLG1","SLC25A14","COX7A2L","COX5A",	   "SLC25A27",	  "ATP5J2","COX17","ATP6AP2","ATP5H","ATP5L","UQCR11","UQCRQ","ATP5S","UQCR10","NDUFA12",	   "NDUFA4L2",	   "ATPIF1","NDUFA11","NDUFS7"),	  ]	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write.csv(tca.sub,	  file="TCA	  genes.csv")	  tca.sub	  	  #	  SELECTION	  OF	  PROBES	  AGAINS	  PENTOSE	  PHOSPHATE	  PATHWAY	  GENES	  pent.sub	  <-­‐	  ggenes[ggenes$Gene.Symbol	  %in%	  c("TALDO1",	  "RPE",	  "G6PD",	  "RPIA",	  "TKT",	  "PGLS",	  "PGD"),	  ]	  write.csv(pent.sub,	  file="PPhosp	  genes.csv")	  phosgenes	  <-­‐	  as.character(pent.sub$Probe.Set.ID)	  	  View(phosgenes)	  	  	  
5.1.4 Present	  and	  Absence	  Calls	  	  #Presence-­‐Absence	  Calls	  on	  AffyMetrix	  HG-­‐U133	  Series	  Microarrays	  with	  panp	  package	  biocLite("panp")	  library(panp)	  	  pa.calls()	  #run	  a	  function	  with	  no	  arguments	  to	  obtain	  a	  summary	  of	  usage	  information	  	  #default	  p-­‐value	  cutoffs	  of	  0.01	  and	  0.02.	  So	  in	  this	  case,	  intensities	  above	  the	  intensity	  at	  the	  0.01	  cutoff	  will	  be	  called	  ”P”	  (present);	  intensities	  between	  the	  two	  cutoffs	  will	  be	  assigned	  an	  ”M”	  (marginal),	  and	  those	  below	  the	  intensity	  at	  the	  0.02	  p-­‐value	  will	  get	  an	  ”A”(absent)	  	  PA	  <-­‐	  pa.calls(eset)	  PAcalls	  <-­‐	  PA$Pcalls	  #The	  presence/absence	  calls	  and	  p-­‐values	  are	  returned	  as	  two	  matrices,	  	  	  Pvalues	  <-­‐	  PA$Pvals	  	  write.table(PAcalls,	  file="PAcalls_rma.csv",	  sep=",",	  col.names=NA)	  	  write.table(Pvalues,	  file="Pvalues_rma.csv",	  sep=",",	  col.names=NA)	  	  ####	  present	  and	  absence	  calls	  for	  the	  probes	  belong	  to	  the	  pathway	  genes	  	  tcagenes	  <-­‐	  as.character(tcagenesnames[	  ,1])	  View(tcagenes)	  tca.sub	  <-­‐	  Pvalues_rma[Pvalues_rma$X	  %in%	  tcagenes,	  ]	  write.csv(tca.sub,	  file="tcasubPvalues.csv")	  	  glygenes	  <-­‐	  as.character(glygenesnames[	  ,1])	  View(glygenes)	  gly.sub	  <-­‐	  Pvalues_rma[Pvalues_rma$X	  %in%	  glygenes,	  ]	  write.csv(gly.sub,	  file="glysubPvalues.csv")	  	  pentgenes	  <-­‐	  Pvalues_rma[Pvalues_rma$X	  %in%	  phosgenes,	  ]	  write.csv(pentsubPvalues,	  file="pentsubPvalues.csv")	  	  glygenes	  <-­‐	  as.character(glygenesnames[	  ,1])	  View(glygenes)	  gly.sub	  <-­‐	  PAcalls_rma[PAcalls_rma$X	  %in%	  glygenes,	  ]	  write.csv(gly.sub,	  file="glysubPAcalls.csv")	  	  tcagenes	  <-­‐	  as.character(tcagenesnames[	  ,1])	  View(tcagenes)	  tca.sub	  <-­‐	  PAcalls_rma[PAcalls_rma$X	  %in%	  tcagenes,	  ]	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write.csv(tca.sub,	  file="tcasubPAcalls.csv")	  	  pentsubPAcalls	  <-­‐	  PAcalls_rma[PAcalls_rma$X	  %in%	  phosgenes,	  ]	  write.csv(pentsubPAcalls,	  file="pentsubPAcalls.csv")	  #	  collection	  of	  data	  from	  the	  PP,	  gly	  and	  tca	  probes	  names	  selected	  	  finalglyprobesdata	  <-­‐	  as.character(glyprobesnamesselected[	  ,2])	  View(finalglyprobesdata)	  gly.final	  <-­‐	  Data[Data$X	  %in%	  finalglyprobesdata,	  ]	  write.csv(gly.final,	  file="finalglyprobesdata.csv")	  	  tca.final	  <-­‐	  Data[Data$X	  %in%	  tcaprobesnamesselected$Probe.Set.ID,	  ]	  write.csv(tca.final,	  file="finalTCAprobesdata.csv")	  	  pp.final	  <-­‐	  Data[Data$X	  %in%	  pentsubPAcalls$Probe.Set.ID,	  ]	  write.csv(pp.final,	  file="finalPPprobesdata.csv")	  	  ###	  with	  A	  calls	  glyprobesselectionwithAvalues	  <-­‐	  as.character(glyprobesselectionwithAvalues[	  ,2])	  	  gly.final	  <-­‐	  Data[Data$X	  %in%	  glyprobesselectionwithAvalues,	  ]	  write.csv(gly.final,	  file="finalglyprobesdatawithAcalls.csv")	  	  finaltcaprobesdata	  <-­‐	  as.character(tcaprobesnamesselected[	  ,1])	  View(finaltcaprobesdata)	  tca.final	  <-­‐	  Data[Data$X	  %in%	  finaltcaprobesdata,	  ]	  write.csv(tca.final,	  file="finaltcaprobesdata.csv")	  	  pentfinal	  <-­‐	  as.character(PPprobesselected[	  ,1])	  pentfinal	  <-­‐	  Data[Data$X	  %in%	  pentfinal,	  ]	  write.csv(pentfinal,	  file="pentfinal.csv")	  	  	  
5.1.5 Selection	  of	  the	  Highly	  and	  Lowest	  Express	  Probes	  
	  ########	  Scaled	  and	  center	  
	  #TCA	  +	  electron	  transport	  chain	  	  datatca	  <-­‐	  TCAprobesforscale	  rnames	  <-­‐	  datatca[,1]	  	  #	  assign	  labels	  in	  column	  1	  to	  "rnames"	  mat_datatca	  <-­‐	  data.matrix(datatca[,2:ncol(datatca)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat_datatca)	  <-­‐	  rnames	  	  colnames(mat_datatca)[1]<-­‐"1321N1"	  	  scaledtca<-­‐biScale(mat_datatca,	  row.center=TRUE,	  row.scale=TRUE,	  col.center=FALSE,	  col.scale=FALSE,	  trace=TRUE)	  View(scaledtca)	  	  write.csv(scaledtca,	  file="scaledtca.csv",	  row.names=TRUE)	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  #Glycolysis	  	  datag	  <-­‐	  glyandpphosforscale	  rnames	  <-­‐	  datag[,1]	  	  #	  assign	  labels	  in	  column	  1	  to	  "rnames"	  mat_datag	  <-­‐	  data.matrix(datag[,2:ncol(datag)])	  #	  transform	  column	  2-­‐5	  into	  a	  matrix	  rownames(mat_datag)	  <-­‐	  rnames	  	  colnames(mat_datag)[1]<-­‐"1321N1"	  	  scaledgly<-­‐biScale(mat_datag,	  row.center=TRUE,	  row.scale=TRUE,	  col.center=FALSE,	  col.scale=FALSE,	  trace=TRUE)	  	  write.csv(scaledgly,	  file="scaledgly.csv",	  row.names=TRUE)	  	  ####	  PENTOSE	  PHOSPHATE	  ####	  	  datapent	  <-­‐	  penttoscale	  rnames	  <-­‐	  datapent[,1]	  	  #	  assign	  labels	  in	  column	  1	  to	  "rnames"	  mat_datapent	  <-­‐	  data.matrix(datapent[,2:ncol(datapent)])	  #	  transform	  column	  2-­‐n	  into	  a	  matrix	  rownames(mat_datapent)	  <-­‐	  rnames	  	  colnames(mat_datapent)[1]<-­‐"1321N1"	  	  scaledpent<-­‐biScale(mat_datapent,	  row.center=TRUE,	  row.scale=TRUE,	  col.center=FALSE,	  col.scale=FALSE,	  trace=TRUE)	  	  write.csv(scaledpent,	  file="scaledpent.csv",	  row.names=TRUE)	  	  #	  USED	  FOR	  THE	  ANALYSIS	  OF	  THE	  16	  CELL	  LINES	  with	  gene	  expression	  data	  	  ###	  Krebs	  cycle	  pathway	  	  select.range<-­‐function	  (scaledtca,	  min,	  max,	  data)	  {	  	  	  if	  (nargs()	  >	  3){	  	  	  	  	  min.cond	  <-­‐	  scaledtca	  >	  min	  	  	  	  	  	  	  max.cond	  <-­‐	  scaledtca	  <	  max	  	  	  	  	  	  cond	  <-­‐	  min.cond	  &	  max.cond	  	  	  	  }	  	  	  else	  cat("Usage:	  select.range(scaledtca,min,max,datavec)\n")	  }	  minmaxtca<-­‐select.range(scaledtca,-­‐1.0,1.0,	  data)	  	  write.csv(minmaxtca,	  file="MinMaxTCA1.0.csv",	  row.names=TRUE)	  	  ###	  glycolysis/gluconeogenesys	  pathway	  	  select.range<-­‐function	  (scaledgly,	  min,	  max,	  data)	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{	  	  	  if	  (nargs()	  >	  3){	  	  	  	  	  min.cond	  <-­‐	  scaledgly	  >	  min	  	  	  	  	  max.cond	  <-­‐	  scaledgly	  <	  max	  	  	  	  	  	  cond	  <-­‐	  min.cond	  &	  max.cond	  	  	  	  	  	  }	  	  	  else	  cat("Usage:	  select.range(scaledgly,min,max,datavec)\n")	  }	  minmaxgly<-­‐select.range(scaledgly,-­‐1.0,1.0,	  data)	  minmaxgly	  	  write.csv(minmaxgly,	  file="MinMaxglyandPP1.0.csv",	  row.names=TRUE)	  	  ###	  pentose	  phosphate	  pathway	  	  select.range<-­‐function	  (scaledpent,	  min,	  max,	  data)	  {	  	  	  if	  (nargs()	  >	  3){	  	  	  	  	  min.cond	  <-­‐	  scaledpent	  >	  min	  	  	  	  	  max.cond	  <-­‐	  scaledpent	  <	  max	  	  	  	  	  	  cond	  <-­‐	  min.cond	  &	  max.cond	  	  	  	  }	  	  	  else	  cat("Usage:	  select.range(scaledpent,min,max,datavec)\n")	  }	  minmaxpent<-­‐select.range(scaledpent,-­‐1.5,1.5,	  data)	  	  write.csv(minmaxpent,	  file="MinMaxPP.csv",	  row.names=TRUE)	  	  	  
5.1.6 Heatmap	  and	  Hierarchical	  Clustering	  	  install.packages("pheatmap")	  library(pheatmap)	  install.packages("softImpute")	  library(softImpute)	  	  library("RColorBrewer")	  display.brewer.all()	  	  colfunc	  <-­‐	  colorRampPalette(c("green",	  "black",	  "red"))	  	  pheatmap	  (mat_datatca,scale="none",col=colfunc(150),	  border_color	  =	  NA,cellwidth	  =	  15,	  cellheight	  =	  7,fontsize_row=6,fontsize_col=7,	  main	  =	  "Heatmap	  of	  genes	  involved	  in	  \nKrebs	  Cycle	  and	  Electron	  Transport	  Chain",	  fontsize	  =	  7,	  filename="tca7.pdf")	  	  pheatmap	  (mat_datagly,scale="none",col=colfunc(150),	  border_color	  =	  NA,cellwidth	  =	  15,	  cellheight	  =	  7,fontsize_row=6,fontsize_col=7,	  main	  =	  "Heatmap	  of	  genes	  involved	  in	  Glycolisys,\n	  Gluconeogenesis	  and	  Pentose	  Phosphate	  Pathways",	  fontsize=7,	  filename="gly7.pdf")	  	  	  #####	  Hierarchical	  Clustering	  #	  Hierarchical	  Clustering.	  Euclidean	  distance.	  hclust	  method	  complete	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  install.packages("plyr")	  library(plyr)	  	  install.packages("rafalib")	  #	  pretty	  clusters	  library(rafalib)	  	  ##	  Bionas	  Capacitance	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  Im	  =	  mean(Bionas.Impedance,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  #	  cluster	  used	  just	  one	  values	  per	  condition	  (mean)	  	  rownames(mm)	  <-­‐	  mm[,1]	  rownames(mm)	  	  Capacitance	  <-­‐	  dist(mm,	  method	  =	  "euclidean")	  #	  distance	  matrix	  Capacitance	  fit	  <-­‐	  hclust(Capacitance)	  	  plot(fit)	  	  colbars1	  <-­‐	  c("orangered","orangered","cadetblue","cadetblue","cadetblue","goldenrod","goldenrod","goldenrod","goldenrod","goldenrod","palegreen","palegreen","palegreen","peachpuff","peachpuff","hotpink","orangered4","turquoise")	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Capacitance	  Cluster	  Dendrogram")	  #	  gives	  title	  	  ####	  O2	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  Oxigen.Consumption	  =	  mean(Bionas.O2,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  rownames(mm)	  <-­‐	  mm[,1]	  	  Oxygen.Consumption	  <-­‐	  dist(mm,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(Oxygen.Consumption)	  	  plot(fit)	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Oxygen	  Consumption	  Cluster	  Dendrogram")	  	  ####	  FET	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  FET	  =	  mean(Bionas.Acid,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  rownames(mm)	  <-­‐	  mm[,1]	  	  Acid.Lactic.Production	  <-­‐	  dist(mm,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(Acid.Lactic.Production)	  	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Acid	  Lactic	  Production	  Cluster	  Dendrogram")	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  ####	  ATP	  	  colbars1	  <-­‐	  c("orangered","orangered","cadetblue","cadetblue","cadetblue","goldenrod","goldenrod","goldenrod","goldenrod","goldenrod","palegreen","peachpuff","peachpuff","hotpink","orangered4","turquoise")	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  ATP	  =	  mean(ATP,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  	  dfsub<-­‐subset(mm,!(is.na(mm["ATP"])))	  #	  take	  out	  nas.	  Cell	  lines	  in	  which	  no	  measurenment	  was	  done	  dfsub	  	  rownames(dfsub)	  <-­‐	  dfsub[,1]	  Intracellular.ATP<-­‐	  dist(dfsub,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(Intracellular.ATP)	  	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Intracellular	  ATP	  Cluster	  Dendrogram")	  	  ####	  Mitomass	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  Mito	  =	  mean(Mitomass,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  rownames(mm)	  <-­‐	  mm[,1]	  	  Cellular.Mitochondrial.Mass<-­‐	  dist(mm,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(Cellular.Mitochondrial.Mass)	  	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Cellular	  Mitochondrial	  Mass	  Cluster	  Dendrogram")	  	  ####	  ROS	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  ROS	  =	  mean(ROS,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  dfsub<-­‐subset(mm,!(is.na(mm["ROS"])))	  #	  take	  out	  nas.	  Cell	  lines	  in	  which	  no	  measurenment	  was	  done	  dfsub	  	  rownames(dfsub)	  <-­‐	  dfsub[,1]	  	  Reactive.Oxygen.Species<-­‐	  dist(dfsub,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(Reactive.Oxygen.Species)	  	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "Reactive	  Oxygen	  Species	  Cluster	  Dendrogram")	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####	  MTT	  	  colbars1	  <-­‐	  c("orangered","orangered","cadetblue","cadetblue","cadetblue","goldenrod","goldenrod","goldenrod","goldenrod","palegreen","hotpink","orangered4")	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  MTT	  =	  mean(MTT,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  dfsub<-­‐subset(mm,!(is.na(mm["MTT"])))	  #	  take	  out	  nas.	  Cell	  lines	  in	  which	  no	  measurenment	  was	  done	  dfsub	  	  rownames(dfsub)	  <-­‐	  dfsub[,1]	  	  MTT<-­‐	  dist(dfsub,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(MTT)	  	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "MTT	  Cluster	  Dendrogram")	  	  ####	  SRB	  	  mm	  <-­‐	  ddply(labexperimentsdata,	  "Cell.Line",	  summarise,	  SRB	  =	  mean(SRB,	  na.rm=T))	  #make	  a	  new	  tablewith	  the	  cell	  lines	  and	  the	  mean	  value	  of	  the	  impedance	  mm	  dfsub<-­‐subset(mm,!(is.na(mm["SRB"])))	  #	  take	  out	  nas.	  Cell	  lines	  in	  which	  no	  measurenment	  was	  done	  dfsub	  	  rownames(dfsub)	  <-­‐	  dfsub[,1]	  	  SRB<-­‐	  dist(dfsub,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(SRB)	  	  fit	  plot(fit)	  	  op	  =	  par(bg	  =	  "grey35")	  myplclust(fit,	  lab.col	  =	  colbars1,	  main	  =	  "SRB	  Cluster	  Dendrogram")	  	  #############	  SCALEING	  AND	  CLUSTERING	  BY	  COLUMNS	  THE	  GENE	  EXPRESSION	  DATA	  (WILL	  BE	  THE	  TOTAL	  GENE	  EXPRESSION	  PER	  CELL	  LINE)	  ###################	  	  #glycolysis/gluconeogenesys	  	  scaledbycolgly<-­‐biScale(mat_datag,	  row.center=FALSE,	  row.scale=FALSE,	  col.center=TRUE,	  col.scale=TRUE,	  trace=TRUE)	  	  write.csv(scaledbycolgly,	  file="scaledbycolgly.csv",	  row.names=TRUE)	  	  rnames	  <-­‐	  ggenetocluster[,1]	  ggenetocluster	  <-­‐	  data.matrix(ggenetocluster[,2:ncol(ggenetocluster)])	  	  rownames(ggenetocluster)	  <-­‐	  rnames	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View(ggenetocluster)	  	  #	  Ward	  Hierarchical	  Clustering	  d	  <-­‐	  dist(ggenetocluster,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(d,	  method="ward")	  	  plot(fit)	  #	  display	  dendogram	  groups	  <-­‐	  cutree(fit,	  k=2)	  #	  cut	  tree	  into	  2	  clusters	  #	  draw	  dendogram	  with	  red	  borders	  around	  the	  2	  clusters	  	  rect.hclust(fit,	  k=2,	  border="red")	  	  #	  krebs	  cycle	  plus	  electron	  transport	  chain	  	  scaledbycoltca<-­‐biScale(mat_datatca,	  row.center=FALSE,	  row.scale=FALSE,	  col.center=TRUE,	  col.scale=TRUE,	  trace=TRUE)	  	  write.csv(scaledbycoltca,	  file="scaledbycoltca.csv",	  row.names=TRUE)	  	  rnames	  <-­‐	  tcagenetocluster[,1]	  	  #	  assign	  labels	  in	  column	  1	  to	  "rnames"	  tcagenetocluster	  <-­‐	  data.matrix(tcagenetocluster[,2:ncol(tcagenetocluster)])	  	  rownames(tcagenetocluster)	  <-­‐	  rnames	  	  	  #	  Ward	  Hierarchical	  Clustering	  d	  <-­‐	  dist(tcagenetocluster,	  method	  =	  "euclidean")	  #	  distance	  matrix	  fit	  <-­‐	  hclust(d,	  method="ward")	  	  plot(fit)	  #	  display	  dendogram	  groups	  <-­‐	  cutree(fit,	  k=2)	  #	  cut	  tree	  into	  2	  clusters	  #	  draw	  dendogram	  with	  red	  borders	  around	  the	  2	  clusters	  	  rect.hclust(fit,	  k=2,	  border="red")	  	  	  
5.1.7 Pearson	  Correlation	  Coefficients	  Estimation	  	  probes	  <-­‐	  as.character(probes.metabolic.assays.and.drugs.IC50.for.pearson[	  ,1])	  View(probes)	  probes.sub	  <-­‐	  All.probes.set.16.cell.lines[All.probes.set.16.cell.lines$Probe.Set.ID	  %in%	  probes,	  ]	  write.csv(probes.sub,	  file="probes.sub.csv")	  	  ##########	  PEARSON	  CORRELATION	  BETWEEN	  extreme	  expresses	  probes	  sets	  and	  metabolic	  assays	  ######	  	  install.packages("Hmisc")	  library(Hmisc)	  	  mat	  <-­‐	  data.matrix(DRUGSPEARSON[,2:ncol(DRUGSPEARSON)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  DRUGSPEARSON[,1]	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  correlation	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	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df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  	  write.csv(df.correlation.r,"correlationmatrixDRUGSPEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  	  write.csv(df.correlation.P,"pvaluescorrelationmatrixDRUGSPEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  rownames(pvaluescorrelationmatrixDRUGSPEARSON)<-­‐	  pvaluescorrelationmatrixDRUGSPEARSON[,1]	  rownames(pvaluescorrelationmatrixDRUGSPEARSON)	  	  #	  selection	  of	  the	  p	  values	  <	  0.05	  	  select.range<-­‐function	  (pvaluescorrelationmatrixDRUGSPEARSON,	  min,	  max,	  data)	  {	  	  	  if	  (nargs()	  >	  3){	  	  	  	  	  min.cond	  <-­‐	  pvaluescorrelationmatrixDRUGSPEARSON	  >	  min	  	  	  	  	  max.cond	  <-­‐	  pvaluescorrelationmatrixDRUGSPEARSON<	  max	  	  	  	  	  	  cond	  <-­‐	  min.cond	  &	  max.cond	  	  	  	  }	  	  	  else	  cat("Usage:	  select.range(pvaluescorrelationmatrixDRUGSPEARSON,min,max,datavec)\n")	  }	  minmaxtca<-­‐select.range(pvaluescorrelationmatrixDRUGSPEARSON,0,0.05,	  data)	  	  write.csv(minmaxtca,	  file="MinMaxpvalues0.05DRUGSPEARSON.csv",	  row.names=TRUE)	  	  ##########	  PEARSON	  CORRELATION	  BETWEEN	  all	  probes	  sets	  and	  metabolic	  assays	  ######	  search	  p	  <	  0.0001	  in	  all	  the	  probes	  	  mat	  <-­‐	  data.matrix(probes.sets.for.pearson5001to10000[,2:ncol(probes.sets.for.pearson5001to10000)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  probes.sets.for.pearson5001to10000[,1]	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  correlation	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe1to5000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe1to5000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  pvaluescorrelationmatrixprobe1to5000PEARSON	  	  max	  <-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	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mat	  <-­‐	  data.matrix(forpearsonprobes5001to10000[,2:ncol(forpearsonprobes5001to10000)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  forpearsonprobes5001to10000[,1]	  rownames(mat)	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  correlation	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe5001to10000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe5001to10000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  df.correlation.P	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	  max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	  	  mat	  <-­‐	  data.matrix(allprobes10001to20000[,2:ncol(allprobes10001to20000)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  allprobes10001to20000[,1]	  rownames(mat)	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  correlation	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe10001to20000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe10001to20000PEARSON.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  df.correlation.P	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	  max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	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mat	  <-­‐	  data.matrix(allprobespearson20001to30000[,2:ncol(allprobespearson20001to30000)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  allprobespearson20001to30000[,1]	  rownames(mat)	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe20001to30000.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe20001to30000.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  df.correlation.P	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	  max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	  	  mat	  <-­‐	  data.matrix(allprobespearson30001to40000[,2:ncol(allprobespearson30001to40000)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  allprobespearson30001to40000[,1]	  rownames(mat)	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe30001to40000.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe30001to40000.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  df.correlation.P	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	  max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	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mat	  <-­‐	  data.matrix(allprobespearson30001toend[,2:ncol(allprobespearson30001toend)])	  #	  transform	  from	  column	  2	  into	  a	  matrix	  rownames(mat)	  <-­‐	  allprobespearson30001toend[,1]	  rownames(mat)	  	  correlation	  <-­‐rcorr(mat,	  type="pearson")	  correlation	  str(correlation)	  #	  shows	  the	  3	  components	  of	  the	  function;r,	  n	  and	  p	  df.correlation.r=data.frame(correlation$r)	  #convert	  the	  r	  part	  to	  a	  data	  frame	  write.csv(df.correlation.r,"correlationmatrixprobe30001toend.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  df.correlation.P=data.frame(correlation$P)	  #convert	  the	  p	  part	  to	  a	  data	  frame	  write.csv(df.correlation.P,"pvaluescorrelationmatrixprobe30001toend.csv")	  #	  the	  data	  frame	  can	  be	  exported	  	  PP	  <-­‐	  df.correlation.P	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	  max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	  	  to5000plusgenename	  <-­‐	  merge(correlationmatrixprobe1to5000PEARSON,genesymbol,by="Probe.Set.ID")	  	  colnames(correlationmatrixprobe1to5000PEARSON)	  rownames(correlationmatrixprobe1to5000PEARSON)	  	  colnames	  (correlationmatrixprobe1to5000PEARSON)	  [1]<-­‐	  "Probe.Set.ID"	  	  class(correlationmatrixprobe1to5000PEARSON)	  #dataframe	  class(genesymbol)#dataframe	  	  a<-­‐	  sub("X","",colnames(correlationmatrixprobe30001toend))	  #column	  names	  without	  the	  X	  as	  first	  letter	  class(a)	  #character	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  	  to5000plusgenename	  =	  data.frame(a,	  correlationmatrixprobe30001toend)	  #	  to	  bind	  dataframe	  a	  with	  dataframe	  correlationmatrixprobe30001toend	  to5000plusgenename	  <-­‐	  to5000plusgenename[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  	  to5000plusgenename	  <-­‐	  merge(a,genesymbol,by="Probe.Set.ID")	  colnames(to5000plusgenename)[1]<-­‐"Probe.Set.ID"	  	  rcorrplusgenename40001toend	  <-­‐	  merge(genesymbol,to5000plusgenename,by="Probe.Set.ID")	  	  rcorrplusgenename40001toend	  <-­‐	  rcorrplusgenename40001toend[,c(1,2,5,6,7,8,9,10,11,12)]	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write.csv(rcorrplusgenename40001toend,	  file="rcorrplusgenename40001toend.xls",	  row.names=TRUE)	  	  	  ####	  probes	  1	  to	  5000	  a<-­‐	  sub("X","",colnames(correlationmatrixprobe1to5000PEARSON))	  #column	  names	  without	  the	  X	  as	  first	  letter	  a<-­‐data.frame(a)	  ###	  give	  me	  just	  the	  first	  column	  with	  the	  probes	  sets	  names	  without	  the	  X	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  	  correlationmatrixprobe1to5000PEARSON	  =	  data.frame(a,	  correlationmatrixprobe1to5000PEARSON)	  	  rcorrplusgenename1to5000	  <-­‐	  merge(genesymbol,correlationmatrixprobe1to5000PEARSON,by="Probe.Set.ID")	  rcorrplusgenename1to5000	  <-­‐	  rcorrplusgenename1to5000[,c(1,2,4,5,6,7,8,9,10,11)]	  rcorrplusgenename1to5000<-­‐	  rcorrplusgenename1to5000[,c(2,1,3,4,5,6,7,8,9,10)]	  write.csv(rcorrplusgenename1to5000,	  file="rcorrplusgenename1to5000.xls",	  row.names=TRUE)	  	  ####	  probes	  5001	  to	  10000	  a<-­‐	  sub("X","",colnames(correlationmatrixprobe5001to10000PEARSON))	  #column	  names	  without	  the	  X	  as	  first	  letter	  a<-­‐data.frame(a)	  ###	  give	  me	  just	  the	  first	  column	  with	  the	  probes	  sets	  names	  without	  the	  X	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  	  correlationmatrixprobe5001to10000PEARSON	  =	  data.frame(a,	  correlationmatrixprobe5001to10000PEARSON)	  	  rcorrplusgenename5001to10000	  <-­‐	  merge(genesymbol,correlationmatrixprobe5001to10000PEARSON,by="Probe.Set.ID")	  rcorrplusgenename5001to10000<-­‐	  rcorrplusgenename5001to10000[,c(1,2,4,5,6,7,8,9,10,11)]	  rcorrplusgenename5001to10000<-­‐	  rcorrplusgenename5001to10000[,c(2,1,3,4,5,6,7,8,9,10)]	  write.csv(rcorrplusgenename5001to10000,	  file="rcorrplusgenename5001to10000.xls",	  row.names=TRUE)	  	  ####	  probes	  10001	  to	  20000	  a<-­‐	  sub("X","",colnames(correlationmatrixprobe10001to20000PEARSON))	  #column	  names	  without	  the	  X	  as	  first	  letter	  a<-­‐data.frame(a)	  ###	  give	  me	  just	  the	  first	  column	  with	  the	  probes	  sets	  names	  without	  the	  X	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  	  correlationmatrixprobe10001to20000PEARSON	  =	  data.frame(a,	  correlationmatrixprobe10001to20000PEARSON)	  	  rcorrplusgenename10001to20000	  <-­‐	  merge(genesymbol,correlationmatrixprobe10001to20000PEARSON,by="Probe.Set.ID")	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rcorrplusgenename10001to20000<-­‐	  rcorrplusgenename10001to20000[,c(1,2,4,5,6,7,8,9,10,11)]	  rcorrplusgenename10001to20000<-­‐	  rcorrplusgenename10001to20000[,c(2,1,3,4,5,6,7,8,9,10)]	  write.csv(rcorrplusgenename10001to20000,	  file="rcorrplusgenename10001to20000.xls",	  row.names=TRUE)	  	  ####	  probes	  20001	  to	  30000	  a<-­‐	  sub("X","",colnames(df.correlation.r))	  #column	  names	  without	  the	  X	  as	  first	  letter	  a<-­‐data.frame(a)	  ###	  give	  me	  just	  the	  first	  column	  with	  the	  probes	  sets	  names	  without	  the	  X	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  	  correlationmatrixprobe20001to30000	  =	  data.frame(a,	  df.correlation.r)	  	  rcorrplusgenename20001to30000	  <-­‐	  merge(genesymbol,correlationmatrixprobe20001to30000,by="Probe.Set.ID")	  rcorrplusgenename20001to30000<-­‐	  rcorrplusgenename20001to30000[,c(1,2,3,4,5,6,7,8,9,10)]	  	  	  rcorrplusgenename20001to30000<-­‐	  rcorrplusgenename20001to30000[,c(2,1,3,4,5,6,7,8,9,10)]	  write.csv(rcorrplusgenename20001to30000,	  file="rcorrplusgenename20001to30000.xls",	  row.names=TRUE)	  	  ####	  probes	  30001	  to	  40000	  a<-­‐	  sub("X","",colnames(correlationmatrixprobe30001to40000))	  #column	  names	  without	  the	  X	  as	  first	  letter	  a<-­‐data.frame(a)	  ###	  give	  me	  just	  the	  first	  column	  with	  the	  probes	  sets	  names	  without	  the	  X	  a	  <-­‐	  a[-­‐c(1),	  ]	  #to	  eliminate	  a	  row	  a<-­‐data.frame(a)	  colnames(a)	  <-­‐	  "Probe.Set.ID"	  	  correlationmatrixprobe30001to40000	  =	  data.frame(a,	  correlationmatrixprobe30001to40000)	  	  rcorrplusgenename30001to40000	  <-­‐	  merge(genesymbol,correlationmatrixprobe30001to40000,by="Probe.Set.ID")	  rcorrplusgenename30001to40000<-­‐	  rcorrplusgenename30001to40000[,c(1,2,4,5,6,7,8,9,10,11)]	  rcorrplusgenename30001to40000<-­‐	  rcorrplusgenename30001to40000[,c(2,1,3,4,5,6,7,8,9,10)]	  write.csv(rcorrplusgenename30001to40000,	  file="rcorrplusgenename30001to40000.xls",	  row.names=TRUE)	  	  pvalues10001to20000	  <-­‐	  pvaluescorrelationmatrixprobe10001to20000PEARSON[,c(1,2,3,	  4,5,6,7,8,9)]	  write.csv(pvalues10001to20000,	  file="pvalues10001to20000.xls",	  row.names=TRUE)	  	  pvalues20001to30000	  <-­‐	  df.correlation.P[,c(1,2,3,	  4,5,6,7,8)]	  write.csv(pvalues20001to30000,	  file="pvalues20001to30000.xls",	  row.names=TRUE)	  pvalues30001to40000	  <-­‐	  pvaluescorrelationmatrixprobe30001to40000[,c(1,2,3,	  4,5,6,7,8,9)]	  write.csv(pvalues30001to40000,	  file="pvalues30001to40000.xls",	  row.names=TRUE)	  	  PP	  <-­‐	  pvalues10001to20000	  class(pvalues10001to20000)	  class(PP)	  	  max1	  <-­‐	  subset(PP,	  PP[,1]	  <	  0.0001)	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max2<-­‐	  subset(PP,	  PP[,2]	  <	  0.0001)	  max3	  <-­‐	  subset(PP,	  PP[,3]	  <	  0.0001)	  max4	  <-­‐	  subset(PP,	  PP[,4]	  <	  0.0001)	  max5	  <-­‐	  subset(PP,	  PP[,5]	  <	  0.0001)	  max6	  <-­‐	  subset(PP,	  PP[,6]	  <	  0.0001)	  max7	  <-­‐	  subset(PP,	  PP[,7]	  <	  0.0001)	  max8	  <-­‐	  subset(PP,	  PP[,8]	  <	  0.0001)	  	  pvaluescorrelationmatrixprobe5001to10000	  <-­‐	  pvaluescorrelationmatrixprobe5001to10000PEARSON[,c(1,2,3,	  4,5,6,7,8,9)]	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